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ABSTRACT OF THE DISSERTATION
Host Immune Signals Regulate Blood-Brain Barrier Function During
Central Nervous System Infection and Autoimmunity
by
Brian Daniels
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2015
Robyn Klein, Chair

A major hallmark of neuroinflammatory diseases is the breakdown of the blood-brain
barrier (BBB). This barrier between the hematogenous circulation and the parenchyma of the
central nervous system (CNS) is a multicellular interface made up of endothelial cells joined by
tight and adherens junctions (TJs and AJs), along with pericytes and the endfeet projections of
astroglia. Together, these cells tightly restrict the movement of solutes and cells from the
circulation into the CNS in a manner crucial for proper CNS homeostasis. Regulation of BBB
function occurs dynamically during neuroinflammatory diseases such as infection and CNS
autoimmunity, resulting in both protective and pathologic outcomes.
In this dissertation, we describe several novel cellular and molecular mechanisms of
immune mediated control of BBB function. In particular, these studies further our understanding
of how host cytokines and chemokines function at the BBB during disease, impacting essential
features of BBB physiology including junction integrity, endothelial polarity, chemokine
localization, and paracellular permeability. Importantly, our studies demonstrate that
x

cytokine/chemokine effects at the BBB are consequential to the pathogenesis of
neuroinflammatory diseases, including the CNS infiltration of autoreactive leukocytes during
autoimmunity, as well as the neuroinvasive potential of West Nile virus, an emerging
neurotropic pathogen. Thus, this work highlights new possibilities for targeted therapeutics for
human diseases that involve BBB dysfunction.
Specifically, we identify S1PR2 as a disease modifying molecule in multiple sclerosis
(MS) and its mouse model experimental autoimmune encephalomyelitis (EAE). Our studies
demonstrate that S1PR2 signaling in CNS vascular endothelia contributes to diminished integrity
of AJs, resulting in enhanced BBB permeability and loss of polarized expression of the
chemokine CXCL12 along basolateral vessel surfaces, resulting in enhanced parenchymal
infiltration of leukocytes, increased lesion formation, and poorer clinical outcome during EAE.
In addition, our studies establish a link between sexually dimorphic expression of S1PR2 in
disease susceptible regions of the CNS in female mice and women with MS to enhanced
susceptibility to CNS autoimmunity. These findings offer exciting new clues as to the
mechanisms underlying sex bias in CNS autoimmunity and identify a new target for therapeutic
interventions at the BBB.
Other studies identified novel protective functions for type I and III interferons (IFNs) at
the BBB during WNV infection. Our studies suggest that expression of innate IFNs following
recognition of WNV pathogen associated molecular patterns results in enhanced BBB integrity.
Type I IFNs are shown to be a key regulator of BBB integrity by preserving TJ integrity and
endothelial permeability, thereby limiting the ability of WNV to traffic across the BBB. This
effect was accomplished via direct signaling mechanisms, as well as by suppression of
inflammatory cytokine signals that permeabilize the BBB. Further studies revealed that the type
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III IFNs display similar properties to type I IFNs at the BBB, restricting the neuroinvasive
capacity of WNV by enhancing BBB integrity. As type III IFN receptor expression is more
highly localized to tissue barriers compared to type I IFNs, these studies suggest new therapeutic
opportunities for IFN therapy in the treatment of neuroinflammatory disease.
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Chapter 1
Introduction

This chapter is adapted from the following publications:
Daniels BP and Klein RS. (submitted) Knocking on closed doors: Host interferons
dynamically regulate blood-brain barrier function during viral infections of the central
nervous system.
Daniels BP and Klein RS. (2015) Viral sensing at the blood-brain barrier: new roles for
innate immunity at the CNS vasculature. Clinical Pharmacology and Therapeutics. 97(4):
372-79.
Durrant DM, Williams JL, Daniels BP, and Klein RS. (2014) Chemokines referee
inflammation within the central nervous system during infection and disease. Advances in
Medicine. 2014: 806741.
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1.1 Introduction
A common feature of neuroinflammatory diseases is breakdown of the blood-brain
barrier (BBB). The BBB is a multicellular interface of glial and vascular cells that tightly
restricts the movement of solutes and cells in the circulation into the CNS parenchyma.
Microvasculature within the CNS features non-fenestrated brain microvascular endothelial cells
(BMECs) joined by tight junctions (TJs) and adherens junctions (AJs). These junctions serve to
limit paracellular permeability as well as maintain the polarized expression of key BBB
transporter proteins, ion pumps, and other molecules that establish the metabolic gradients that
are also a key component of BBB function and CNS homeostasis (1). BMECs at the BBB are
supported by close association with pericytes and the endfeet projections of astrocytes, both of
which are important sources of soluble factors that enhance junction integrity and barrier
function (2, 3). While BMECs are the major structural component of the BBB, pericytes and
astrocytes exert considerable regulatory control on BMECs, and thus, all three cell types are
targets for modulation of blood-brain barrier function by viruses and host immune factors.
This dissertation describes several new cellular and molecular mechanisms by which
BBB function is regulated during neuroinflammatory diseases, including viral infection and CNS
autoimmunity. In particular, this work highlights the ways in which host cytokines and
chemokines contribute to the diverse functions of the BBB during disease states. This
introductory chapter will review our current understandings of how cytokines and chemokines
contribute to essential BBB functions, including the maintenance of CNS “immune privilege”
and the restriction of neuroinvasive pathogens from the CNS parenchyma. Special attention is
given to recent advances in our understanding of BBB biology in the context of neurotropic viral
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infections, an area of considerable importance to global health and the primary focus of the latter
chapters of this work.

3

1.2 The BBB, CNS immune privilege, and autoimmunity
A key function of the BBB is the maintenance of the so-called “immune privilege” of the
CNS. While our conceptual understanding of immune privilege has evolved considerably since
its original descriptions, it is known that the BBB serves to tightly control the access of
circulating leukocytes to the CNS parenchyma (4, 5). This regulatory control is essential during
homeostatic processes such as immune surveillance, as well as for effective cellular immune
responses during CNS infections (4, 6). Though several features of BBB physiology contribute
to CNS immune privilege, work in our laboratory has extensively characterized the importance
of BBB chemokine expression and localization in the careful coordination of leukocyte
trafficking into the CNS. Chemokine signals are known to be important in all neurovascular cell
types, though their actions in endothelial cells and astrocytes are most well understood. Immune
cells that infiltrate the CNS via the circulation first enter a space between vascular endothelia and
glial endfeet known as the perivascular space, where they are subject to the regulatory actions of
chemokines and other CNS immune factors from multiple cellular sources (7).
In BMECs, the expression and localized display of CXCL12 is known to be a major
regulator of CNS immune privilege. Under homeostatic conditions, CXCL12 is expressed
exclusively along basolateral/ablumenal surfaces of BMECs (8, 9). Upon extravasation into the
perivascular space, CXCR4+ leukocytes are captured by endothelial CXCL12, restricting them to
the perivascular space and preventing their parenchymal infiltration. This process is responsible
for much of the “perivascular cuffing” that occurs during inflammatory episodes of the CNS, as
large numbers of infiltrating leukocytes accumulate on the basolateral surfaces of vascular
endothelium. This restriction of leukocyte access to the CNS parenchyma is essential to limit
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immunopathology and bystander injury of neurons, which have limited capacity for repair in
comparison to peripheral tissues (10).
Due to this essential function, disease states that alter CXCL12 expression and
localization at the BBB can lead to uncontrolled neuroinflammation, resulting in axonal injury,
demyelination, and neuronal death. In the CNS autoimmune disease multiple sclerosis (MS) and
its mouse model experimental autoimmune encephalomyelitis (EAE), myelin-specific Tlymphocytes invade the CNS parenchyma, forming lesions characterized by demyelinated and
injured axons. In both MS and EAE, the homeostatic localization of CXCL12 is disturbed, with
loss of polarized expression along basolateral surfaces of BMECs. Loss of CXCL12 polarity
results in impaired perivascular capture of infiltrating leukocytes, with subsequent accumulations
of CXCR4+ cells in parenchymal tissues leading to progressive neuropathology. In mouse studies,
blockade of CXCL12-CXCR4 interactions at the BBB via administration of the CXCR4
antagonist AMD3100 resulted in enhanced clinical disease severity during EAE, associated with
enhanced parenchymal immune infiltrates, increased microglial activation, and increased CNS
expression of Th1 inflammatory mediators (9). In studies of tissue from MS patients, uninflamed
vessels exhibited normal basolateral vascular expression of CXCL12, while inflammatory
lesions contained vessels with CXCL12 expression that was redistributed to vessel lumena. Of
note, the extent of pathological CXCL12 expression within MS lesions positively correlated with
levels of neuroinflammation and demyelination (8). Together, these studies established a critical
role for CXCL12 at the BBB in the orchestration of leukocyte trafficking during CNS
autoimmunity.

Mediators of CXCL12 signaling during CNS autoimmunity
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Given the central role of CXCL12 at the BBB during homeostasis and neuroinflammation,
understanding the mechanisms by which CXCL12 is regulated at this site is crucial in the
development of targeted therapeutics. Endothelial CXCL12 is subject to regulation by a number
of factors, including reciprocal regulation by infiltrating immune cells. In particular, mouse
studies have established that expression of the inflammatory cytokine IL-1β contributes to loss of
CXCL12 polarity in vascular endothelium during the induction of EAE, facilitating later CNS
parenchymal invasion by autoreactive leukocytes (11). During EAE, infiltrating CD4+, CD8+,
and γδ T cells are sources of IL-1β within the CNS. IL1R-/- mice are resistant to EAE, and, in
contrast to WT controls, exhibit intact CXCL12 polarity at the BBB following myelin
oligodendrocyte glycoprotein (MOG)-immunization. Administration of recombinant IL-1β also
potently induced the relocalization of CXCL12 to vessel lumena in spinal cords of naïve WT
mice. Bone marrow chimera experiments revealed that IL1R signaling on both leukocytes and
resident CNS cells contributed to changes in CXCL12 polarity at the BBB during EAE,
suggesting that IL1R signaling is a key systemic regulator of CXCL12 within the inflamed CNS.
While leukocyte-derived factors play a role in regulating CXCL12 at the BBB,
endothelial cells, themselves, express key regulators of CXCL12 expression and polarity that
contribute to autoimmune pathogenesis. A key CXCL12 regulatory protein is the atypical
chemokine receptor CXCR7/ACKR3 (CXCR7). BMECs are among the primary expressers of
CXCR7 within the CNS (12). Endothelial CXCR7 serves as a scavenging receptor for CXCL12,
sequestering the chemokine into lysosomal compartments, thereby negatively regulating
CXCL12-CXCR4 signaling. Studies in mice demonstrated that CXCR7 expression was
upregulated in vascular endothelium during EAE (12). This was due, in part, to the actions of the
T-cell cytokines IL-1β and IL-17, which enhanced CXCR7 expression and CXCL12
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internalization in BMECs in vitro. Administration of the CXCR7 antagonist CCX771 diminished
the clinical symptoms of EAE by preserving CXCL12 polarity at the BBB, thereby reducing
parenchymal infiltration of autoreactive leukocytes. This preservation of CNS immune privilege
was further shown via in vivo diffusion tensor imaging to prevent axonal injury during EAE (13).
In addition to direct regulation via CXCR7, CXCL12 is also indirectly regulated at the
BBB by mediators of endothelial cell biology. In particular, we recently reported that
sphingosine-phosphate-1 receptor 2 (S1PR2) signaling in neurovascular cells contributed to BBB
dysregulation during CNS autoimmunity (14). S1PRs at the BBB respond to the bioactive lipid
metabolite S1P, which is expressed broadly by endothelial cells, erythrocytes, and neuronal
lineage cells. In BMECs, S1PRs regulate a variety of cytoskeletal processes that influence
intercellular junctions, paracellular permeability, and apicobasal polarity. In our study, S1PR2
signaling in CNS vascular endothelium was associated with increased BBB permeability and loss
of CXCL12 polarity in mice with EAE and in a human in vitro BBB model (14, 15).
Pharmacological blockade or genetic deletion of S1PR2 ameliorated clinical symptoms and
parenchymal leukocyte infiltrates and was shown to preserve BBB integrity and CXCL12
polarity in CNS microvessels. S1PR2 dysregulation of endothelial barrier integrity was
associated with disassembly of endothelial AJs, and was dependent on signaling through the
cytoskeletal regulatory GTPases RhoA and CDC42, as well as the caveolin-mediated endocytic
pathway. Of note, changes to BBB permeability and adherens junction formation were always
associated with loss of CXCL12 polarity, indicating that CXCL12 display on basolateral surfaces
of BMECs can be controlled both directly via CXCR7-mediated relocation, as well as by general
disruption of AJ-mediated apicobasal polarity via cytoskeletal and endocytic regulatory
pathways.
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S1PR2 signaling at the BBB may prove to be a particularly attractive therapeutic target,
due to its recently discovered contribution to sexually dimorphic patterns of CNS autoimmunity.
MS exhibits a strong sexual bias in humans; women comprise the majority of patients, and are
more susceptible to remitting-relapsing forms of the disease. The EAE model in the SJL mouse
strain exhibits similar sexual dimorphism, with female mice exhibiting enhanced susceptibility to
EAE and experiencing a remitting-relapsing course of clinical disease. In contrast, males are less
susceptible, and exhibit monophasic disease similar to that observed in other mouse strains with
other EAE, including C57BL/6. Our recent study found sexually dimorphic expression of S1PR2
in the SJL mouse strain, with increased expression in the cerebella of naïve female SJL and in
cerebella and spinal cords of female SJL with EAE compared to males. In addition, we reported
enhanced expression of S1PR2 in cerebella of female patients with MS compared to males.
Remarkably, the enhanced expression of S1PR2 in EAE-susceptible CNS regions of female SJL
mice was associated with similarly sexually dimorphic pathological expression of CXCL12.
Naïve female SJL mice exhibited dysregulated CXCL12 polarity in lower CNS regions,
contributing to their enhanced susceptibility to EAE, and this dysregulation was further
exacerbated compared to males during disease. S1PR2 was found to contribute significantly to
sexually dimorphic differences in CXCL12 expression and localization, as pharmacological
blockade and genetic deletion of S1PR2 signaling preserved CXCL12 polarity during EAE,
resulting in ameliorated disease. Together, these findings suggest that targeting S1PR2 signaling
may be a powerful tool in addressing sex-specific disease processes in MS, including the
dysregulation of chemokine signals that regulate CNS immune privilege.
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1.3 The BBB and viral infections of the CNS
Viral infections of the central nervous system (CNS) cause severe morbidity and
mortality in >0.5 million individuals worldwide each year (16). Encephalitis, inflammation of the
CNS parenchyma, and meningitis, inflammation within the meninges, often occur concomitantly,
leading to the classic presentation of fever, meningismus, and headache with various ranges of
altered mental status. Indeed, viral infections can influence neuronal function (17) and gene
expression (18), contributing to dementia, memory loss, and other cognitive and behavioral
abnormalities (18-20). The extent of CNS injury, neuroinflammation and overall outcome
depend on the specific pathogen and the immunologic status of the patient. With the exception of
rabies virus, most neurotropic viruses gain access to the CNS in a minority of cases, suggesting
that barriers to the CNS entry of virus do exist and, for most individuals, prevent infection.
Indeed, under normal conditions, viruses and other pathogens are completely excluded
from the CNS by the BBB. However, diminished BBB integrity during infancy, advanced age, or
illness renders some individuals susceptible to neuroinvasive infections. Preterm infants and
neonates, in particular, do not yet have a completely developed BBB (21), making them
particularly susceptible to neurotropic viruses (22). However, even in otherwise healthy adults,
many viruses are capable of crossing the BBB and establishing CNS infection. Thus, discovering
the viral and host factors that impact BBB permeability has been a key goal of recent research
aiming to understand how neuroinvasive viral infections occur, with the ultimate goal of finding
targets for effective treatment and prevention strategies. At the center of this research have been
investigations of host cytokine and chemokine responses, which are known to be powerful
regulators of BBB permeability and junction integrity (7), but, in some cases, have only recently
been well studied in the context of CNS viral infections. Viral factors and host cytokines and
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chemokines can impact the BBB directly and indirectly via the induction of inflammatory
responses and immune cell migration. These impacts on BBB function have been shown to result
in both protective and pathological processes.

Neurotropic viruses
The mammalian CNS is susceptible to infection by a number of viruses, the majority of
which are incidental and/or opportunistic in nature. Many of the most devastating causes of viral
encephalitis are zoonotic infections, caused by pathogens that are relatively benign in their
primary hosts, but neuroinvasive and highly pathogenic when spread to “dead-end” hosts that do
not typically transmit virus back to primary hosts. Examples in humans include rhabdovirus and
flavivirus infections (23). Arthropod-borne viruses (arboviruses) carried by mosquitoes and ticks
are a major source of viral encephalitis in humans, with thousands of reported neuroinvasive
infections in the U.S. every year (24, 25) (Table 1). Replication of neurotropic viruses within the
CNS often results in viral and immune-mediated damage to nervous tissue, leading to severe
neuropathology and death. However, neuropathogenesis differs widely by virus species and by
host species, age, and health.

Retroviruses
Members of the viral family Retroviridae are single stranded RNA (ssRNA) viruses
capable of causing severe CNS infection and disease. Neurotropic retroviruses include human
immunodeficiency virus-1 (HIV-1) and the related simian (SIV) and feline (FIV)
immunodeficiency viruses. In humans, HIV-1 infection is most associated with the development
of acquired immune deficiency syndrome (AIDS), which is often characterized by virally
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mediated damage to nervous tissue, resulting in HIV-associated neurocognitive impairments and
dementia (26, 27). Immunodeficiency during HIV-1 infection also significantly enhances
susceptibility to other neuroinvasive infections by opportunistic pathogens, compounding
already-existing neuropathology (26). The human CNS is also susceptible to retroviral infection
by human T-cell lymphotropic virus-1 (HTLV-1), which can result in progressive
neurodegeneration and spinal cord myelopathy (26, 28).

Flaviviruses
Another prominent family of neurotropic ssRNA viruses are the Flaviviridae, which
include West Nile virus (WNV), Japanese encephalitis virus (JEV), dengue virus (DenV), tick
borne encephalitis virus (TBEV), and others. Flavivirus infections are a major cause of viral
encephalitis worldwide. WNV, in particular, is an emerging human pathogen which, over the
past decade, has become the leading cause of epidemic viral encephalitis in the United States (29)
(Table 1). While most flavivirus infections are mild or asymptomatic, a subset of infected
individuals develops severe neuroinvasive disease and encephalitis, often resulting in permanent
neurological injury or death (29, 30). While recent progress has been made with JEV and TBEV,
there are still few effective vaccines or treatments for other flaviviruses, including WNV and
DenV, greatly hindering attempts to address the growing public health burden caused by these
viruses (31).

Other viruses
Newly emerging viruses, including the paramyxoviruses Hendra virus (HeV) and Nipah
virus (NiV) are also causes of encephalitis in human hosts, but remain poorly understood (32,
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33). Other more common infections such as Herpes simplex virus-1 (HSV-1) establish dormant
infection in peripheral nerves, but can cause sporadic, severe encephalitis in some individuals
(23, 34). Other neurotropic viruses, including rabies virus (RabV) and mouse adenovirus-1
(MAV-1) can cause significant neuropathology, but access the CNS via alternative means
compared to retroviruses and flaviviruses (23, 35, 36). The broad variation among neurotropic
viruses highlights the considerable challenge of understanding when and how these viruses infect
the CNS. Recent research, however, has shed much light on how viruses and the host factors
they elicit impact both viral neuroinvasion and subsequent pathogenesis.

Cytokine regulation of BBB function during viral infections
A complex network of pathogen and host factors governs BBB permeability during viral
infections. Recent studies have furthered the work of clarifying how networks of cytokine and
chemokine signals work together to modulate BBB function. Inflammatory cytokines, including
TNF-α, IL-1β, and IFN-γ, are among the best-characterized regulators of BBB permeability
during CNS viral infections. Most significantly, these molecules have been widely shown to
enhance BBB permeability, both via direct signaling mechanisms as well as by reciprocal
induction of other inflammatory mediators such as CXCL10. In contrast, recent work has also
begun to identify how other host cytokines, such as the type I and III interferons (IFNs), can
preserve BBB integrity and act as a counterregulator of BBB permeability against inflamatory
stimuli. Together, these cytokine and chemokine signals regulate BBB function dynamically
across time and CNS regions, impacting access of viruses to the CNS, as well as subsequent
leukocyte infiltration into the CNS parenchyma. Thus, regulation of BBB function by host
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immune factors plays a pivotal role in disease pathogenesis and recovery during CNS infection
by many different viruses.

Inflammatory cytokines
Though inflammatory cytokines have been known for decades to influence vascular
permeability, recent research has begun to show how these molecules are induced and signal at
the BBB during CNS viral infections. TNF-α, IFN-γ, and IL-1β, in particular, have previously
been shown to increase endothelial barrier permeability, both in vivo and in culture models (3740). The most well studied of these is TNFα, which has been implicated in increased vascular
permeability, poor tissue perfusion, and endothelial cell death during viral infections (41, 42).
Specifically at BBB endothelium, TNF-α signaling has been associated with enhanced BBB
permeability in the context of many neurotropic viral infections, including WNV (43, 44), JEV
(45, 46), NiV(32), HeV (32), HIV-1 (47), FIV (48), and others. TNF-α-mediated BBB
breakdown occurs via several distinct mechanisms. Recent studies have demonstrated that
abrogation of TNF-α signaling during viral infections reduces the expression of other TNF-α induced inflammatory cytokines and chemokines, with an associated rescue of BBB permeability
(43, 46) and/or peripheral vascular leakage (41). In addition, TNF-α signaling acts directly on
endothelial cells to enhance permeability via interaction with cytoskeletal regulatory pathways.
For example, our laboratory recently demonstrated that TNF-α activates the RhoA/Rho Kinase
pathway in BMECs following WNV infection or viral pattern recognition receptor (PRR)
agonism, increasing endothelial permeability in in vitro BBB culture models. Likewise, TNF-α
and RhoA have been implicated in BBB dysfunction during HIV-1 infection (47, 49).
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IFN-γ is also known to disrupt BBB integrity during neurotropic viral infections. A recent
study by Chai et al. featured a pathway analysis that identified IFN-γ at the center of the cytokine
network responsible for BBB disruption during laboratory-attenuated RabV infection.
Subsequent experiments showed that treatment with an IFN-γ neutralizing antibody signficantly
rescued BBB permeability in RabV infected animals (35). Notably, the actions of IFN-γ in this
study were associated with high expression of CXCL10, which has also been show to enhance
BBB permeability during RabV infection (50). This finding is in line with a recent report
demonstrating a positive feedback loop between IFN-γ and CXCL10 expression via astrocytes
that contributes to chronic neuroinflammation and neuropathology during CNS infection with
HTLV-1 (28). Another recent report suggests that astrocytes are also a prominent source of
CXCL10 in the context of Theiler’s murine encephalitis virus (TMEV) infection (51). Together,
these studies support a model by which migration of IFN-γ expressing lymphocytes across the
BBB activates CXCL10 expression in the CNS, which in turn dysregulates BBB integrity,
allowing the influx of greater numbers of IFN-γ expressing CXCR3+ lymphocytes into the CNS
parenchyma. While CXCL10-mediated BBB breakdown and lymphocyte recruitment has been
shown to promote viral clearance and survival during RabV (35, 50) and WNV (52, 53) infection,
this process must be carefully regulated in order to prevent bystander injury and neuropathology
caused by cytokines, glial activation, and cytotoxic T lymphocyte responses within the CNS (43,
54-56).
While IL-1 has been shown to increase BBB permeability in vitro (37, 39) and during
CNS injury in vivo (57), the role of this cytokine at the BBB during CNS viral infections has
been less well characterized. For example, despite its activity in vitro, we have recently shown
that that Il1r1-/- mice do not exhibit enhanced BBB permeability following subcutaneous WNV
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infection (55) and that WT BMECs do not produce detectable levels of IL-1β following WNV
infection in vitro (44). Instead, we found that IL-1 played a more indirect role at the BBB during
WNV infection via its regulation of BBB chemokine expression. Most notably, we found that IL1 signaling was critical for CXCL12-mediated localization of infiltrating lymphocytes into
perivascular spaces, which was necessary for proper dendritic-cell mediated T-cell reactivation.
Thus, IL-1 signaling at the BBB during WNV infection serves as an important regulator of CNS
immune privilege, as loss of IL-1R1 signaling resulted in enhanced inflammatory chemokine
expression in the CNS, along with greatly enhanced lymphocyte infiltration, CNS
immunopathology, and loss of virologic control (54, 55). However, it is certainly possible that
IL-1 signaling plays a more direct role in regulating BBB permeability in the context of other
viral infections, as IL-1 family cytokines are upregulated following infection with a number of
viruses that feature BBB disruption, including RabV (35), JEV (58), and HIV-1 (59).

Type I IFNs
In contrast to inflammatory cytokines, a growing body of evidence has demonstrated that
type I IFN signaling at the BBB acts to promote barrier integrity. The BBB-stabilizing effects of
type I IFNs have been well demonstrated using in vitro BBB models (44, 60) and in the
autoimmunity literature, where type I IFN treatment has been shown to preserve BBB integrity
and limit infiltration of autoreactive leukocytes into the CNS during multiple sclerosis and its
mouse model experimental autoimmune encephalomyelitis (61). However, despite the canonical
function of type I IFNs as antiviral molecules, their role at the BBB during neurotropic viral
infections has only recently been addressed. Recent studies indicate that type I IFN signaling
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also serves to promote BBB integrity during CNS viral infections via multifaceted mechanisms,
highlighting a novel protective function for these cytokines.
Recent work in our laboratory demonstrated that detection of WNV by PRRs at the BBB
induces local type I IFN responses that promote BBB integrity (44), as in vitro BBB cultures
prepared with type I IFN receptor deficient (Ifnar-/-) BMECs and mice lacking intact type I IFN
signaling exhibited enhanced permeability following WNV infection or chemical agonism of
PRRs. Type I IFNs accomplished this via two major mechanisms, the first being suppression of
inflammatory cytokine production, thereby suppressing a major source of BBB disruption
following infection. In vitro, type I IFN modestly suppressed the expression of TNF-α and
completely abolished expression of IL-1β by BMECs following exposure to WNV or PRR
agonism. While the mechanisms of type I IFN suppression of IL-1 signaling at the BBB have not
been established, type I IFN has been shown to suppress IL-1β expression in other contexts via
inhibition of inflammasome activity and/or suppression of pro-IL-1α and pro-IL-1β expression
(62, 63). Similarly, a recent report by Pinto et al. demonstrated that loss of IFN signaling in
whole animals or in subsets of myeloid cells resulted in greatly enhanced inflammatory cytokine
production following WNV infection, associated with profound vascular leakage and sepsis
syndrome (41). These findings highlight the complex interactions of type I IFN and IL-1 during
CNS infections, as, while type I IFN suppressed the actions of IL-1 at the BBB in our study, a
recent study has demonstrated synergistic antiviral signaling between type I IFN and IL-1 in
neurons during WNV infection (64). Thus, interactions between type I IFNs and inflammatory
cytokines is likely to vary significantly across time and cell types within the CNS.
In addition to suppressing inflamatory cytokine expression in our study, type I IFNs were
also shown to preserve BBB integrity via counterregulation of the BBB-disrupting effects of
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inflammatory stimuli. In vitro, induction of enhanced BBB permeability following treatment
with recombinant inflammatory cytokines could be reversed by subsequent addition of
recombinant IFN-β or WNV, the effect of which was shown to be type-I IFN-dependent (44).
This effect was mediated through preferential activation of cytoskeletal regulatory proteins, as
type I IFN signaling resulted in greater Rac1 activation and inhibition of RhoA activation by
inflammatory cytokines (Figure 1). These findings are corroborated by recent in vitro studies
demonstrating the protective effects of type I IFNs on peripheral vascular permeability following
DenV-2 infection (42, 65). In this report, TNF-α-induced vascular permeability was rescued
following recombinant IFN-β treatment or DenV-2 infection, the effect of which was also type I
IFN-dependent. DenV-2 and type I IFN-mediated enhancement of endothelial barrier integrity
was shown to occur via CD73, an enzyme richly expressed in endothelial cells that functions to
increase intracellular cAMP levels, which has been shown to promote endothelial barrier
function (66). Based on these findings, it is possible that viral induction of type I IFNs at the
BBB promotes barrier function via multiple cell-intrinsic signaling mechanisms.

Type III IFNs
The recently classified type III IFNs are comprised of three IFN-λ subtypes, each of
which signal through a receptor complex made up of the IFN-λ receptor (IFNLR1) and an
IL10Rβ subunit. In contrast to type I IFNs, the expression of type III IFNs are restricted to
primarily tissue barriers, including intestinal, airway, vaginal, and skin epithelia (67). Though
IFN-λ signals through similar mechanisms as type I IFNs, recent research has demonstrated that
IFN-λ plays essential, nonredundant antiviral functions in barrier epithelia in the context of
gastrointestinal infections (68-70). However, though the roles of IFN-λ at epithelial barriers
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during viral infections have been increasingly well characterized, it has remained unclear
whether IFN-λ also signals at endothelial barriers.
In a recent study by our group and others, we showed that IFNLR1 is expressed on
neurovascular cells, including BMECs and astrocytes (71). In the setting of WNV infection, IFNλ signalling at the BBB served to preserve BBB function by enhancing TJ integrity, thereby
limiting the neuroinvasive potential of WNV. This effect was observed in the absence of direct
antiviral effects of IFN-λ on neurons or other cells normally targeted by WNV. IFN-λ-mediated
effects on BBB function were also independent of protein synthesis and STAT1 activation. In
addition, Ifnlr1-/- exhibited normal adaptive immune responses following WNV infection, in
contrast to mice deficient in type I IFN signalling (41). Thus, though IFN-λ preserves BBB
integrity through similar mechanisms as type I IFN during WNV infection, the restriction of
IFNLR1 to tissue barriers and the specificity of IFN-λ signaling to effects on the BBB during
WNV infection make IFN-λ an exciting potential therepeutic option for neuroinvasive infections
and other diseases that involve breakdown of the BBB, including CNS autoimmunity.

Neurotropic viruses and BBB junctions
A key determinant of BBB function are the proper assembly of TJs and AJs between
BMECs. Neurotropic viral infections have been shown to alter junction protein expression and
function in several ways, including direct mechanisms via viral proteins and downstream
immune-mediated regulation of junction integrity. To date, the effects of retroviruses on BBB
junctions have been most extensively chacterized. Several retroviruses, including HIV-1, HTLV1, SIV, and FIV, have been shown to diminish expression of BBB TJ proteins in vitro and in vivo
(26, 72). Several key retroviral proteins, in particular, are known to induce endothelial cell
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activation and BBB breakdown. The HIV-1 protein Tat, a key retroviral transcriptional regulator,
has been shown in numerous studies to activate BBB endothelium, decrease TJ protein
expression, and degrade junctions via MMP-9 and RhoA-mediated cleavage of the TJ protein
occludin (72, 73). Similarly, the HIV-1 virion envelope protein gp120 has been shown to
enhance BBB permeability by decreasing expression of several TJ proteins, including claudin-5
(74) and Zo-1 (75), and by inducing proteosome-mediated degradation of Zo-1 and Zo-2 (76). In
addition to viral proteins, recent work suggests that elevated CCL2 levels during HIV-1 infection
also likely contribute to BBB breakdown and junction disruption via multiple mechanisms (72),
including disruption of AJs in brain endothelium via phophorylation and sequestration of βcatenin (77). Other studies have linked CCL2 to endothelial barrier disruption in the context of
MAV-1 (36) and DenV (78) infections, as well.
Aside from retroviruses, interest in the impact of flaviviruses on BBB junctions has also
received considerable attention in the literature, but with much less clear results. As others have
noted, the impact of WNV infection on BBB junction protein expression has been highly
variable in published reports, with conflicting findings among studies using different in vitro
methodologies, in vivo models, and those looking at mRNA vs. protein readouts (79). One
explanation for these discrepancies is that junction protein regulation downstream of WNV
infection may occur more indirectly through the action of inducible inflammatory mediators, as
opposed to directly via viral proteins. Thus, variations such as viral inoculum and experimental
timecourse may result in differential expression of cytokines, chemokines, MMPs, etc., resulting
in different expression profiles of TJ proteins (44, 80).
For example, in our recent study (44), we observed that inflammatory cytokine signaling
following WNV infection resulted in loss of TJ integrity as indicated by loss of Claudin-5 and
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Zo-1 colocalization in BMECs along intercellular borders. However, viral induction of type I
IFNs suppressed the effects of inflammatory cytokines on TJ organization. Moreover, triple
blockade of type I IFN, TNF, and IL-1 receptor signaling resulted in essentially no alteration to
TJ organization following BMEC exposure to WNV in vitro, indicating that these three innate
cytokines represent a cell-intrinsic regulatory axis by which BBB TJ integrity is regulated
following detection of WNV at the BBB. Expression of inflammatory mediators by other BBB
cell types is also likely to contribute to BBB disruption during flavivirus encephalitis, as was
demonstrated by a recent report showing that JEV-infected pericytes secrete IL-6, leading to
proteosomal degradation of Zo-1 in BMECs in BBB coculture systems (81). Indeed,
inflammatory cytokines and chemokine expression via multiple cellular sources has been linked
to suppression of BBB junction protein expression and degradation of existing junctions during
many viral infections, including studies using retroviruses (26, 72, 77), RabV-1 (35), MAV-1 (36)
and others.

Protective versus pathological outcomes of BBB disruption during viral infections
While enhancement of BBB permeability has traditionally been thought of as a hallmark
of neuropathology, recent research has expanded our appreciation of the nuanced and dynamic
nature of BBB function in the context of viral infections. While BBB disruption is a putative
mechanism by which many neurotropic viruses gain access to the CNS parenchyma, BBB
disruption is also necessary in some contexts to facilitate CNS immune trafficking and
subsequent viral clearance and recovery. However, even this protective function of BBB
breakdown can contribute to pathogenesis, as infected leukocytes may participate in viral
seeding of the CNS (the so-called “Trojan horse” method of neuroinvasion) and the antiviral
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activity of infiltrating cells can cause significant tissue injury within the CNS, a site with limited
capacity for repair. Thus, the physiological outcomes of BBB disruption during neurotropic viral
infections are multifaceted and are influenced by myriad viral and host factors.

BBB breakdown and CNS viral entry
While the methods by which most neurotropic viruses access the CNS remain poorly
understood, the trans- or paracellular trafficking of free virions across the disrupted BBB is
thought to be a major route of viral neuroinvasion. A growing body of studies using in vitro BBB
models have shown the ability of free viruses, including WNV and HIV-1, to traffic across BBB
endothelium and have shown that enhanced permeability and/or junction disruption is linked to
higher rates of viral migration in culture systems (44, 47, 82, 83). In the case of WNV infection,
BBB permeability has been shown to increase days before initial detection of virus within the
CNS in mouse models, likely as a result of circulating inflammatory mediators, and this early
increase in BBB permeability during high viremia has been linked to initial WNV neuroinvasion,
as abrogation of inflammatory signals that preserve BBB integrity also delay or prevent
neuroinvasion (43, 44, 84, 85). Despite this understanding, the precise route of entry for free
flaviviruses across the BBB is still poorly understood. While the transcellular trafficking of
WNV and JEV through BBB endothelium has been suggested in culture systems (83, 86), there
is little evidence that either virus enters or infects BMECs in vivo (79), though such events may
be so infrequent and/or stochastic that detection with traditional histological methods is difficult.
In our recent study, we showed that trafficking of WNV across in vitro BBB cultures could occur
independently of BMEC infection, and that trafficking of free virus was correlated closely with
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paracellular permeability (44). Thus, it is possible that free flaviviruses cross the BBB via both
trans- and paracellular routes.
Another potential mechanism of viral entry into the CNS invokes the “Trojan horse”
phenomenon. In this case, virus-infected peripheral immune cells cross the BBB, either due to
BBB damage or in the normal process of immune surveillance. Once there, they shed infectious
virions within the CNS parenchyma and perivascular spaces, establishing CNS infection. This
method of neuroinvasion is most frequently associated with retroviruses such as HIV-1, which
access the CNS via trafficking of infected CD4+ T cells and monocytes (26), a process enhanced
by HIV-1 mediated inflammatory signals that disrupt BBB function (59, 73, 74). The Trojan
horse mechanism may also be yet another means by which flaviviruses access the CNS, as
blockade or deletion of several immune trafficking molecules has been shown to inhibit BBB
disruption and neuroinvasive disease in mouse models of WNV infection (84, 85, 87).

The BBB and antiviral CNS immune trafficking
The regulation of CNS immune trafficking during viral infections is an incredibly
complex process, which, though it may expose the CNS to viral pathogens in some contexts, is
also often critical for effective antiviral immune responses within the CNS. Indeed, BBB
breakdown observed during many CNS infections is thought to primarily serve to facilitate
antiviral leukocyte trafficking. This is particularly true for viruses known to enter the CNS via
non-BBB routes, such as transneuronal trafficking by RabV and HCV (34, 35), resulting in
increased BBB permeability that is largely secondary to CNS infection. In the case of RabV
infection, recent studies have demonstrated that induction of BBB permeability is associated
with ameliorated disease pathogenesis and enhanced antiviral immunity within the CNS (35, 50).
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Even for viruses that may utilize BBB breakdown and/or immune trafficking to access
the CNS, these processes are often critical for effective virologic control and clearance. In the
case of WNV, even though the abrogation of some leukocyte trafficking molecules can inhibit
WNV neuroinvasion (84, 85, 87), multiple studies have shown that intact cellular immune
trafficking within the CNS is absolutely essential for survival and recovery from WNV
encephalitis (52, 53, 88, 89). Despite these findings, other reports have shown that immune cell
trafficking during WNV and other neuroinvasive infections is a significant source of CNS injury
(90, 91). Thus, host inflammatory responses must be carefully regulated, such that viruses are
effectively cleared without the induction of major immune pathology. This can be accomplished
in regulation of both the numbers and the activation state of antiviral leukocytes. As we have
recently shown, in the context of WNV infection, loss of proper IL-1 mediated T cell
reactivation at the BBB resulted in greatly enhanced immune infiltrates during WNV
encephalitis, but these cells were ineffective at viral clearance and, instead, contributed to
enhanced immunopathology and glial cell activation (54, 55). In contrast, prior work in our
laboratory demonstrated that blockade of CXCL12-mediated sequestration of virus-specific T
cells in perivascular spaces via pharmacological inhibition of CXCR4 resulted in enhanced
penetration of T-cells into the CNS parenchyma, where they both cleared virus and decreased
immunopathology (92). These findings and others illustrate the potential benefits of carefully
regulated disruption of normal BBB function during viral infections of the CNS, and provide
clues as to how these processes may be targeted for therapeutic interventions.
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Concluding Remarks
The notion that viruses interact with and are sensed by the BBB is a novel concept that
highlights evolutionary adaptations in mammals that limit CNS infection. The signaling
pathways that directly impact BBB permeability and function outlined here are just the
beginning of a new direction in infectious diseases research on neurotropic pathogens that
focuses on mechanisms of neurotropism and host responses critical for preventing neuroinvasion.
Most patients infected with the viruses discussed do not develop viral encephalitis, suggesting
that the innate immune mechanisms operative at the BBB normally succeed in preventing viral
entry into the CNS. These mechanisms are also likely to increase the stringency with which
leukocyte entry into the CNS is regulated, providing avenues to prevent neural injury by both
viruses and the ensuing inflammation triggered by CNS infections. Further studies are needed to
determine whether viruses alter BBB apicobasal polarity, leukocyte capture and transendothelial
cells migration, and to identify additional signals involved in BBB stability. Understanding the
impact of neurotropic viruses on BBB biology is a critical part of the neuropathogenesis of
disease in those patients that develop encephalitis and may lead to new targets to treat
immunopathology in both infectious and autoimmune diseases.
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1.4 Figures

Figure 1. Innate immune responses to viruses regulate BBB permeability. (a) Following
binding of nonself RNA ligands within the endosomal compartment, Toll-like receptor 3
(TLR3), TLR7 signal through their adaptor proteins, TRIF (TIR domain-containing adaptor
inducing IFNβ), and MYD88 (myeloid differentiation 88) to promote nuclear factor kappa B
(NF-κB)-, IRF3-, and IRF7-dependent gene expression, which leads to expression of Th1
cytokines, TNF-α, and pro-IL-1β, and IFN-β, respectively. (b) Type I IFN signaling through
IFNAR inhibits production of IL-1β and activates Rac1 GTPase. (c) Inflammasome activation in
response to viral infections results in cleavage of pro-interleukin-1β (pro-IL-1β) into the mature
IL-1β form. IL-1β is secreted from the cell and binds to IL-1 receptor (IL-1R), which signals
through MyD88 and activates RhoA GTPase. (d) Activation of Rac1 GTPase promotes BBB
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permeability via cytoskeletal rearrangements that assemble tight junction complexes that include
claudins, occludens, and zonular occluden family members. Rac1 also inhibits RhoA, which
promotes cytoskeletal rearrangements that disassemble tight junctions. Gray color indicates
pathways previously identified while colorization highlights newly identified effects of IFNAR
and IL-1R1.
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1.5 Tables
Reported	
  cases	
  of	
  major	
  neurotropic	
  arboviral	
  infection	
  in	
  the	
  U.S.	
  
Virus	
  
Nonneuroinvasive	
  
Neuroinvasive	
  
West	
  Nile	
  
	
  
	
  
2014	
  
823*	
  
1,262*	
  
2013	
  
1,202	
  
1,267	
  
2012	
  
2,801	
  
2,873	
  
2011	
  
226	
  
486	
  
La	
  Crosse	
  
	
  
	
  
2014	
  
-‐	
  
-‐	
  
2013	
  
8	
  
77	
  
2012	
  
7	
  
71	
  
2011	
  
14	
  
116	
  
Eastern	
  equine	
  
	
  
	
  
encephalitis	
  
	
  
	
  
2014	
  
-‐	
  
-‐	
  
2013	
  
0	
  
8	
  
2012	
  
0	
  
15	
  
2011	
  
0	
  
3	
  
Powassan	
  
	
  
	
  
2014	
  
-‐	
  
-‐	
  
2013	
  
3	
  
12	
  
2012	
  
0	
  
7	
  
2011	
  
4	
  
12	
  
-‐	
  Data	
  not	
  available	
  
*	
  Provisional	
  data,	
  subject	
  to	
  revisions	
  
Data:	
  Centers	
  for	
  Disease	
  Control	
  and	
  Prevention;	
  ArboNET	
  

Total	
  
	
  
2,085*	
  
2,469	
  
5,674	
  
712	
  
	
  
71*	
  
85	
  
78	
  
130	
  
	
  
	
  
8*	
  
8	
  
15	
  
3	
  
	
  
8*	
  
15	
  
7	
  
16	
  

Table 1. Reported cases of major neurotropic arboviral infection in the United States.
Data reported are aggregate reported case data for indicated years.
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Chapter 2
Immortalized human cerebral microvascular endothelial cells maintain the
properties of primary cells in an in vitro model of immune migration across
the blood-brain barrier

This chapter is adapted from the following publication:
Daniels BP, Cruz-Orengo L, Paseika TJ, Couraud PO, Romero IA, Weksler B, Cooper J,
Doering TL, and Klein RS. (2013) Immortalized human cerebral microvascular
endothelial cells maintain the properties of primary cells in an in vitro model of immune
migration across the blood brain barrier. Journal of Neuroscience Methods. 212(1): 17379.
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2.1 Introduction
Central nervous system (CNS) homeostasis is largely dependent on the presence of the
blood brain barrier (BBB), a highly specialized arrangement of vascular endothelial cells joined
by tight and adherens junctions, and associated with pericytes and astrocytic endfeet (3). This
complex endothelial barrier exerts tight regulation over solutes and cells in the systemic
circulation, restricting access to parenchymal CNS tissue. Importantly, the capacity of the BBB
to control immune cell entry into the CNS during episodes of inflammation is critical, both for
effective pathogen clearance during an infection and for protection from immunopathology
during injury and disease (93). Our group and others have demonstrated that immune-mediated
structural and functional changes to the BBB during disease can orchestrate both protective and
pathological physiological processes in the CNS (92, 94)
In vitro models of the BBB are a powerful tool for specific mechanistic studies of BBB
physiology (95). Most commonly, these models consist of transwell culture systems in which
brain microvascular endothelial cells (BMECs) are grown on a porous filter membrane, and the
integrity of the in vitro barrier is assessed by measurements of transendothelial electrical
resistance (TEER) or the diffusive capacity of fluorescently labeled solutes. While such models
have traditionally been composed of endothelial cells derived from animal origins, the growing
availability of both primary and immortalized human endothelial cells and astrocytes promises to
further increase the usefulness of in vitro BBB models in basic and clinical investigations (96,
97).
In particular, the development of the immortalized human cerebral microvascular
endothelial cell line HCMEC/D3 (98) represents a significant advance for in vitro BBB models.
This well characterized cell line maintains fundamental properties of primary human BMECs
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(HBMECs), including tight junction/transporter protein expression and contact growth inhibition,
for up to 35 passages. While studies using primary HBMECs are typically costly and lowthroughput due to the scarcity of these cells and the challenges of isolating them from fresh
tissue (discussed in Naik and Cucullo 2012), the HCMEC/D3 cell line allows much more
efficient and high-throughput in vitro investigations of the human BBB. However, while several
reports have asserted that this cell line preserves the properties of primary HBMECs in various
experimental systems, there have been few direct experimental comparisons of HCMEC/D3 to
primary HBMECs.
Here, we report that in vitro BBBs generated using HCMEC/D3 exhibit remarkable
similarity to those constructed with primary cells in a model of trans-BBB immune migration.
Using this experimental system, we were able to observe key BBB features, such as increased
barrier integrity after coculture of endothelial cells with astrocytes, dysregulation of barrier
integrity after inflammatory cytokine treatment, and enhanced trafficking of primary human T
lymphocytes after stimulation of total peripheral blood mononuclear cells (PBMCs) with the
standard experimental leukocyte stimulators phorbol myristate acetate (PMA) and ionomycin.
Importantly, both primary HBMECs and HCMEC/D3 exhibited statistically indistinguishable
responses to every experimental manipulation, both in terms of changes to barrier properties and
differential leukocyte migration. This report is the first to validate that in vitro BBBs created
with the HCMEC/D3 cell line can reproduce the barrier phenotype of primary HBMECs for in
vitro investigations of immune migration across the BBB. While a growing list of studies have
characterized HCMEC/D3 in various experimental systems, our report is the first extensive
validation of the HCMEC/D3 cell line in a neuroimmunological setting and the first to explicitly
demonstrate that in vitro BBBs generated with HCMEC/D3 maintain interaction effects between
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experimentally relevant neurobiological and immunological manipulations, including astrocyte
coculture, leukocyte stimulation, and inflammatory cytokine treatment. In light of this validation,
the significant advantages of using an immortalized cell line for BBB investigations in vitro
promises to enhance the usefulness of transmigration experiments for addressing important
neuroimmunological questions.
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2.2 Results
HCMEC/D3 barrier formation is similar to that of primary HBMECs
To compare in vitro BBBs composed of either HCMEC/D3 or primary HBMECs alone,
we first tested them in the absence of astrocytes. BBBs of the two cell types exhibited extremely
similar barrier formation kinetics (Figure 1B, solid and dashed black lines). Strikingly, barrier
resistance was indistinguishable between the primary and immortalized cells for days 3-10 of
culture (p>0.05), with only day 2 showing a significant difference between them (p<0.05). For
both cell types, astrocyte coculture yielded more robust in vitro barriers (Figure 1B, solid and
dashed red lines), characterized by higher TEER values (p<0.001) and exhibiting statistically
indistinguishable TEER values over each of the 10 days of culture (p>0.05). Comparisons of
mean area under the curve (Figure 1C) for cultures with and without astrocytes revealed nearly
identical values for primary and cell line cultures in both conditions (p=0.3644 and 0.0822,
respectively).

Astrocyte coculture and PMA/ionomycin stimulation impact PBMC trafficking across in
vitro BBBs
Flow cytometric analysis revealed that several leukocyte subsets migrated across the in
vitro BBB after their addition to the top culture chamber, and that PMA/ionomycin stimulation
of PBMCs affected both leukocyte migration and endothelial barrier integrity. Transmigration of
unstimulated PBMCs did not impact barrier resistance in cultures with or without astrocytes
(Figure 2A). However, prior stimulation of PBMCs resulted in a significant reduction in
endothelial barrier resistance after 12h (p<0.001). This decrease in resistance was further
augmented in barriers cocultured with astrocytes (p<0.001; interaction effect: p<0.05).
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PMA/ionomycin stimulation also significantly enhanced the migration of CD4+ (Figure 2B) and
CD8+ (Figure 2C) T-lymphocytes (p<0.01, <0.001, respectively), regardless of whether
astrocytes were present (interaction effect: p>.05).
In contrast to results observed with T lymphocytes, the presence of astrocytes had a
significant interaction effect with PMA/ionomycin stimulation on the migration of both CD11b+
(Figure 2D) and CD19+ (Figure 2E) leukocyte subsets. Astrocytes significantly enhanced the
migration of CD11b+ cells when PBMCs were unstimulated (p<0.05), but exerted no effect on
the migration of CD11b+ cells when PBMCs were stimulated (p>0.05; interaction effect: p<0.05).
Astrocytes similarly enhanced the migration of CD19+ cells when PBMCs were unstimulated
(p<0.05), but decreased the migration of those cells when PBMCs were stimulated (p<0.05;
interaction effect: p<0.05). Neither astrocyte coculture nor PBMC stimulation had a significant
effect on the migration of CD11c+ (Figure 2F) cells (p>0.05 for all comparisons).

HCMEC/D3 maintains the immune barrier properties of primary HBMECs
Although stimulation of PBMCs and coculture with astrocytes had significant effects on
both PBMC migration and TEER changes after leukocyte trafficking across the in vitro BBB,
our results indicate that the HCMEC/D3 cell line maintains the properties of primary HBMECs
in this system. For every culture condition (with/without astrocytes, stimulated/unstimulated
PBMCs), there were no significant differences in migration between cultures with HCMEC/D3
and primary HBMECs for any of the leukocyte subsets analyzed (p>0.05 for all comparisons).
Moreover, while stimulation of PBMCs and coculture with astrocytes significantly affected the
change in TEER occurring after PBMC migration (effect of astrocytes: p<0.05; effect of
stimulation: p<0.001; interaction effect: p>0.05), these changes were also virtually identical
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between HCMEC/D3 and primary HBMEC cultures (p>0.05 for all comparisons).

Inflammatory cytokine production and regulation of barrier integrity is comparable in
HCMEC/D3 vs HBMEC cultures
In order to assess characteristics of the inflammatory response in our model, we measured
inflammatory cytokine production in both the top (luminal) and bottom bottom (abluminal)
chamber of each BBB culture after 12h of PBMC migration via cytokine bead array detection of
IL-1β, IL-17, TNF- α, and IFN-γ (Figure 3). Stimulation of PBMCs significantly enhanced
expression of each of these cytokines in both luminal and abluminal chambers (p<.001 for both).
In addition, coculture with astrocytes suppressed upregulation of IL-1β in both chambers (Figure
3A-B, p<0.01 for both), whether or not PBMCs were stimulated (interaction effect: p>0.05).
Astrocyte coculture suppressed TNF- α expression in both chambers if PBMCs were
unstimulated (Figure 3G-H, p<.01 for both), but had no effect when PBMCs were stimulated
(p>0.05; interaction effect: p<0.05). Although astrocyte coculture and PBMC stimulation
significantly regulated the production of inflammatory cytokines, each of these changes was
identical between HCMEC/D3 and primary HBMEC cultures. Moreover, the presence of an
endothelial barrier was necessary to elicit the inflammatory cytokine responses we observed, as
measurements of media in transwell systems with no endothelial cells or astrocytes (only
PBMCs added to empty filter inserts) revealed cytokine levels that were largely below limits of
detection (data not shown).
In light of these findings, we next evaluated the impact of inflammatory cytokine
expression on endothelial barrier integrity. Treatment with either IFN-γ or TNF- α (100ng/ml, 6h)
resulted in barrier disruption (Figure 4A), indicated by significant reductions in TEER (p<.001
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for both). Moreover, astrocyte coculture enhanced barrier disruption by TNF- α (p<.01) but not
IFN-γ (p>.05). Ultimately, while inflammatory cytokine treatment resulted in substantial
decreases in TEER, this effect was equivalent in HCMEC/D3 and primary HBMEC cultures
(p>0.05 for all comparisons).
In order to further compare inflammatory cytokine regulation of barrier integrity in both
endothelial cell types, we performed fluorescent immunocytochemical staining for the adherens
junction marker VE-cadherin in either HCMEC/D3 or primary HBMEC monolayers. Both
HCMEC/D3 and primary HMBEC cells exhibited similar fluorescence intensities for VEcadherin, characterized by discrete localization of VE-cadherin to intercellular borders where
adherens junctions form between adjacent endothelial cells and contribute to proper barrier
function (Figure 4B). TNF- α, but not IFN-γ, treatment (100ng/ml, 6h) substantially reduced the
staining intensity of VE-cadherin in both cell types, suggesting that inflammatory cytokine
regulation of molecular barrier properties is similar in HCMEC/D3 and primary HBMEC
cultures.
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2.3 Discussion
We report that the immortalized HCMEC/D3 cell line can be used to construct in vitro
BBBs for use in immune-CNS transmigration experiments. In terms of barrier formation kinetics,
immune migration profiles, and inflammatory cytokine responses, HCMEC/D3 maintained all
properties of primary HBMECs, demonstrating that the HCMEC/D3 cell line will be useful for
less expensive and higher-throughput studies of immune migration across the BBB. Although the
utility of HCMEC/D3 for investigations of drug transport across the BBB has been established
(97, 99), there are a number of important experimental systems, including neuroimmunological
and neuroinfectious disease models, for which the usefulness of HCMEC/D3 has not yet been
thoroughly addressed. While the effects of astrocyte coculture and leukocyte migration in
HCMEC/D3 BBBs have been addressed separately in previous reports, our report additionally
performs direct comparisons of HCMEC/D3 to primary HBMECs in these systems in order to
validate the fidelity of this cell line to primary cells. Moreover, our report is the first to
demonstrate

that

interaction

effects

between

immunologically

relevant

experimental

manipulations (astrocytes, leukocyte stimulation, cytokine treatment) are preserved in
HCMEC/D3, as prior reports have primarily investigated these facets of the model in isolation.
Such comparisons are critical to ensure that investigations using HCMEC/D3 produce results
that actually model the behavior of primary cells in a given experimental system.
The fidelity of HCMEC/D3 to primary HBMECs was evident across a number of
parameters in this study, including both the magnitude and time course of their responsiveness to
astrocyte coculture (Figure 1B). Prior reports have demonstrated that coculture with astrocytes
enhances the barrier integrity of endothelial monolayers in transwell cultures (96, 100, 101). Our
data support this observation, with equivalent results from HCMEC/D3 and primary HBMECs. It
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should be noted, however, that previous reports on permeability and the responsiveness of
HCMEC/D3 to astrocytes have been mixed. While we report TEER values of >1000 ohm/cm2,
TEER values for HCMEC/D3 have varied in previous reports, with reported TEER values of
between ~30-65 ohm/cm2 (96, 98) in static transwell cultures, and TEER values of >1000
ohm/cm2 in “dynamic,” flow-based BBB models in which HCMEC/D3 are grown in the lumen
of hollow microporous fibers and exposed to shear stress from pulsatile flow of culture media.
Additionally, while Weksler et al. (2005) and Cucullo et al. (2008) reported that HCMEC/D3
were relatively unresponsive to stimulation by astrocytes, Hatherell et al. (2011) observed a
significant increase in TEER values of HCMEC/D3 cocultured with several human astrocyte cell
lines (although primary HBMECs were not included in this analysis).
Variations in TEER and responsiveness to astrocytes among reports using static transwell
cultures may arise from a number of experimental factors, including media formulation,
type/condition of astrocytes, and the porosity and coating substrate of the transwell filters used.
For example, Hatherell et al. (2011) used fibronectin coated filters with 8 µm porosity, while our
study utilizes collagen I coated filters with 3 µm porosity. The timing of measurements is likely
also important, as Weksler et al. (2005) report TEER values after only 2 days of culture, while
our maximum TEER values were observed on ~day 10 after culture. The substantially higher
TEER values obtained by Cucullo et al. (2008) arise from the incorporation of physiological
sheer stress and dynamic flow into the BBB culture system; however, while these dynamic flow
systems have obvious and important advantages, they also pose significant technical and
logistical challenges when compared to static transwell models, which are less expensive, easier
to manipulate and maintain, and allow for much higher throughput investigations of relatively
simple experimental manipulations (Naik and Cucullo 2012), which is the focus of this report.
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While each of these distinctions may be important depending on the experimental system one
uses, our data suggest that TEER values, alone, do not substantially influence leukocyte
migration, as many leukocyte subsets had identical migration through barriers with and without
astrocyte coculture (which had significant differences in TEER).
In addition to comparing effects on permeability, we have further demonstrated that
HCMEC/D3 maintains the properties of primary HBMECs in the context of immune migration.
Like primary cells, HCMEC/D3 allowed the migration of unstimulated leukocytes without a
significant reduction in TEER (Figure 2A). However, the addition of PBMCs stimulated with
PMA/ionomycin significantly reduced barrier resistance, most likely as a result of the production
of large concentrations of inflammatory cytokines (Figure 3), which have been shown to enhance
BBB permeability (102). In addition, enhanced migration of stimulated leukocytes may result in
physical disruption of the endothelial barrier, with a resultant reduction in TEER. While
stimulation enhanced the migration of T-lymphocytes (Figs. 2B and 2C), it seemed to decrease
the migration of CD11b+ (Figure 2D) and CD19+ (Figure 2E) leukocytes, an effect modulated by
the presence of astrocytes in culture. Remarkably, each of these findings in BBBs generated with
primary HBMECs was preserved in those constructed with HCMEC/D3.

Moreover, the

production of inflammatory cytokines by PBMCs during transmigration (Figure 3) and the
effects of inflammatory cytokine treatment on TEER and VE-cadherin expression were
indistinguishable in cultures of both cell types (Figure 4). Together, these data demonstrate that
the mechanisms that regulate immune cell transmigration across the vascular endothelium at the
BBB are preserved in the HCMEC/D3 cell line in this in vitro system. In particular, the novel
findings demonstrating that interaction effects between astrocyte coculture and PBMC
stimulation/inflammatory cytokine treatment are preserved in HCMEC/D3 in this system are
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strong indication that important interactions between immune and resident CNS cells exist in the
setting of the in vitro BBB, and that these more nuanced neuroimmunological phenomena are
equally well-modeled by HCMEC/D3 and primary cells.
Key studies have used an in vitro BBB model to study immune migration across the BBB
during inflammatory episodes in the CNS (103, 104). Unfortunately, the significant experimental
challenges presented by working with primary HBMECs (105) limit the application of this
powerful experimental tool. Here, we report that immortalized HCMEC/D3 maintain the
properties of primary HBMECs in an in vitro model of trans-BBB immune migration. Using this
cell line in model BBBs will significantly increase the feasibility of investigating important
neuroimmunological processes, including inflammation during CNS autoimmunity or infectious
disease.
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2.4 Materials and methods
Cell culture
In vitro human BBB cultures were generated using either primary HBMECs or
HCMEC/D3, cultured alone or cocultured with primary human astrocytes. HBMECs and
primary human astrocytes were obtained from ScienCell (Carlsbad, CA). HBMECs available
from ScienCell have been broadly characterized by groups performing in vitro BBB
investigations in a number of experimental systems (106-108), including immune transmigration
(109), and have been specifically shown to form more robust barriers and develop specific BBB
characteristics in culture when compared to non-CNS endothelial cells (Cucullo et al. 2008).
HCMEC/D3, first described by Weksler et al. (2005), is a human brain endothelial cell line,
immortalized with human telomerase reverse transcriptase and Simian vacuolating virus 40
(hTERT/SV40) large T antigen. All cells were grown in endothelial basal medium-2 (EBM-2;
Lonza Group, Ltd.), supplemented with 5% Fetal Bovine Serum “Gold” (PAA, The Cell Culture
Company), 5µg/ml ascorbic acid (Sigma), 1% chemically defined lipid concentrate (Invitrogen,
Gibco), 10mM HEPES buffer (PAA, The Cell Culture Company), and 1% penicillinstreptomycin (Invitrogen, Gibco). HCMEC/D3 cells were used between passages 25 and 35,
while primary endothelial cells and primary astrocytes were used only in their second passage.
All cells were maintained under 5% carbon dioxide at 37°C.

In vitro BBBs
In vitro BBBs were generated using a well-established transwell system (schematized in
Figure 1A). Briefly, HCMEC/D3 or primary HBMECs were seeded at 1x105 cells/cm2 on the
apical side of a 0.9 cm2 polyethylene terephthalate filter insert with 3.0 µm porosity (BD Falcon),
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coated with 150 µg/ml Cultrex® Rat Collagen I (R&D Systems). For coculture chambers, 105
primary human astrocytes were seeded in 12-well plates and cultured for 2 days (to reach
confluence) prior to addition of the endothelial cell inserts. TEER values (ohm/cm2) were
measured via chopstick electrode recording with an EVOM apparatus (World Precision
Instruments). Resistance values are reported as recorded values for each replicate minus the
resistance of cell-free inserts (~90 ohm) measured alone. Measurements were taken 24 hours
after initial seeding of endothelial cells (day 1); subsequent measurements were taken daily for
10 days, at which point cultures were used for PBMC migration studies.

Isolation and stimulation of primary human PBMCs
Fresh whole blood was taken from healthy volunteers and PBMCs were isolated by
density centrifugation in 10 ml of Histopaque 1077 over 10 ml of Histopaque 1119 (Sigma) at
700g (4°C) for 30 min. Buffy coats were then rinsed, once in 45 ml of sterile Dulbecco’s
phosphate buffered saline (DPBS, Sigma) and twice more in C5 media (1% glutamine, 1%
penicillin-streptomycin, 5% FBS in Dulbecco’s Modified Eagle Medium [Sigma]; 10 min at
250g [4°C] between rinses). After the final rinse, PBMCs were resuspended at 2 X 106 cells/ml
in C5 media and then treated for 6h at 37°C with either stimulation media (5ng/ml PMA [Sigma]
and 1ug/ml ionomycin [Sigma] in C5 media) or a matched non-stimulating vehicle (0.1% DMSO
in C5 media).

Migration Assay
After stimulation, 5x105 PBMC’s in 200ul of C5 media were added to the top chamber of
each in vitro BBB (~ 5:1 ratio, PBMC to endothelial cell) and allowed to incubate for 12h at
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37°C. Medium was then harvested from top and bottom chambers and PBMCs in each fraction
were collected by centrifugation (1500, 10 min, 4°C). Cell pellets were next resuspended in
200ul of FACS buffer (2% FBS, 0.5mM EDTA, 0.02% sodium azide in sterile DPBS), and
leukocyte subsets were identified and counted with an LSRII (BD) flow cytometer using FCS
Express™ Diva 4.0 from De Novo Software™. Data were analyzed with FlowJo™: version 9
(Tree Star, Inc.). The following antibodies were utilized to identify leukocyte subsets: CD3-FITC
(BD), CD4-Brilliant Violet (Biolegend), CD8-PerCP-Cy5.5 (Biolegend), CD19-APC-Cy7
(Biolegend), CD11b-PE (BD), CD11c-PE-Cy5 (Biolegend), and GFAP-Alexa 647 (BD).
Leukocytes isolated from the bottom chamber were counted after prior gating for live cells and
GFAP- cells (in case of contamination from astrocytes in the bottom chamber). CD4+ and CD8+
lymphocytes were counted after prior gating for CD3+ cells. For each leukocyte subset, migration
was quantified as the number of cells present in the bottom chamber after 12h divided by the
total number of that cell type added to the top chamber (proportion migrating).

Cytokine analysis
Supernatants from both top and bottom chambers were saved after the collection of
PBMCs at 12h in the migration experiments. Samples from both chambers of each culture
replicate were added to separate wells of a BioPlex™ human cytokine bead array plate (Biorad)
customized to detect IL-1β, IL-17, TNF- α, and IFN-γ. Assay was performed according to
manufacturers instructions. Cytokine concentrations are reported as pg/ml.

Cytokine treatment assays
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On day 10 of culture, either TNF- α or IFN-γ (100ng/ml) was added to both chambers of
in vitro BBB cultures. TEER values were recorded both before and 6h after addition of cytokine
to culture media. TEER changes after cytokine treatment are expressed as % change at 6h.
Alternatively, 5x104 cells of either primary HBMEC or HCMEC/D3 were seeded into 8-well
BioCoat™ chamber slides (BD), coated with human fibronectin (by manufacturer). Chamber
slides were additionally coated with 150 µg/ml Cultrex® Rat Collagen I (R&D Systems). On day
2-3 of culture, when cultures were confluent, cells were treated with either TNF- α or IFN-γ
(100ng/ml) for 6 h. Cells were then fixed in 4% paraformaldehyde for 30 min, followed by
blocking and permeabilization in 0.1% Triton X-100 and 10% goat serum for 30 min at room
temperature. Cells were then incubated in primary antibody (mouse anti-human CD144/VEcadherin, BD, 1:200) in blocking buffer for 1h at room temperature. Cells were then washed
three times in PBS, followed by incubation in fluorescently conjugated goat anti–mouse Alexa
Fluor 555 (Invitrogen, 1:1000) secondary antibody in blocking buffer for 15 min at room
temperature. Cells were then washed in PBS, counterstained with ToPro3 (1:500), and
coverslipped before being visualized via scanning confocal microscopy.

Statistical Analysis
TEER measurements were compared via repeated measures two-way ANOVA.
Bonferroni’s posthoc test was used to compare individual time points. Area under the curve
statistics (AUC) were calculated individually for each experimental replicate, then averaged to
generate a mean AUC. AUCs were compared with a two-tailed student’s t-test. Migration and
cytokine response statistics were compared via two-way ANOVA (non-repeated measures) and
individual groups were compared via Bonferroni’s posthoc test. For all graphs, error bars

43

represent +/- 1 standard error of the mean. For TEER measurements (Figures 1B and 1C), data
are the average of 3 independent experiments (n=15, total for each group of HCMEC/D3; n=9,
total for each group of HBMECs). For migration results (Figure 2) and cytokine responses
(Figures 3 and 4) data are the average of 2 independent experiments (n=6 per group). All
statistical analysis was performed with GraphPad Prism software, version 5.0. P values <0.05
were considered significant for all comparisons.
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2.6 Figures

Figure 1: HCMEC/D3 maintain the barrier formation characteristics of primary HBMECs
as assessed by measurement of transendothelial electrical resistance (TEER). (A) Schematic
depiction of in vitro BBBs; see text for details. (B) HCMEC/D3 exhibited virtually identical
TEER values for each day of culture in both monoculture and astrocyte coculture systems
(p>0.05). (C) Area under the curve (AUC) analysis revealed no significant difference in overall
barrier formation kinetics between HCMEC/D3 and HBMEC cultures, with or without astrocyte
coculture. Data are mean values of 15 (HCMEC/D3) or 9 (HMBEC) replicates +/- SEM, taken
from 3 independent experiments.
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Figure 2: Leukocyte migration patterns are preserved for in vitro BBBs constructed with
HCMEC/D3 compared to primary HBMECs. Stimulated (PMA/ionomycin) or unstimulated
primary human PBMCs were used in model BBB transmigration assays as described in the text.
TEER values were recorded before and after transmigration experiments (reported as percent
change) and cells that migrated to the bottom chamber were identified via flow cytometry
(reported as the proportion of total cells added to top chamber). (A) Only stimulated PBMCs
caused a change in barrier resistance; this response was identical for barriers composed of
HCMEC/D3 and HBMEC. (B – F) The migration of (B) CD4+, (C) CD8+, (D) CD11b+, (E)
CD19+, and (F) CD11c+ leukocytes was statistically indistinguishable (p>.05) between cultures
of HCMEC/D3 (patterned bars) and HBMEC (open bars). These barriers influenced migration
identically in every condition tested, including those where significant differences were induced
by PBMC stimulation (B, C) or the presence of astrocytes (D, E). (*=p<.05; **=p<.01;
***=p<.001). Data are mean values +/- SEM of 6 replicates taken from 2 independent
experiments.
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Figure 3: Inflammatory cytokine production is similar for in vitro BBBs constructed with
HCMEC/D3 compared to primary HBMECs. At the end of the 12h PBMC migration
experiments, supernatants in both luminal (top) and abluminal (bottom) chambers of each BBB
culture were examined for the presence of inflammatory cytokines via BioPlex™ human
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cytokine bead array. The expression of (A-B) IL-1β, (C-D) IL-17, (E-F) IFN-γ, and (G-H) TNFα was statistically indistinguishable (p>.05) between cultures of HCMEC/D3 (patterned bars)
and HBMEC (open bars). In both luminal and abluminal chambers, significant changes to
cytokine expression due to PBMC stimulation (A-H, p<0.001) or astrocyte coculture (A-B; G-H,
p<.01) were similar in HCMEC/D3 and HBMEC cultures. (*=p<.05; **=p<.01; ***=p<.001).
Data are mean values of 6 replicates +/- SEM taken from 2 independent experiments.
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Figure 4: Barrier responses to inflammatory cytokine treatment are similar in HCMEC/D3
compared to HBMEC cultures. (A) BBB cultures of both cell types were treated for 6h with
either 100ng/ml IFN-γ, TNF- α, or a PBS vehicle. TEER values were taken before and after
cytokine treatment (reported as percent change). Both IFN-γ and TNF- α significantly reduced
TEER in BBB cultures (p<0.001), while astrocyte coculture enhanced the effect of TNF- α
treated cultures only (p<0.01). These effects were statistically indistinguishable between
HCMEC/D3 and HBMEC cultures (p>0.05). (B) Confluent monolayers of either HBMEC or
HCMEC/D3 were treated for 6h with either 100ng/ml IFN-γ, TNF- α, or a PBS vehicle, then
probed via immunocytochemistry for expression of VE-cadherin.

Both HBMEC and

HCMEC/D3 exhibited discrete staining of VE-cadherin at intercellular junctions, which was
diminished by TNF- α but not IFN-γ treatment. (*=p<.05; **=p<.01; ***=p<.001). TEER data
are mean values +/- SEM of 6 replicates taken from 2 independent experiments.
Immunocytochemistry pictures are representative 63x images of 6 images taken per condition
from 2 independent experiments. IC= isotope control.
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Chapter 3
Enhanced sphingosine-1-phosphate receptor 2 expression underlies female
CNS autoimmunity susceptibility

This chapter is adapted from the following publication:
Cruz-Orengo L*, Daniels BP*, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE,
Piccio L, Schmidt RE, Cross AH, Crosby SD, and Klein RS. (2014) Enhanced
sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity
susceptibility. Journal of Clinical Investigation. 124(6): 2571-84. (*Equal Contribution)
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3.1 Introduction
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the CNS that has a
strong sex bias, with the female to male ratio currently from 3 to 4:1 (110-112). Relapsingremitting (RR) MS, the most common form of the disease in women and men, is a condition in
which recurrent relapses of new neurological dysfunction (relapses) are separated by periods of
clinical stability. The mechanisms underlying sex differences in MS and whether they
predominantly affect immune responses, CNS susceptibility to inflammation, or both, are unclear.
Experimental autoimmune encephalomyelitis (EAE) in the inbred SJL mouse strain is
commonly used to model the sexual dimorphism observed in MS. Female SJL mice exhibit
increased sensitivity to EAE and a relapsing-remitting phenotype, while male SJL mice exhibit
monophasic disease resembling EAE induced in both sexes of other mouse strains, such as
C57BL/6. Gonadal hormones and epigenetic regulation of sex chromosomes are postulated to
contribute to sex differences in SJL mice during EAE and other autoimmune disorders (113,
114). Several studies also indicate that the CNS itself may be responsible for the observed sex
differences in disease expression, primarily via alterations in endothelial cell-mediated regulation
of immune cell entry (115-118).
Studies of endothelium in peripheral organs implicate cadherins and sphingosine 1phosphate (S1P) signaling in mediating alterations in cadherin-dependent barrier properties
between endothelial cells (119). Cadherins are plasma membrane proteins associated with
adherens junctions (AJs) whose expression at cell-cell contacts depends on endocytic transport
(120-122). Vascular endothelial (VE)-cadherin expression is required for CNS endothelial
polarity and vascular lumen organization (123), and cytokine-mediated alterations in VEcadherin expression in CNS endothelium influence leukocyte entry (124, 125). S1P, a bioactive
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metabolite of sphingolipids, is produced by erythrocytes in the plasma, vascular and lymphatic
endothelial cells, and neuronal lineage cells within the CNS (126-128). S1P signals via five G
protein-coupled receptors (S1PRs) to regulate various physiological responses including vascular
permeability (129-131). Endothelia express different combinations of S1P receptors (S1PRs),
which regulate endothelial cell survival, migration, AJ assembly, and barrier integrity (129, 130,
132). S1PRs have received considerable attention in the MS field due to recent success with the
broad S1PR inhibitor, Fingolimod, (FTY720-phosphate) which binds to S1PR subtypes S1PR1,
S1PR3, S1PR4 and S1PR5, but not S1PR2 (133), and inhibits vascular endothelial cell growth
factor (VEGF)-induced vascular permeability in vivo (131). Several in vivo studies demonstrate
roles for S1PR2 in vascular biology, including regulation of portal vein pressure (134), the
formation of atherosclerotic plaques (135), inflammation (136) and retinal angiogenesis (137). In
vitro studies implicate S1PR2 in the regulation of vascular integrity via phosphorylation of VEcadherin, preventing its translocation to cell-cell contact sites (138). The expression or function
of S1PR2 at endothelial barriers within the CNS or during induction of CNS autoimmunity has
not been investigated.
Here we identify a sexually dimorphic target for the treatment of relapsing-remitting CNS
autoimmunity. Microarray analysis of specimens from naïve male and female adult SJL mice
revealed a significant increase in the expression of S1PR2 in disease-susceptible CNS regions
only in females. Expression and activity of S1PR2 was associated with decreased VE-cadherin at
AJs and reversal of endothelial cell polarity, as assessed by movement of the abluminal
chemokine CXCL12 (94, 139, 140) to lumenal locations. Naïve female SJL mice exhibited
relocation of CXCL12 along venule lumena exclusively in white matter compared with naïve
male SJL mice and both sexes of other murine strains. S1PR2-deficient mice and female, but not
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male, SJL mice treated with the S1PR2 antagonist, JTE-013, each exhibited decreased disease
severity during EAE induced by active immunization with myelin peptide, accompanied by
diminished lymphocyte entry, persistent abluminal expression of CXCL12, and decreased BBB
permeability to fluorescein. S1PR2 appears to play an essential role in regulating CNS
endothelial polarity, which influences lumenal localizing cues and capture of infiltrating
lymphocytes.
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3.2 Results
Whole transcriptome analysis of sexually dimorphic genes detects elevated S1PR2 in
disease-susceptible CNS regions in naïve female SJL mice.
The inbred SJL mouse strain has been used as a model of the sexual dimorphism
observed in MS, as SJL females are more susceptible to EAE than males and exhibit a relapsingremitting disease pattern similar to that observed in MS patients (141). We hypothesized that
sexual dimorphism in this MS model arises from sexually dimorphic and CNS-region specific
expression of genes that regulate BBB permeability and leukocyte entry. Thus, we used a wholetranscriptome microarray to identify sexually dimorphic RNA transcripts that are differentially
expressed in disease-susceptible versus nonsusceptible CNS regions of male and female SJL
mice. Profiling total RNA from the cerebella and frontal cortices of naïve female versus male
SJL mice revealed differential expression of 44 and 23 gene transcripts, respectively, with 20
being unique to the cerebellum (Table S1). Fifteen of these uncharacterized loci are linked to the
Y chromosome, and one is autosomal. The three loci that were dimorphic in both cortex and
cerebellum are linked to the X or Y chromosomes, including Xist, which regulates Xchromosome inactivation (Table S1). Of the four novel autosomal loci that were unique to the
cerebellum, two were of interest for autoimmune disease: the IL-20 receptor b, a receptor
associated with skin autoimmune diseases (142-145) and sphingosine phosophate receptor 2
(S1PR2), which regulates vascular permeability in peripheral organs (138, 146, 147) (Figure 1A).
Because S1PR2 belongs to a family of G protein-coupled receptors expressed by cells of the
vascular, immune, and nervous systems and S1PR2 signaling, in particular, disrupts endothelial
AJs, we focused our studies in CNS autoimmunity on this protein (138). QPCR evaluation of
sexually dimorphic expression of S1PR2 in cerebella of SJL mice validated microarray results
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(P=0.0255) (Figure 1B). Western blot analysis confirmed microarray and QPCR data, revealing
significantly enhanced expression of S1PR2 in the cerebellum of naïve female SJL compared to
males (P<0.05), while no sexual dimorphism was observed in naïve C57BL/6 mice (Figure 1C)
and whole brain extracts from S1PR2-deficient mice confirmed antibody specificity (Figure
S1A). Of interest, Western blot examination of S1PR2 levels within the cerebella of naïve SJLChr YB10.S male mice compared with SJL male and female mice did not suggest that a Ychromosome polymorphism (148) is responsible for sexually dimorphic S1PR2 expression in the
CNS of SJL mice (Figure S2).
Because S1PR2 has known roles in vascular biology, we assessed disruption of the BBB,
via administration of sodium fluorescein to naïve male and female animals of both B6 and SJL
backgrounds. Consistent with increased S1PR2 expression in the cerebellum of naïve female SJL
animals, fluorescein permeability was significantly increased in the cerebellum of naïve female
SJL compared to males (P<0.01) (Figure 1D). Similar to wild-type B6 mice, S1PR2-deficient
mice and their wild-type controls, which are both on a 129S/B6 background, do not exhibit
sexual dimorphism and deficiency of S1PR2 does not alter BBB permeability in naïve animals
(Figure S1B). Immunohistochemical detection of extravasated albumen in CNS white matter of
naïve SJL mice also exhibited sexual dimorphism (Figure 1E). Of note, sexual dimorphism in
S1PR2 expression and vascular permeability was not observed in the spinal cord, which is a
disease susceptible CNS region in SJL mice. Alterations in levels of claudin 5, as assessed by
Western blotting, however, did not exhibit sexual dimorphism in naïve B6 or SJL mice (Figure
S3). IHC analysis of cellular sources of S1PR2 in the CNS of naïve female and male SJL mice
revealed localization mostly along endothelial cells with some astrocytes and pericytes as
additional sources (Figure 2).
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Female SJL and humans exhibit increased vascular S1PR2 during CNS autoimmunity.
To assess sexually dimorphic alterations in blood-brain barrier permeability during CNS
autoimmunity, we administered sodium fluorescein to male and female animals of both B6 and
SJL backgrounds after induction of EAE via immunization with appropriate myelin peptides.
During the course of EAE, fluorescein permeability increased in all CNS regions in both sexes
and strains, with significantly higher permeability in female SJL compared to male SJL at peak
of disease and during remission in cortex (peak: P<0.05; remission: P<0.05) and cerebellum
(peak: P<0.05 and remission: P<0.001) (Figure 3A). Expression of S1PR2 was also sexually
dimorphic during EAE, as S1PR2 expression was increased in disease-susceptible regions
(cerebellum [P<0.05] and spinal cord [P<0.001]) in female SJL at peak of EAE, with no
detectable differences in cortex (Figure 3B). Again, no such sexual dimorphism was observed in
C57BL/6 mice. Although ovariectomy and estrogen exposure impacts disease in female SJL
mice (141, 149-153), levels of S1PR2 expression in all CNS regions of naïve female SJL mice or
of female SJL mice immunized with PLP139-151 were unaffected by ovariectomy with or without
17b-estradiol replacement (Figure S4). Of note, sham and ovariectomized mice were evaluated
when they attained clinical scores = 2 whereas ovariectomized mice treated with 17b-estradiol
did not develop symptomatic EAE. Thus, suppression of clinical symptoms by 17b-estradiol in
PLP139-151 –immunized mice did not impact CNS levels of S1PR2 expression. These data are also
consistent with studies demonstrating that 17b-estradiol does not impact on systemic
inflammation in the setting of active immunization (149).
S1PR2 immmunoreactivity was localized to endothelium, vessel-associated astrocytes,
and occasional pericytes, within the CNS of SJL mice with EAE (Figure 3C) and within human
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post-mortem cerebellar specimens derived from MS and non-MS patients (Table S2) (Figure 4A,
B). Furthermore, quantitative IHC assessment of human specimens showed significantly higher
levels of vessel-associated S1PR2 in MS versus non-MS patients (P=0.01) and a trend toward
increased S1PR2 expression in female versus male MS patients (Figure 4C). Of interest, the
highest levels of S1PR2 expression in female MS patients had relapsing-remitting disease (2
cases) and the one male patient with high levels of S1PR2 had a history of occipital head trauma.
These results suggest that S1PR2 may play a role in sexually dimorphic patterns of BBB
dysfunction in the setting of CNS autoimmunity.

Clinical disease severity and BBB permeability during EAE are reduced by pharmacologic
or genetic inactivation of S1PR2 .
To investigate whether S1PR2 modulates the pathogenesis of EAE, we evaluated clinical
disease scores in the setting of both pharmacologic blockade and genetic deletion of S1PR2.
Female SJL mice treated with the specific S1PR2 antagonist, JTE-013 (1.5 mg/kg) (154),
beginning when mice reached a clinical score of 2 and continuing for 10 (Figure 5A, top) or 30
(Figure 5A, bottom) days, exhibited less severe daily clinical scores (P<0.0001, both lengths of
treatment), maximum severity scores (P<0.0001, both lengths of treatment), and mean
cumulative scores (P<0.01 for 10 days treatment, P<.001 for 30 days treatment), while male SJL
did not respond to treatment (Figure S5). No changes in body weight were observed after JTE013 treatment, regardless of treatment duration (Figure S6A-C). Consistent with clinical
assessments, hematoxylin and eosin (H & E) staining revealed significantly fewer inflammatory
foci within the white matter of both spinal cord (P<0.01) and cerebellum (P<0.05) of JTE-013
versus vehicle-treated female SJL at peak of EAE (Figure 5B), and cerebellar lesions were
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significantly reduced (P<0.05) during remission. Luxol fast blue (LFB) staining further revealed
that JTE-013 treatment reduced demyelination of spinal cord and cerebellar white matter during
peak and remission phases of EAE (Figure 5B). Female SJL with EAE treated with JTE-013 for
5 days also exhibited significantly reduced fluorescein permeability in both cerebellum (P<0.001)
and spinal cord (P<0.01) compared to vehicle controls (Figure 5C, top) and a significant
reduction in spinal cord permeability after prolonged treatment for 30 days (P<0.01) (Figure 5C,
bottom). Similar results were observed via immunohistochemical detection of extravasated
albumen within the white matter of diseases mice (Figure S7A).
Consistent with results after antagonist treatment, S1PR2-deficient mice immunized with
MOG35-55 exhibited significantly decreased severity of EAE compared to wild-type controls,
indicated by lower daily clinical scores (P<0.0001), maximum severity scores (P<0.0001), and
mean cumulative scores (P<0.0001) (Figure 6A). S1PR2-/- animals also exhibited less
demyelination and fewer inflammatory foci during peak of EAE compared to wild-type mice in
the spinal cord (P = 0.03) but not the cerebellum (Figure 6B), in addition to significant
reductions in fluorescein permeability in the spinal cord during both acute (P<0.01) and chronic
(P<0.01) EAE (Figure 6C). There was also less detection of extravasated albumen in the spinal
cord of S1PR2-/- mice compared with wild-type animals at peak of disease (Figure S7B).

S1PR2 signaling enhances BBB permeability via caveolin-endocytosis, Rho/Rock, and
CDC42-dependent pathways.
To further assess the impact of S1PR2 signaling on BBB function, we utilized a wellcharacterized transwell in vitro model of the blood brain barrier consisting of human cerebral
microvascular endothelial cells (HCMEC) grown on porous filter membranes over primary
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human astrocytes (155). Barrier integrity was evaluated by electrode recording of
transendothelial electrical resistance (TEER). Treatment with exogenous S1P permeabilized in
vitro BBBs in a dose-dependent manner over the course of 4h, indicated by significant
reductions in TEER (P<0.001, all comparisons) (Figure 7A). This disruption of barrier integrity
was S1PR2-dependent, as treatment with an S1PR2 antagonist (Figure 7B), but not an S1PR1
antagonist (Figure 7C), rescued TEER reduction after S1P treatment. Moreover, treatment with
an S1PR1-specific agonist led to a small increase in TEER in both vehicle and S1P treated
cultures (P<0.05) (Figure S8A), in contrast to the TEER decreases produced by S1P via S1PR2.
Use of RNA interference to specifically knock-down S1PR1 and S1PR2 similarly demonstrated
S1PR2-dependent disruption of barrier integrity (Figure S9A, B). Further characterization of the
signaling components that contribute to S1PR2 dysregulation of the in vitro BBB revealed that
pharmacological blockade of the caveolin-dependent endocytic pathway (Figure 7D) prior to
S1P treatment prevented TEER reductions (P<0.001), while blockade of clathrin-dependent
endocytosis (Figure S8B) or macropinocytosis (Figure S8C) produced either small or no changes
in TEER after S1P administration, respectively. TEER reductions after S1P treatment were also
prevented by pretreatment with inhibitors of the Rho GTPase effectors Rho/ROCK (P<0.001)
(Figure 7E) and CDC42 (P<0.001) (Figure 7F), but not Rac (Figure S8D).

S1PR2 signaling leads to breakdown of AJs and loss of polarized expression of CXCL12 on
basolateral/abluminal surfaces.
We next examined if S1PR2-dependent disruption of BBB function resulted in molecular
changes to the structure of the BBB endothelium. Similar to results with TEER recording, S1P
treatment resulted in a breakdown of AJs, indicated by loss of intensity and discreteness of VE-
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cadherin staining at intercellular borders (Figure 7G, left). Diminished AJ integrity was also
associated with a loss of polarized protein expression on the apical and basolateral surfaces of
endothelial cells, as assessed via z-plane confocal microscopy (imaging on same plan of
microscopy z-axis) for canonical markers of apical (gamma-glutamyl transpeptidase [GGT]) and
basolateral (CXCL12) BBB surface markers (Figure 6G, right). Again, loss of AJ integrity and
polarized GGT/CXCL12 expression after S1P treatment was specific to S1PR2, as it could be
reversed by JTE treatment (Figure 7H), but not by treatment with a specific antagonist (Figure 7I)
or agonist (Figure S8E) of S1PR1. Knock-down S1PR2, but not S1PR1, RNA in the context of
S1P treatment also led to loss of AJ integrity (Figure S9C). Similarly, pretreatment with
inhibitors of caveolin-dependent endocytosis (Figure 7J) and Rho/Rock or CDC42 (Figure 7K, L)
prevented loss of AJs and endothelial polarity, while inhibition of clathrin-dependent endocytosis,
macropinocytosis, and Rac (Figure S8F, G, H) had no effect.
Given the mouse strain- and sex-specific differences in CNS levels of expression of
S1PR2, we next analyzed polarized CXCL12 expression at the BBB in naive female and male
mice of various strains susceptible to EAE via quantification of fluorescence intensity across
vessels using confocal microscopy (140). In the spinal cord white matter, CXCL12 expression
was primarily abluminal on the vessels of male SJL mice and in C57BL/6 and B10.PL mice of
either sex, whereas vessels in female SJL mice instead exhibited a unique pattern of primarily
lumenal CXCL12 expression (Figure S10A). Similar analyses of brain vasculature in female and
male SJL mice revealed predominantly lumenal display of CXCL12 in the brainstem and
cerebellar white matter tracts in the female only, while vessels in all brain regions of males and
in supratentorial brain regions of females exhibited proper abluminal patterns of CXCL12 (139,
140) (Figure S10B). After induction of EAE, inflamed vessels within infratentorial regions of
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male mice exhibited a shift in CXCL12 expression from abluminal to lumenal locations while
female mice exhibited loss of CXCL12 expression (Figure S11), as previously reported (94). To
test whether inactivation of S1PR2 altered BBB expression of CXCL12 in vivo, we analyzed the
location of CXCL12 at CNS vasculature within the cortices, cerebella and spinal cords of female
SJL treated with vehicle versus JTE-013 and wild-type versus S1PR2-/- mice at peak of disease.
JTE-013 treated female SJL exhibited significantly increased levels of abluminal CXCL12 in
infratentorial CNS regions (cerebellum: P<0.01; spinal cord: P<0.05) with no changes observed
in cortical vessels (Figure 8A, B). Similarly, S1PR2-/- mice exhibited significantly higher levels
of abluminal CXCL12 within spinal cord white matter regions than wild-type controls at peak
EAE (P<0.001) (Figure 8C, D). These data suggest that S1PR2 activity dysregulates proper
abluminal expression of CXCL12 and that this impacts disease course during CNS autoimmunity.
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3.3 Discussion
We have defined a sexually dimorphic role for S1PR2 in the disruption of polarity at the
BBB. Elevated levels of S1PR2 were detected in EAE-susceptible CNS regions in female versus
male SJL mice and versus C57BL/6 mice of both sexes. Consistent with this, antagonism of
S1PR2 ameliorated clinical disease severity during EAE in female, but not male, SJL mice
immunized with PLP139-151 to induce EAE. S1PR2 was detected on endothelial cells and
vasculature-associated astrocytes within the CNS, and was significantly higher in white matter
regions of MS patients compared with non-MS controls, with female MS patients exhibiting
higher levels than males. In vivo and in vitro studies evaluating the role of S1PR2 in BBB
permeability revealed its critical involvement in loss of apicobasal expression of canonical
markers of BBB polarity including the chemokine CXCL12 (94, 139, 140). As abluminal levels
of CXCL12 control parenchymal entry of leukocytes (92, 140), our data provide strong evidence
that S1PR2 acts as a general regulator of BBB fence function and may be targeted to treat MS in
certain patients.
Recent research has characterized genetic, hormonal, and environmental contributions to
sex bias in MS; however, an understanding of sexual dimorphism in CNS autoimmunity has yet
to result in novel, successful therapeutics that target these mechanisms (113, 114, 156, 157).
This report identifies a potential contributor to MS sex bias, and is the first to identify a sexually
dimorphic regulator of the BBB. The identification of sexually dimorphic changes in mRNA
levels within different CNS regions were not due to direct effects of sex steroids on
transcriptional programs. Thus, analysis of S1PR2 expression in the cerebella of SJL/J-Chr
YB10.S male mice did not link sexually dimorphic effects to the Y chromosome (148) and
analysis of S1PR2 expression in the CNS of naïve or diseased, ovariectomized mice with or
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without estradiol replacement also did not reveal acute regulation of S1PR2 by gonadal
hormones. Most current therapies for RRMS are immunomodulators, while others address the
consequences of relapses by managing symptoms or improving function (158, 159). However,
these drugs often have off-target side effects because they do not specifically target myelinreactive leukocytes (160, 161). Targeting S1PR2 may avoid common off-target effects and
maybe more CNS specific than the use of FTY720, which targets several S1PRs but not S1PR2
(58,59). As S1PR2 also maintains germinal center B cells (162), its blockade is unlikely to lead
to the lymphopenia observed with FTY720. FTY720 is also associated with severe adverse
events including fatal herpesvirus infections, hemorrhagic focal encephalitis, and vasospasm of
the brachial artery, mostly mediated by S1PR3 signaling after prolonged use (163-169).
S1PR2 activity in our study was associated with several critical markers of endothelial
barrier dysfunction, including higher transendothelial permeability and loss of apicobasal
polarity, in vitro and in vivo. Our findings corroborate in vitro prior reports suggesting
counterbalancing roles of S1PR1 and S1PR2 in maintaining vascular endothelial integrity via
Rho GTPase signaling, with S1PR1 enhancing barrier function primarily via Rac activation (129,
170, 171) and S1PR2 disrupting barrier function through cytoskeletal contraction, stress fiber
formation, and junction protein disassembly via RhoA-ROCK signaling (138, 172). Our results
also implicate potentially complementary roles for RhoA and CDC42, a key regulator of cellular
polarity (173), in S1PR2-mediated BBB dysregulation, perhaps by convergent downstream
effector signaling (174). The caveolin-dependent endocytic pathway, but not the clathrindependent endocytic or macropinocytic pathways, also appears to be an important mediator of
barrier dysregulation via S1PR2, likely due to the enrichment of S1P receptors in close proximity
with their associated effectors in membrane caveolae (171), though evidence also suggests that

65

AJs can be disrupted via caveolin-mediated endocytosis of junction proteins (122, 175, 176). Of
interest, interferon-beta, which prevents inflammatory events in RRMS, also promotes stability
of VE-cadherin (60), suggesting that the specific targeting of this pathway could greatly improve
therapy. Finally, as S1PR2 antagonism does not impact on receptor expression by endothelial
cells (177), targeting the receptor to prevent alterations in BBB permeability should not lead to
long-term effects on BBB function.
Association of S1PR2 with endothelial permeability by VE-cadherin-mediated tight
junction dysfunction was first reported by Sanchez using an in vitro model of HUVEC
genetically modified to express S1PR2 (178). However, the observed amelioration of EAE in
S1PR2–deficient mice could potentially be attributed to other immune mechanisms that do not
incorporate effects of endothelial barriers. Among the possibilities are the effects of receptor
deficiency on astrocytes or pericytes(2, 179-181), the absence of antigen capture, as observed in
vitro for Langerhans cells (182) and alveolar macrophages (183), or loss of B cell retention at
germinal centers (184, 185), which could alter their ability to function as effector or antigen
presenting cells within the CNS. Lastly, S1PR2 signaling is required for degranulation and
cytokine release by activated mast cells (186, 187), which have recently been implicated in the
neuropathogenesis of MS and EAE (188).
We previously reported that post-capillary venules in the center of MS lesions display the
normally abluminal chemokine, CXCL12, aberrantly along lumenal surfaces (94, 139, 140, 189).
In our study, altered patterns of CXCL12 expression at the BBB were found to be specifically
associated with MS versus other neuroinflammatory conditions including viral encephalitis and
CNS lymphoma (139). Redistributed CXCL12 was associated with increased activation of
CXCR4 on leukocytes within vessel lumen, suggesting that altered CNS vasculature polarity
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increases leukocyte capture at endothelial cell surfaces. The finding that humans with
susceptibility for MS exhibit high levels or sexually dimorphic expression of S1PR2 suggest that
the molecule may underlie susceptibility to CNS autoimmunity and might be a disease
modifying target in MS, similar to that observed in the female SJL mouse. The identification of
S1PR2 as a target for BBB stabilization that preserves CXCL12 polarity and therefore immune
privilege is an exciting advance towards the development of novel MS therapies that limit CNS
inflammation without compromising immune function.
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3.4 Materials and Methods
Animals.
SJL/JOrlCrl (SJL, Charles River), C57BL/6, C57BL/10 and SJL/J-Chr YB10.S (The
Jackson Laboratory), B6129SF1 and 129S6/SvEvTac (Taconic Farms), and S1PR2-/- mice were
maintained in pathogen free conditions (Department of Comparative Medicine, Washington
University, St. Louis, MO. The S1PR2-/- mice, which are on a B6129S background, were
generated and genotyped as previously described (190). All mice were ten weeks old when used
for experiments.

Microarray analysis
Naïve littermates, female and male, SJL mice (n = 6) were intracardially perfused with
RNAlater® (Ambion-Life Technologies, Grand Island, NY) followed by dissection of the
cerebella and frontal cortices (2mm). Tissue was quickly frozen in TRIzol® (Ambion-Life
Technologies) and RNA extracted via standardized protocols. Transcriptional profiling was done
using the Illumina Mouse6 Expression BeadChip, v2 (Illumina, Inc. San Diego, CA). 100ng of
total RNA was used to produce an amplified pool of biotin-labeled RNA corresponding to the
polyadenylated-mRNA fraction. Biotinylated-RNA was hybridized to the array and stained with
fluorescently labeled anti-biotin antibody. Then, the BeadChip was scanned on an Illumina
BeadArray Reader (Illumina, Inc.). Raw data was imported into Partek® Genomics Suite™
(Partek Incorporated, Saint Louis, MO) for further characterization of sexually dimorphic gene
expression in female cerebella. Microarray data were deposited in GEO (accession no.
GSE55718).
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Antibodies
The following antibodies were used for immunohistochemistry or Western blotting: goat
anti-mouse albumin conjugated to HRP (Novus), biotinylated rabbit polyclonal anti-human
CXCL12 (Peprotech, Rocky Hills, NJ), rabbit anti-S1PR2/Edg-5 and rabbit anti-S1P1/Edg-1
antibodies (Acris Antibodies, Inc., San Diego, CA), mouse anti-β-tubulin (Sigma-Aldrich, St.
Louis, MO), monoclonal mouse anti-human VE cadherin, monoclonal rat anti-mouse and rat
anti-human CD31 (BD Bioscience, San Jose, CA), mouse monoclonal anti-human glial fibrillary
acidic protein (GFAP), goat anti-mouse PDFG-Rb (R&D Systems), rabbit anti-VE
cadherin/phospho Y658, rabbit anti-gamma-glutamyl transferase-1 (GGT-1) (Abcam Inc.,
Cambridge, MA), and rat anti-human GFAP (Invitrogen-Life Technologies, Grand Island, NY),
IgG isotype antibodies (mouse and rabbit: Invitrogen-Life Technologies; rat: BD Bioscience,
San Jose, CA), conjugated-secondary antibodies, streptavidin-conjugates, and nuclear stains
(Molecular Probes) and IRDye-conjugated secondary antibodies for Western blots (LI-COR
Biosciences Inc.).

Quantitative PCR
Total RNA derived from CNS tissues was prepared and qPCR was performed as
previously

described

(52).

Amplification

of

S1PR2

was

done

using

5′-

ATGGGCGGCTTATACTCAGAG-3′ (sense) and 5′-GACGGAGAAGATGGTGACCAC-3′
(anti-sense) primers as reported by Edsbagge (191). qPCR product was validated via sequencing
by the Protein and Nucleic Acid Chemistry Laboratory at Washington University, St. Louis, MO.

Western blotting for S1PR2 in murine CNS

69

Protein lysates (40 µg) of CNS tissues derived from 10 week-old SJL and C57BL/6 mice
of both sexes (n = 8) and after ovariectomy with and without treatment with 17β-estradiol or
placebo and were prepared in RIPA buffer supplemented with 1:100 protease inhibitor cocktail
and 1:100 phosphatase inhibitor cocktail-3 (all from Sigma-Aldrich) and resolved with 10% BisTris gels and transferred onto iBlot Nitrocellulose transfer membranes (both from Invitrogen)
according to standard protocols. Blots were probed with polyclonal rabbit anti-S1PR2 antibody.
Total protein loading per lane was evaluated with mouse anti-β-tubulin antibody. This was
followed by incubation with IRDye® conjugated secondary antibodies (LI-COR (Lincoln, NE)).
Blots were imaged with the Odyssey fluorescent scanning system (LI-COR).

Ovariectomy and hormone replacement in female SJL mice
Female SJL mice were ovariectomized at 6 week-old mice prior to sexual maturity via
standard protocols (141). Briefly, anesthetized animals underwent a 1 cm transverse midlumbar
skin incision followed by blunt dissection of underlying musculature. The ovarian fat pad was
exteriorized, ovarian vessels ligated and ovaries excised, followed skin closure with nonabsorbable sutures. Hormonal replacement was initiated 14 days after ovariectory by
subcutaneous implantation of either 0.25 mg 17β-estradiol or placebo (vehicle) 21-day release
pellets (Innovative Research of America, Sarasota, FL). A cohort of these mice was immunized
with PLP139-151, together with sham-ovariectomized mice, to induce EAE 7 days after hormone
replacement. Immunized animals were followed for EAE progression by monitoring clinical
score and body weight. Tissues were obtained from sham and placebo treated mice when they
reached a score of 2 at 14-days post-immunization and from 17β-estradiol-treated mice, which
remained free of disease, at 21 days post-immunization. Protein lysates were prepared from CNS
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tissues while uteri and upper 1/3 vagina of all mice were drop-fixed in 4% PFA for 48 hours.
Following fixation, uterine tissue was trimmed of fat and connective tissue prior to determination
of uterine weight.

Experimental autoimmune encephalomyelitis (EAE) induction and in vivo treatment with
JTE-013
EAE was induced in SJL/J mice via active immunization with proteolipid protein PLP139151;

200 µg) (GenScript USA, Inc., Piscataway, NJ) emulsified in complete Freund’s adjuvant,

containing Mycobacterium tuberculosis (Mtb, H37Ra; Difco Laboratories, Detroit, MI). In
addition, mice were injected with 200 ng of pertussis toxin (Ptx; List Biologicals Laboratories,
Inc., Campbell, CA) at time of immunization and two days after. Mice were graded for clinical
manifestations of EAE by the following criteria: 1, tail weakness; 2, difficulty righting; 3,
hindlimb paralysis; 4, forelimb weakness or paralysis; 5, moribund or dead. JTE-013 (1.5 mg/kg;
Cayman Chemical Company, Ann Harbor, MI) or vehicle (25% ETOH) was administered to
mice daily via intraperitoneal injection, as previously described (154), when they achieved a
clinical score of 2. B6129SF1 and S1PR2-/- mice were similarly immunized with 200 µg myelin
oligodendrocyte glycoprotein (MOG35-55; GenScript USA, Inc) and 200 µg Mtb adjuvant.
C57BL/6 mice were immunized as previously described (140).

In vivo assessment of BBB permeability
Mice were intraperitonealy injected with fluorescein sodium salt (100 mg/ml, SigmaAldrich) followed by collection of blood, intracardial perfusion and harvesting of CNS tissues.
Homogenates and serum were incubated overnight at 4°C at 1:1 dilution in 2% trichloroacetic
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acid (TCA, Sigma-Aldrich) and diluted in equal volumes of borate buffer, pH 11 (SigmaAldrich). Fluorescence emission at 538 nm was determined via a microplate reader Synergy™
H1 and Gen5™ software (both from BioTek Instruments, Inc., Winooski, VT). Tissue values
were standardized against plasma values for individual mice.

Human subjects
The use of human post-mortem biopsies for this study was approved by the Human
Studies Committee. Post-mortem CNS tissue from two groups of patients was studied: eleven
patients with clinically defined MS followed in the Washington University Multiple Sclerosis
Center and nine control individuals without histories of MS (Table S2). The control group
consisted of eight patients without any clinical histories of neurological disease plus one patient
with a history of CNS lymphoma.

Immunohistochemistry (IHC) of S1PR2 in human CNS
Human post-mortem specimens were collected within 18 hours after death from 5 female
and 5 male patients with MS, and the same number of non-MS controls. Tissue preparation and
evaluation of extent of inflammation was performed as previously published (139). For IHC,
tissue sections were hydrated and fixed in 4% paraformaldehyde, blocked in 0.1% triton X-100
and 10% goat serum followed by incubation with rabbit anti-S1PR2, rat anti-human CD31,
mouse anti-human GFAP, and/or monoclonal mouse anti-human VE cadherin antibodies.
Primary

antibodies

were

detected

with

goat

anti-rabbit

AlexaFluor®555,

anti-rat

AlexaFluor®488 or goat anti-mouse AlexaFluor®488 antibodies, as appropriate, followed by
To-Pro®-3 nuclear staining, confocal microscopy (Carl Zeiss USA, Thornwood, NY) and
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quantitative analysis with Volocity® 3D Image Analysis software (PerkinElmer, Inc., Waltham,
MA). HRP conjugated primary antibodies were detected via development in DAB solution (Cell
Marque).

Histological and immunohistochemical analyses of murine samples
Murine CNS tissues underwent histological analyses (hematoxylin and eosin; luxol fast
blue staining) and IHC detection of CD31, GFAP, PDFG-Rb, VE-cadherin and CXCL12 as
performed previously (94). Analysis of polarized expression of CXCL12 across vasculature was
performed as previously described (140). IHC detection of S1PR2, was performed in a similar
fashion as outlined for human CNS tissues. Visualization was done by confocal microscopy, as
described above.

Preparation of in vitro human BBB
In vitro human BBB cultures were generated using HCMEC/D3, an endothelial cell line
developed from brain tissue derived from the temporal lobe of an adult human female with
epilepsy (98). HCMEC/D3 were cocultured with primary human astrocytes (ScienCell, Carlsbad,
CA), within a transwell system in which transendothelial electrical resistance (TEER) values
(Ω/cm2) were measured via chopstick electrode recording with an EVOM apparatus (World
Precision Instruments, Sarasota, FL), as previously described (155). Resistance values are
reported as recorded values for each replicate minus the resistance of cell-free inserts (~90 Ω)
measured alone. Measurements were taken 24 hours after initial seeding of endothelial cells (day
1); subsequent measurements were taken daily for 10 days, at which point cultures were ready
for experimentation. Changes in permeability were evaluated via TEER measurements after
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vehicle or spingosine-1 phosphate (S1P, Cayman Chemical Company) were added to top and
bottom chambers (10-1000 nM) and incubated for 2 hours followed by addition of vehicle or
JTE-013 (10-1000 nM). Similar experiments were done using the following agents: S1PR1specific agonist W146 (1000 nM), S1PR1-specific antagonist SEW2871 (1000 nM, both from
Cayman Chemical Company), caveolin endocytosis inhibitor, methyl-beta cyclodextrin (MBCD,
10 nM),

clathrin endocytosis inhibitor; chlorpromazine (CPMZ, 10 µg/ml), or the

macropinocytosis/PI3K inhibitor, Wortmannin (100 nM, all from Sigma-Aldrich). To determine
the effector molecules involved in S1PR2 signaling, we also pretreated for 2 hours with the Rac1
inhibitor, Z62954982 (1000 nM), the Rho/ROCK inhibitor, H-1152P (10 nM, both from Cayman
Chemical Company), and the Cdc42 inhibitor, ML141 (100 nM, Tocris-R&D Systems).

In vitro RNA interference
HCMEC/D3 cells in BBB cultures or grown on chamber slides were treated with 25nM
siRNA smartpools against S1PR1, S1PR2, or a non-targeting control pool (ON-TARGETplus,
ThermoScientific) complexed with a 1:500 dilution of DharmaFect 1 transfection reagent
(ThermoScientifc) in antibiotic free culture medium for 48 hours. Knockdown was confirmed via
immunocytochemical analysis of S1PR1 and S1PR2 protein expression. Following siRNA
treatment, cells were rinsed 3x with PBS, returned to normal culture medium, and immediately
used for immunostaining or TEER measurement experiments.

Immunocytochemical evaluation of in vitro human BBB
Analysis of polarized expression of CXCL12 within HCMEC/D3 was performed after
fixation with 4% paraformaldehyde for 60 minutes and permeabilization with 0.1% triton X-100
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and 10% goat serum for 30 minutes at room temperature. HCMEC/D3 cultures were incubated
with primary antibodies against: GGT-1, VE-Cadherin, and biotinylated CXCL12 in 10 % goat
serum for 60 minutes at room temperature. Cells were washed three times in 1X dPBS, then
incubated in goat anti-rabbit AlexaFluor®555 and goat anti-mouse AlexaFluor®488 or
AlexaFluor® 555, and Streptavidin-AlexaFluor® 555 secondary antibodies in 10 % goat serum
for 15 minutes at room temperature. Cells were washed, counterstained with To-Pro®-3, and
coverslipped before being visualized via confocal microscopy.

Statistical analyses
All microarray statistical analyses for the characterization of sexually dimorphic gene
expression in female cerebella were performed using Partek® Genomics Suite™
(Partek Incorporated,

Saint

Louis,

MO).

Data

was

filtered

for

detectable

probes

(Illumina detection p <0.05 in at least one sample, yielded 27,333 probes), quantile
normalized by CNS region, and submitted to two-way ANOVA for sex-and-region specific gene
regulation. Transcripts which demonstrated up or down regulation of >1.3 with an FDR<0.2
were selected for further characterization. Two tailed, Student’s t-Test was used to determine the
statistical significance of immunohistochemical, mean maximal disease severity and cumulative
clinical score analyses. Statistical significance of qRT-PCR, disease severity curve, fluorescein
permeability, and TEER measurements were done by two-way ANOVA followed by
Bonferroni’s post-hoc test with appropriate correction for repeated measures. Comparison of
CXCL12 polarity was done via Chi-squared test. For all graphs, error bars represent + 1 standard
error of the mean. All statistical analysis was performed with GraphPad Prism software, version
5.0. P values <0.05 were considered significant for all comparisons.
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Study Approval
This study was carried out in strict accordance with the requirements pertaining to animal
subjects proteins within the Public Health Service Policy and USDA Animal Welfare
Regulations. All experiments were performed in compliance with Washington University
Institutional Animal Care and Use Committee (Animal Welfare Assurance #A3381-01), which
approved our animal protocol (#20120160, 8/3/12). All efforts were made to minimize the
suffering of animals used in this study. Post-mortem human tissues banked for research purposes
are exempt from Institutional Review Board and researchers do not have direct access to any
identifying

information.
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3.6 Figures

Figure 1. S1PR2 exhibits sexually dimorphic gene expression within the CNS of naïve SJL
mice. A. Microarray analysis of S1PR2 (left) and IL-20RB (right) expression within cerebella
(green) of female (red circles) and male (blue circles) littermates demonstrate significant
alterations compared with frontal cortex (purple). Data expressed as fold-changes + S.E.M and as
individual values of Illumina probe levels; p < 0.05, ANOVA for sex- and region-specific gene
expression (CB only). B. QPCR evaluation of S1PR2 expression in CTX, CB and spinal cord
(SC) of same cohort. Data expressed as mean S1PR2/GAPDH copies + S.E.M. for female (red
bars) and male (blue bars) samples; (n = 5), *p < 0.05, two-way ANOVA. C. Western blot
analysis of S1PR2 in CTX, CB and SC in male (B6: light blue bars; SJL: blue bars) and female
(B6: pink bars; SJL: red bars) C57BL/6 and SJL mice. Data expressed as mean + S.E.M.
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densities normalized to male B6 (n = 5); *p < 0.05, two-way ANOVA. D. Male (light and dark
blue bars) and female (pink and red bars) naive C57BL/6 and SJL mice were examined for BBB
NaFluorescein permeability within CTX, CB, and SC, normalized to serum values for individual
mice (5-8 mice/group). Data reported as arbitrary fluorescence values, normalized to mean +
S.E.M. values for naïve male C57BL/6 in each CNS region. E. Immunohistochemical detection
of albumen in CTX, CB and SC of naïve female and male SJL mice. Scale bar: 25 mm; images
representative of 3 images each from 2-3 mice/sex.
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Figure 2. S1PR2 is primarily expressed by CNS endothelial cells. A. Immunofluorescence
detection of S1PR2 (red) in female and male SJL endothelial cells (CD31, green), located in the
cortex (CTX), cerebellum (CB) and spinal cord (SC) and in SC astrocytes (GFAP, green).
Arrowheads identify S1PR2+ astrocytes. B. Immunofluorescence detection of S1PR2 (green) in
female and male SJL pericytes (PDGF-Rb, green), located in the cortex (CTX), cerebellum (CB)
and spinal cord. C. Immunofluorescence detection of S1PR2 (red) in spinal cords of 129S/B6
wild-type (WT) and S1PR2-/- mice. All nuclei stained with Topro3 (blue). Scale bars: 25 mm
Data are representative of 10 images each from 5 female and 5 male animals.
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Figure 3. Female SJL exhibit sexually dimorphic enhancement of BBB permeability and
S1PR2 expression during EAE. A. Male and female C57BL/6 and SJL mice at peak of EAE
(clinical score of 3-4), or first remission (clinical score of 2), were examined for BBB
permeability to NaFluorescein within cortex (CTX), cerebellum (CB), and spinal cord (SC),
normalized to serum values for individual mice (5-8 mice per group). Data are reported as
arbitrary fluorescence values, normalized to mean values for naïve male C57BL/6 in each CNS
region. B. Protein lysates from CNS regions of male and female C57BL/6 and SJL mice at peak
of EAE (clinical scores 3-4) were probed for S1PR2 (red), with β-Tubulin (green) as a loading
control. Data are reported as density values of S1PR2 normalized to density values for β-Tubulin.
Data are normalized to mean values for male C57BL/6 mice in each CNS region. A-B. Bar
graphs depict mean + SEM findings for male (B6: light blue bars; SJL: blue bars) and female
(B6: light red bars; SJL: red bars) for 4 mice/group. All data were analyzed via 2-way ANOVA.
*p<0.05; **p<0.01; ***p<0.001. (c) Immunofluorescence detection of S1PR2 (red, top and
middle; green, bottom) in vessels (CD31, green, top), astrocytes (GFAP, green, middle) and
pericytes (PDGFR-b, red, bottom) in CTX, CB, and SC of female SJL at peak of EAE. All nuclei
stained with Topro3 (blue). Scale bar: 25 mm. Data are representative of 10 images each from 5
male and 5 female animals. Arrows indicate areas of co-localization.
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Figure 4. BBB expression of S1PR2 is increased in MS. A. Endothelial cell (CD31, green) and
B. astrocyte (GFAP, green) localization of S1PR2 (red) in female (top panels) and male (bottom
panels) cerebellar tissue obtained from non-MS (left panels) (A) and MS (middle and right
panels) patients (A-B). Nuclei are counterstained with ToPro3 (blue), scale bars = 25 mm.
Control stains in which sections are first blocked with immunogen (1mg/ml) prior to detection of
CD31 (green) and S1PR2 (red) are included (A, right panels). C. Quantification of amounts of
vessel-associated S1PR2 fluorescence in female (red circles) and male (blue circles) non-MS and
MS patient samples. Levels of S1PR2 fluorescence were determined by examining S1PR2
staining in venule ROIs in 10 images per patient (4-6 patients per group) normalized by area of
CD31 staining to control for size and numbers of vessels. Note that the outlier in the male MS
group also had a history of occipital head trauma.
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Figure 5. S1PR2 inactivation ameliorates EAE and alterations in BBB permeability. A-B.
Female SJL mice immunized with PLP139-151 were treated with vehicle (black) versus JTE-013
(JTE; white) (1.5 mg/kg) when mice reached a clinical score of 2. A. Clinical scores of mice
treated for 10 (top) or 30 (bottom) consecutive days. Inserts show means of cumulative scores
(MCS) and of highest severity scores (MHSS) + S.E.M. for 10-15 mice/group. B. H & E (left
panels) and LFB (right panels) stained sections from spinal cords (SC) and cerebella (CB) of
vehicle- and JTE-treated mice at peak EAE (top) or remission (below). Bar graphs depict mean
numbers of white matter lesions (WML) within both CNS regions for either peak or remission +
S.E.M. for 5-6 mice/treatment group. Arrows highlight inflammatory foci. Scale bar = 25 mm. C.
Relative BBB permeability of CTX, CB and SC tissues from vehicle- and JTE-treated mice at
peak of EAE (top) or remission (below); data are depicted as mean fluorescence intensity
normalized against serum values for individual mice + S.E.M. for 6 mice/treatment group, with
means normalized against mean values for untreated, naïve controls.
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Figure 6. S1PR2 deficiency ameliorates EAE and alterations in BBB permeability A-C.
Wild-type (WT; black) versus S1PR2 -/- (white) mice immunized with MOG and followed for
disease progression. A. Clinical EAE scores, inserts show mean of cumulative score (MCS) (top)
and highest severity score (MHSS) (below) + S.E.M. for 10-15 mice/genotype. B. H & E (left
panels) and LFB (right panels) stained sections derived from SC and CB of WT versus S1PR2 -/mice at peak of EAE, Scale bar = 25 mm. Bar graphs depict mean numbers of white matter
lesions (WML) within both CNS regions + S.E.M. for 4-6 mice/genotype. C. Relative BBB
permeability of CTX, CB and SC tissues derived from WT and S1PR2 -/- mice at peak (top) and
chronic (bottom) stages of monophasic EAE; data are depicted as mean fluorescence intensity
normalized against plasma values for individual mice + S.E.M. for 4-6 mice/genotype, with
means normalized against mean values for WT naïve controls. For all statistical analyses: *p
<0.05; **p <0.01; ***p <0.001.
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Figure 7. S1PR2 signaling dysregulates CNS endothelial barrier structure and function
through Rho/ROCK, CDC42, and caveolin endocytosis-dependent pathways. A-F.
Paracellular permeability of in vitro BBB cultures was assessed by electrode recording of
transendothelial electrical resistance (TEER), reported in ohm/cm2. A. TEER after treatment of
in vitro BBB cultures with 10, 100, or 1000 nM exogenous S1P for 4h, or (B-C) 1000 nM S1P
for 4 hours +/-. B. 1000nM JTE013 at 2h or (C) the S1PR1 specific antagonist W146 (1000nM)
at 2h. D-F. TEER after 1000 nM S1P treatment of BBB cultures pretreated for 2h with (d) the
caveolin endocytosis inhibitor methyl-beta cyclodextrin (MBCD, 10 mM), (E) Rho associated
protein kinase (ROCK) inhibitor H1152P (10 nM), or (F) CDC42 inhibitor ML 141 (100nM).
TEER values are means + S.E.M. of 6-9 replicates of 2-3 independent experiments, analyzed via
repeated

measures

two-way

ANOVA,

*p<0.05;

**p<0.01;

***p<0.001.

G-L.

Immunocytochemical (ICC) staining of AJs in HCMEC/D3 cells via labeling of VE-cadherin
(red, left and middle panels, scale bar = 30 mm) and confocal z-stack reconstruction of
HCMEC/D3 cells (right panels, scale bar =15 mm) demonstrating polarized expression of
canonical apical marker gamma-glutamyltranserfase-1 (GGT1, green) and basolateral CXCL12
(red) after treatment with (G) vehicle or 1000 nM S1P for 4h, or vehicle/1000 nM S1P for 4h
followed by treatment with (H) JTE, (I) W146 (J) MBCD, (K) H1152P, (L) ML141 treatment at
2h. Inhibitor concentrations in (H-L) are identical to (B-F). ICC images are representative
images of 2-3 independent experiments. IC = isotype controls.
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Figure 8. In vivo S1PR2 inactivation preserves BBB polarity during EAE. Detection of
CD31 (green) and CXCL12 (red) within cortex (CTX), cerebellum (CB) and spinal cord (SC) of
(A-B) female SJL mice treated with vehicle or JTE-013 (1.5 mg/kg) or (C-D) wild-type versus
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S1PR2-/- mice, all at peak of EAE. Nuclei have been stained with Topro3 (blue). Scale bar = 10
mm. Data are representative of ~30 images each from 3-5 mice/treatment group. Quantification
of fluorescence intensity during confocal microscopy for CXCL12 (red line) and CD31 (green
line) are shown below microphotographs. Arrows indicate location transected in line plot
depictions. (B-D) Quantitative analysis of location of CXCL12 expression on CD31+ venules
within CNS tissues of vehicle- versus JTE-013-treated (B) and wild-type versus S1PR2-/- (D)
mice at peak of EAE. Data derived from venules analyzed within 30 images per brain region for
3-5 mice/treatment group and are expressed as the mean + S.E.M. percentages of vessels with
abluminal (white box), lumenal (black box) or absent (gray box) CXCL12 signal; *p<0.05;
**p<0.01; ***p<0.001for chi-squared comparisons between CXCL12 locations within each
brain region.
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3.7 Supplemental figures

Figure S1. S1PR2-deficient mice on a 129S/B6 background do not exhibit sexually
dimorphism in BBB permeability. A. Western blot analysis of S1PR2 in brain extracts from
wild-type (WT) and S1PR2-/- mice. B. Male (light and dark blue bars) and female (pink and red
bars) S1PR2-/- mice were examined for BBB NaFluorescein permeability within CTX, CB, and
SC, normalized to serum values for individual mice (5-8 mice per group). Data are reported as
arbitrary fluorescence values, normalized to mean + S.E.M. values for naïve male C57BL/6 in
each CNS region.
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Figure S2. Sexually dimorphic expression of S1PR2 in SJL cerebella is not controlled by
the Y chromosome. Protein lysates derived from CNS regions of naïve male and female SJL
and male SJL carrying a B10.S Y chromosome (SJL.YB10.S) were probed for S1PR2 (red), with
β-Tubulin (green) probed as a loading control. Data are reported as density values of S1PR2
normalized to density values for β-Tubulin. Group data are normalized to mean values for
normal male SJL mice in each CNS region. Data are mean values of 3-4 mice per group. Error
bars represent +/- 1 SEM. All data were analyzed via 1-way ANOVA. *p<0.05.
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Figure S3. Sex and strain differences in BBB permeability are not due to dimorphic
expression of Claudin-5. Protein lysates derived from CNS regions of naïve male and female
C57/Bl6 and SJL mice were probed for S1PR2 (red), with β-Tubulin (green) probed as a loading
control. Data are reported as density values of Claudin-5 normalized to density values for βTubulin. Group data are normalized to mean values for male C57/Bl6 mice in each CNS region.
Data are mean values of 3 mice per group. Error bars represent +/- 1 SEM. All data were
analyzed via 2-way ANOVA.
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Figure S4. Sexually dimorphic expression of S1PR2 in female SJL cerebella is not
controlled by gonadal hormones. A. Representative images of uterine horns and upper 1/3 of
the vagina of placebo- versus 17β-estradiol(17βE2)-treated, ovariectomized female SJL mice,
and sham-operated, placebo- and 17βE2-treated, ovariectomized female SJL mice after
immunization with PLP peptide (PLP immunization). B. Mean distribution of the uterine weights
and upper 1/3 of the vagina in same groups of mice as in (A). Uterine weights of 17βE2-treated,
ovariectomized SJL females with or without PLP immunization were significantly increased
compared with sham and placebo tissues, as assessed via one-way ANOVA; p <0.0001, followed
by Bonferroni post-hoc test, for 5 mice per group. C. Sham- and placebo-treated, PLPimmunized mice exhibited similar cumulative body weights while 17βE2-treated, PLP
immunized SJL females differ significantly. One-way ANOVA; p<0.0001, followed by

94

Bonferroni post-hoc test, for 5 mice per group. D. Mean of cumulative clinical scores for shamovariectomized, and placebo-, and 17β-estradiol-treated, ovariectomized mice after PLP
immunization. Note that 17β-estradiol-treated, ovariectomized mice do not develop EAE. Oneway ANOVA p <0.0001, followed by Bonferroni post-hoc test, for 5 mice per group. E. Protein
lysates derived from CNS regions of sham and ovariectomized naïve SJL female mice and from
those immunized with PLP, with and without 17b-estradiol (17bE2) replacement, were probed
for S1PR2 (red), with β-Tubulin (green) probed as a loading control. Data are reported as density
values of S1PR2 normalized to density values for β-Tubulin. Group data are normalized to mean
values for normal male SJL mice in each CNS region. Data are mean values of 5 mice per group.
Error bars represent +/- 1 SEM. All data were analyzed via 1-way ANOVA.
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Figure S5. Inhibition of S1PR2 signaling does not improve EAE progression in male SJL. A.
Clinical score of male SJL immunized with PLP and treated with either vehicle (black) or 1.5
mg/kg JTE-013 (white) when mice reached a score of 2, for 10 consecutive days (gray bar). B.
Mean of highest severity score and (c) mean of cumulative scores of mice in (A). Tx: treatment;
error bars ± 1 S.E.M.
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Figure S6. Pharmacological blockade of S1PR2 signaling does not enhance retention of
body weight during EAE. A-C. Body weight of SJL immunized with PLP and treated with
either vehicle (black) or 1.5 mg/kg JTE-013 (white) when mice reached a score of 2, for either
(A) females treated 10 or (B) 30 consecutive days or (C) males treated for 10 consecutive days
(gray bar). D. Transformed body weight of WT (black) or S1PR2 -/- or wild type mice
immunized with MOG. Error bars ± 1 S.E.M.
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Figure S7. S1PR2 inactivation ameliorates alterations in BBB permeability. A.
Immunohistochemical detection of albumen in the CTX, CB and SC of vehicle- (veh) versus
JTE0-13-treated female SJL mice with EAE at peak of disease. Images are representative of 3
images each from 4-5 mice/group. B. Immunohistochemical detection of albumen in the CTX,
CB and SC of wild-type (WT) versus S1PR2 -/- mice mice. Images are representative of 3
images each from 3-4 mice/group. Scale bars = 50 mm.
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Figure S8. S1P dysregulates CNS endothelial barrier structure and function independent of
S1PR1, Rac1, clathrin-dependent endocytic, and macropinocytic pathways. A-D.
Paracellular permeability of in vitro BBB cultures was assessed by electrode recording of
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transendothelial electrical resistance (TEER), reported in ohm/cm2 (A) TEER after treatment of
in vitro BBB cultures with 1000 nM exogenous S1P for 4h, +/- treatment with the S1PR1
specific agonist SEW2871 (1000 nM) at 2h (B-D) TEER after 1000 nM S1P treatment of BBB
cultures pretreated for 2h with (B) the clathrin endocytosis inhibitor chlorpromazine (CPMZ,
10ug/ml), (C) the macropinocytosis/PI3K inhibitor wortmannin (100nM) or (D) Rac1 inhibitor
Z62954982 (1000 nM). E-H. Immunocytochemical (ICC) staining of AJs in HCMEC/D3 cells
via labeling of VE-cadherin (red, left and middle panels) and confocal z-stack reconstruction of
HCMEC/D3 cells (right panels) demonstrating polarized expression of the canonical apical
marker gamma-glutamyltranserfase-1 (GGT1, green) and basolateral CXCL12 (red) were
performed after treatment with vehicle (left panels) or 1000 nM S1P (middle panels) for 4h, both
with SEW2871 (E), CPMZ (F), wortmannin (G), or Z62954982 (H) treatment at 2h. Inhibitor
concentrations in E-H are identical to those in A-D. TEER values are means of 6-9 replicates
taken from 2-3 independent experiments, analyzed via repeated measures two-way ANOVA.
ICC images are representative images taken from 2-3 independent experiments. *p<0.05;
**p<0.01; ***p<0.001.
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Figure S9. SiRNA knockdown confirms pharmacological data showing S1PR2-mediated
dysregulation of CNS endothelial barriers in vitro. A. Immunocytochemical staining in
HCMEC/D3 showing specificity of knockdown for S1PR1 (top) and S1PR2 (bottom) after 2d
incubation in normal culture medium, or with 25nM siRNA targeting S1PR1, S1PR2, or a nontargeting control siRNA. Protein levels are assessed by fluorescence intensity, normalized to
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mean values for untreated cells. B. Paracellular permeability of in vitro BBB cultures was
assessed by electrode recording of transendothelial electrical resistance (TEER), reported in
ohm/cm2. Cultures were incubated for 2d with 25nM siRNA targeting S1PR1, S1PR2, or a nontargeting control siRNA. After this, cultures were treated with either vehicle or 1000nM S1P for
4h, with TEER measurements every 2h. C. Immunocytochemical (ICC) staining of adherens
junctions in HCMEC/D3 cells via labeling of VE-cadherin (red). Cultures were incubated for 2d
in normal culture medium, or with 25nM siRNA targeting S1PR1, S1PR2, or a non-targeting
control siRNA. After this, cultures were treated with either vehicle or 1000nM S1P for 4h,
followed by fixation and immunostaining. Fluorescence intensities are means of 3 replicates, +/SEM, compared via one-way ANOVA. TEER values are means of 6 replicates taken from 2
independent experiments, analyzed via repeated measures two-way ANOVA. ICC images are
representative images of 6 replicates, taken from 2 independent experiments. *p<0.05; **p<0.01;
***p<0.001.
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Figure S10. CXCL12 exhibits a sexually dimorphic expression in female SJL in the same
CNS regions where S1PR2 is also dimorphic. A-B. Spinal cord expression of CXCL12 (red)
and CD31 (green) in naïve male and female mice from three different mouse strains, commonly
used for EAE: A. B10.PL (top row), C57BL/6 (middle row), and SJL (lower row), nuclei stained
with ToPro (blue) nuclear stain (IC, isotype control). B. Percentage of apicobasal distribution of
CXCL12 in relation to CD31 in spinal cord venules. C. Supra-spinal expression of CXCL12 (red)
and CD31 (green) in naïve male and female SJL, nuclei stained with ToPro (blue) nuclear stain.
D. Percentage of apicobasal distribution of CXCL12 on supra-spinal CNS regions: A: prelimbic
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cortex, B: motor cortex, C: retrosplenial cortex, D: hippocampus, E: corpus callosum, F: colliculi,
G: = pons, H: cerebellum; white columns: abluminal, black columns: lumenal. Data derived from
venules analyzed within 30 images per brain region for 3-5 mice/treatment group and are
expressed as the mean percentages of vessels with abluminal (white box), lumenal (black box) or
absent (gray box) CXCL12 signal; *p<0.05; **p<0.01; ***p<0.001for chi-squared comparisons
between CXCL12 locations within each brain region.
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Figure S11. Distribution of CXCL12 at peak of EAE in SJL is also sexually dimorphic. (a)
Expression of CXCL12 (red) and CD31 (green) in brainstem (BS), cerebellum (CB) and spinal
cord (SC) with ToPro (blue) nuclear staining. IC: isotype control. (b) Percentage of apicobasal
distribution of CXCL12 in relation to CD31 in spinal cord venules. Data derived from venules
analyzed within 30 images per brain region for 3-5 mice/treatment group and are expressed as
the mean percentages of vessels with abluminal (white box), lumenal (black box) or absent (gray
box) CXCL12 signal; *p<0.05; **p<0.01; ***p<0.001for chi-squared comparisons between
CXCL12 locations within each brain region.
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3.8 Supplemental tables

Table S1: Summary of sexually dimorphic genes or loci in SJL cerebella and
frontal cortices and chromosome locations. Four novel autosomal loci were
differentially
expressed
in
cerebella
(bold).
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Patient number Age (yrs)

Sex

PMI (hrs)

Diagnosis

CNS level

Inflammation

Demyelination

ORO

non‐MS
1

62

female

unknown

post‐surgical dehiscence sepsis

cerebellum

—

—

—

94

73

male

3

CA, CAD, HTN, MI, atypical lower
MND*

cerebrum

—

—

—

210

41

male

24

non‐ischemic cardiomyopathy,
HTN, small bowel ischemia

cerebellum

—

**

—

509

71

female

7

pancreatic cancer

—

—

—

525

81

male

3

MI

—

—

—

561

77

male

6

CAD***

cerebrum
periventricular
white matter
cerebellum

—

—

—

632

56

female

18

emphysema & artherosclerosis

cerebellum

—

—

—

908

84

female

6

pulmonary embolism

cerebellum

—

—

—

938

39

female

4

CNS lymphoma

cerebellum

—

—

—

58

64

female

10

RRMS

cerebellum

—

†

—

71

69

male

6

PPMS

cerebellum

—

—

—

101

46

female

6

SPMS

cerebellum

—

—

—

107

88

male

6

PRMS

cerebellum

—

—

—

234

95

female

8

SPMS

cerebellum

—

—

—

271

50

female

20

SPMS

cerebellum

—

††††

—

303

45

female

3

PPMS

cerebellum

††††

†

††††

305

70

male

8

SPMS

cerebellum

—

—

—

388

69

female

9

RRMS

cerebellum

—

—

—

650

35

male

10

PPMS

cerebellum

†

†

††

1101

54

male

7

SPMS

cerebellum

—

—

—

MS cases

PMI: post‐mortem interval, PPMS: primary progressive MS, PRMS: progressive‐relapsing MS, RRMS: relapsing‐remitting MS, SPMS: secondary progressive MS, CA: cardiac
arrest, CAD: coronary artery disease, HTN: hypertension, MI: myocardial infraction, MND: motor neuron disease, *Patient received intravenous immunoglobulin
treatment. **Biopsy showed a slightly pale site, presumably an artifact as assessed by its location and shape. ***Biopsy showed some features similar to Alzheimer's but
patient has no clinical history of AD.

Table S2: Patient information for IHC analyses in human postmortem
specimens.
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Chapter 4
Viral pathogen-associated molecular patterns regulate blood-brain barrier
integrity via competing innate cytokine signals

This chapter is adapted from the following publication:
Daniels BP, Holman DW, Cruz-Orengo L, Jujjavarapu H, Durrant DM, and Klein RS.
(2014) Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity
via competing innate cytokine signals. mBio. 5(5):e01476-14.
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4.1 Introduction
The CNS is normally protected from pathogens by the blood brain barrier (BBB),
composed of brain microvascular endothelial cells (BMECs) joined by tight junctions (TJs). TJs
are formed by the intercellular association of transmembrane proteins, including claudins and
occludins, whose anchoring to the endothelial cytoskeletal network by adaptor proteins,
including the zonula occludens (ZO) family, represents a major regulatory mechanism by which
paracellular permeability is controlled (1). Viruses may cross the BBB via several routes,
including direct infection of BMECs, trans- or paracellular viral trafficking across
endothelium(83), or via entry of infected peripheral leukocytes (192, 193). Trafficking of virus
across the BBB is likely made possible by enhanced permeability of BBB endothelium, caused
either directly by viral factors or indirectly by host immune factors, including innate cytokines
such as TNFα and IL-1ß (43, 194). However, the mechanistic explanation of this effect and the
functions of innate immune responses at the BBB interface during viral infections have not been
explored.
West Nile virus (WNV), a mosquito-borne flavivirus, is the most common cause of
epidemic viral encephalitis in the United States (29). Following infection, the pattern recognition
receptors (PRRs) TLR3, TLR7, RIG-I, and MDA5 are key sensors of WNV pathogen-associated
molecular patterns (PAMPs), inducing expression of innate Th1 cytokines that limit viral
replication, facilitate antigen presentation, and direct trafficking of antiviral leukocytes (195,
196). Studies in mice have shown that TNFα signaling is key for CD8+ T cell-mediated clearance
of WNV in the CNS (197), as well as protection from CXCR3-mediated apoptosis in neurons
(198). Likewise, IL-1β signaling has been shown to limit WNV replication in neurons (64), and
is essential for dendritic cell-mediated reactivation of WNV-specific T cells in the CNS (54).
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Despite these beneficial effects in the CNS, Th1 cytokine signaling can also contribute to
neuropathology, including disruption of the BBB (35, 43).
PRR activation also induces expression of type I interferons (IFNs) (IFNα and IFNβ) that
share a common type I IFN receptor (IFNAR). PRR-mediated expression of IFN ligands results
in amplification of type I IFN signals via both autocrine and paracrine signaling through IFNAR,
which stimulates further IFN ligand expression and an array of interferon-stimulated antiviral
and immunomodulatory genes (199). Type I IFNs act directly as potent suppressors of viral
replication (200) and indirectly by promoting host adaptive immune responses (201). Thus, mice
lacking type I IFN receptors, ligands, and key transcription factors exhibit expanded viral
tropism and replication, resulting in accelerated and enhanced mortality (200, 202, 203). In the
context of CNS autoimmunity, type I IFNs can enhance BBB function and are used clinically in
humans to prevent the CNS entry of autoreactive leukocytes in patients with multiple sclerosis
(204, 205). However, the functions of type I IFN at the BBB interface during viral infections of
the CNS have not yet been explored.
Here, we demonstrate a novel mechanism underlying the dynamic regulation of BBB
structure and function by innate cytokines during viral encephalitis. Using an in vitro BBB
model, we show that, in the presence of WNV, the induction of type I IFN directly regulates
endothelial permeability and TJ formation via regulation of the small GTPases Rac1 and RhoA,
and indirectly via suppression of barrier-dysregulating effects of TNFα and IL-1ß. This
regulatory regime modulates transendothelial WNV trafficking, as type I IFN responses
significantly decreased the movement of virus across an intact barrier in vitro, while TNFα and
IL-1ß increased this crossing. In vivo, genetic attenuation of type I IFN signaling resulted in
enhanced BBB permeability with associated TJ disruption following peripheral or intracranial
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inoculation with WNV. Together, these data demonstrate an additional, previously undescribed
regulatory role for PRR-mediated cytokine expression at the BBB during WNV infection.
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4.2 Results
Innate cytokines differentially regulate barrier function following WNV infection.
To assess the kinetics of BBB permeability following murine WNV infection, we utilized
an established model of WNV neuroinvasive disease in which 5 week old (wo) C57Bl/6 mice are
subcutaneously infected in the footpad with 102 pfu of a virulent strain of WNV-NY. 5wo mice
uniformly develop CNS infection, with detectable CNS viral loads first emerging ~6 days (D6)
following infection (92, 206) (Figure S1A). Fluorometric assessment of BBB permeability
following i.p. administration of sodium fluorescein revealed that BBB permeability increased
significantly over the course of peripheral infection (D0-D4) in all CNS regions analyzed (Figure
1A). Of interest, BBB permeability exhibited a significant decrease at D6 in cortical and
subcortical cerebral tissues, coincident with the timing of detection of virus within the CNS
(Figure S1A). After this, BBB permeability rebounded and returned to elevated levels on D8,
coinciding with increased trafficking of leukocytes into the CNS (92).
The biphasic kinetics of BBB permeability after WNV infection suggested potentially
differential regulation of the BBB by viral and host factors over the course of infection. To
assess this, we utilized a standard, transwell in vitro BBB system in which primary murine
BMECs are grown on a porous filter membrane in a chamber suspended above primary murine
astrocytes. The integrity of the endothelial barrier is assessed via electrode recording of
transendothelial electrical resistance (TEER). We treated in vitro BBB cultures in the top
(BMEC only) chamber overnight with cytokines or infected for 6h with 0.01 MOI WNV, which
had been purified via ultracentrifugation through a sucrose gradient. We utilized a low MOI for
BMEC experiments in light of the relatively low viremia present in mammalial hosts during
WNV infection (207) and high MOIs can trigger fast, necrotic cell death (208), compromising
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monolayer integrity and confounding the interpretation of TEER results. Similarly, 6h infections
were chosen because this period of time is insufficient for completion of viral lifecycle and
induction of apoptosis in BMECs, as assessed via multistep growth curves and TUNEL staining
(Figure S1B-C). Treatment with Th1 cytokines TNFα (100ng/ml), IL-1β (100ng/ml) and IFNγ
(100ng/ml) decreased TEER, while IFNβ (100pg/ml) and WNV infection both significantly
enhanced TEER (Figure 1B). TEER effects induced by Th1 cytokines could be rescued by
subsequent infection with WNV, while infection of IFNβ treated cultures produced no additional
increase in TEER (Figure 1C). Similar to WNV, addition of IFNβ to cultures pretreated with Th1
cytokines also rescued TEER (Figure 1D). These data suggest that WNV infection may increase
TEER either via type I IFN or through convergent mechanisms.
To assess whether type I IFN expression by BMECs and/or astrocytes contributes to
increasing TEER, we performed checkerboard experiments using BMECs and astrocytes isolated
from WT and/or Ifnar-/- mice. While TEER increased after 6h infection in cultures with WT
BMECs, similarly infected cultures generated with Ifnar-/- BMECs instead exhibited significant
reductions in TEER (Figure 1E). While type I IFN signaling in BMECs robustly controlled
TEER responses after infection, type I IFN signaling in astrocytes produced smaller but
significant modulations of TEER responses as well. Experiments using neutralizing antibodies to
IFNAR and IFN ligands recapitulated results using Ifnar-/- BMECs (data not shown). Given the
dramatic change in TEER responses in the absence of type I IFN signaling, we next assessed the
expression of innate cytokines in BMECs following infection. In WT BBB cultures, both IFNβ
and TNFα protein expression are induced within 6h in top chambers of BBB cultures, with
mostly undetectable levels of IL-1β. However, infection of Ifnar-/- BBB cultures yielded lower
levels of type I IFNs (Figure 1F and Figure S2A-B), consistent with a loss of IFNAR-mediated
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amplification, as well as modestly enhanced TNFα and more robustly enhanced IL-1β expression
(Figure 1F). Baseline expression of cytokines in uninfected cultures did not differ between
genotypes (Figure S2), and cytokine expression in bottom culture chambers did not differ
substantially from top chambers (data not shown). These data indicate that type I IFN signaling
in BMECs can modulate permeability both directly and indirectly through the suppression of
Th1 cytokine expression.
To determine if permeability changes are associated with structural changes involving
TJs, BMEC monolayers treated overnight with cytokines, followed by subsequent 6h WNV
infection, were evaluated by immunocytochemistry (ICC) for the TJ proteins Zo-1 and Claudin-5.
Infection in WT cells enhanced TJ protein colocalization at intercellular borders, indicating
recruitment and stabilization of these proteins in functional TJ complexes (Figure 1G-H). In
contrast and consistent with TEER responses, infection of Ifnar-/- BMECs resulted in decreased
TJ protein colocalization, suggesting that type I IFN is necessary to enhance TJ formation in the
presence of WNV. Also mirroring our prior TEER results, TNFα or IL-1β treatment resulted in
decreased TJ protein colocalization, which could be rescued by subsequent WNV infection in
WT, but not Ifnar-/- BMECs. These data indicate that innate cytokine signaling in BMECs
following exposure to WNV results in rapid modulation of TJ complexes, which are key
regulators of paracellular permeability, and that barrier dysregulation by Th1 cytokines can be
controlled by the actions of type I IFN.

PRR activation is sufficient to induce cytokine-dependent changes to endothelial barrier
integrity
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As type I IFN signaling enhances both TJ formation and BBB permeability after WNV
infection, we assessed whether this was the result of classical innate immune signaling through
PRRs. First, we inactivated purified WNV via either 2h exposure to UV light (WNV-UV) or
incubation with 0.1% v/v β-propiolactone (WNV-BPL), generating viral stocks that are unable to
replicate within cells as assessed via standard plaque assay (data not shown), but do induce both
IFNβ and IFNα protein expression in BMECs after 6h (Figure S2A-B). Treatment of in vitro
BBB cultures consisting of WT vs. Ifnar-/- BMECs (both over WT astrocytes) with either WNVUV or WNV-BPL (Figure 2A) for 6h revealed enhanced TEER in WT cultures, but reduced
TEER in Ifnar-/- cultures, largely phenocopying the effect of normal virus. These results suggest
that type I IFN-dependent changes in TEER require viral detection but not replication in BMECs.
We next determined if direct activation of PRRs was sufficient to alter TEER. TLR3
agonism via 6h treatment with naked (non-transfected) Poly I:C significantly decreased TEER in
both WT and Ifnar-/- BBB cultures (Figure 2A). However, similar 6h treatments with agonists for
TLR7 (CL264), MDA5 (high molecular weight Poly(I:C) transfected into cytoplasm), or RIG-I
(5’ppp-dsRNA transfected into cytoplasm) instead resulted in increased TEER in WT cultures,
but decreased TEER in Ifnar-/- cultures, similar to results with both infectious and inactivated
WNV. ELISA analysis confirmed that both IFNβ and IFNα protein expression were induced by
all treatments, including TLR3 agonist (Figure S2A-B). Consistent with these results, ICC
analysis of Zo-1 and Claudin-5 similarly showed enhanced colocalization in WT BMECs treated
for 6h with WNV-UV, WNV-BPL, and TLR7, MDA5, RIG-I, but not TLR3, agonists, with
decreases in TJ protein colocalization after these treatments in Ifnar-/- BMECs (Figure 2B-C).
TLR3 agonism, however, resulted in decreases in TJ protein colocalization in both WT and Ifnar/-

cultures.

116

We next assessed if differences in barrier responses to PRR agonists in WT vs. Ifnar-/BBB cultures and between TLR3 and other PRR agonists were due to differential cytokine
expression. Similar to experiments with WNV, Ifnar-/- BBB cultures had small modulations of
type I IFN and TNFα signaling after stimulation with inactivated virus and PRR agonists (Figure
S2A-C), and, strikingly, significantly enhanced expression of IL-1β compared to WT cultures
(Figure S2D). Moreover, TLR3 agonism resulted in IL-1β expression even in WT cultures
(Figure 2D), in contrast to cultures treated with other PRR agonists, including the TLR7 agonist
CL264, which induced detectable levels of IL-1β only in Ifnar-/- BBB cultures (Figure 2D, Figure
S2D). To determine if differential expression of Th1 cytokines contributed to differences in
TEER responses in BBB cultures exposed to WNV or PRR agonists for 6h, we measured TEER
in the presence of cytokine neutralizing antibodies. Blockade of TNFα augmented increases in
TEER in WT cultures following exposure to WNV or TLR7 agonist (Figure 2E), and partially
rescued decreases in TEER in Ifnar-/- cultures. In contrast, blockade of IL-1β did not impact
TEER in WNV and TLR7 agonist treated WT cultures, which do not express IL-1β within 6h,
but did partially rescue decreases in TEER in Ifnar-/- cultures, which do exhibit IL-1β expression.
Similarly, blockade of either TNFα or IL-1β partially rescued TEER responses in TLR3 agonist
treated cultures of either genotype (Figure 2E). Of note, simultaneous blockade of both TNFα
and IL-1β in Ifnar-/- cultures following exposure to WNV or PRR agonists held TEER levels at
baseline values. Together, these data suggest that innate cytokine signaling in BMECs
orchestrates barrier responses following exposure to WNV PAMPs, and that the relative balance
of type I IFN vs. TNFα and IL-1β governs these changes. Type I IFN signaling in BMECs is able
to prevent BBB dysregulation by Th1 cytokines, which, in the absence of type I IFN, are able to
increase barrier permeability and disassemble TJs. Moreover, PRR activation in BMECs, even in
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the absence of direct infection, is sufficient to induce cytokine-mediated changes in BBB
physiology.

WNV modulates BMEC Rho GTPase signaling in an innate cytokine-dependent manner
To assess the signaling events that regulate BBB physiology downstream of WNV and
cytokine signaling, we examined if WNV infection resulted in changes to the activity of Rho
GTPases, a family of signaling molecules that regulate cytoskeletal dynamics, including TJs and
paracellular permeability (173). WT and Ifnar-/- BMEC monolayers were infected for 6h with
WNV, and protein lysates were collected and incubated with Rhotekin or PAK agarose beads to
pull-down GTP-bound, activated Rac1, RhoA, and CDC42. Western blot detection of activated
forms of these GTPases revealed a significant increase in activated Rac1 in WNV-infected WT
BMECs (Figure 3A-B), with a significantly smaller increase in activated Rac1 in Ifnar-/- BMECs.
In contrast, while activated RhoA is not increased in WNV-infected, WT BMECs, Ifnar-/BMECs exhibited significantly increased amounts of activated RhoA (Figure 3A, C). Levels of
activated CDC42 were not affected by WNV infection in either WT or Ifnar-/- BMEC cultures
(Figure 3A, D). As these experiments suggested a dynamic range of Rho GTPase activation
responses following WNV infection, we next assessed the manner in which individual innate
cytokines regulated Rho GTPase activation. In agreement with infection experiments in WT vs.
Ifnar-/- BMECs, 2h incubation of WT BMECs with recombinant IFNβ resulted in significantly
enhanced Rac1 activation (Figure 3E-F) and significantly diminished RhoA activation (Figure
3E,G). In contrast, 2h incubation with TNFα resulted in decreased Rac1 activation and greater
activation of RhoA, while 2h IL-1β treatment increased activation of both GTPases, with greater
fold-change induction of RhoA activation.
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Innate cytokine-dependent modulation of Rac1 and RhoA after WNV infection regulates
BBB permeability and TJ formation
We next examined whether modulation of BMEC Rho GTPase signaling in the context of
WNV infection contributed to type I IFN-dependent regulation of TEER and TJ responses.
Pharmacological blockade of Rac1 signaling via 2h pretreatment with its specific inhibitor,
Z62954982, abolished the increase in TEER after 6h WNV infection in WT cells, with TEER
values significantly decreased in WNV-infected, WT barriers in the absence of Rac1 signaling,
while responses remain unchanged in similarly infected and treated Ifnar-/- barriers (Figure 3H).
Conversely, inhibition of RhoA signaling via 2h pretreatment with its specific inhibitor, H1152P,
did not impact TEER changes induced by WNV infection in WT barriers, but significantly
rescued reductions in TEER in similarly infected and treated Ifnar-/- barriers. Inhibition of
CDC42 via 2h pretreatment with ML 141, a specific inhibitor of CDC42, did not significantly
alter TEER in either WT or Ifnar-/- barriers after WNV infection. As changes to TEER responses
could simply be explained by altered IFN expression by BMECs following infection in the
presence of GTPase inhibitors, we confirmed via ELISA that inhibition of Rac1 or RhoA did not
significantly alter IFNβ levels in luminal chambers following 6h infection, nor did any of the
inhibitors impact TEER in 6h mock infected cultures (Figure S3A-C).
Consistent with analyses of TEER, ICC analysis further revealed that inhibition of Rac1
signaling in WT cells completely abolished the increase in co-localization of Zo-1 and Claudin-5
observed in WNV-infected WT BMECs (Figure 3I-J), while inhibition of RhoA or CDC42 did
not impact TJ formation in WT cells. However, inhibition of RhoA rescues loss of TJ formation
in WNV-infected Ifnar-/- BMECs, abolishing decreases in TJ protein colocalization observed in
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untreated Ifnar-/- BMECs. Inhibition of Rac1 or CDC42 did not significantly impact TJ
formation in Ifnar-/- BMECs. Control experiments also confirmed that 2h pretreatment with
GTPase inhibitors followed by 6h mock infection did not change baseline levels of TJ protein
co-localization (Figure S3D). Together, these data suggest that cytokines expressed in BMECs
following exposure to WNV differentially influence Rho GTPase activity, with type I IFN
contributing to preferential activation of Rac1, thereby stabilizing barrier physiology. This
regulation counteracts the activity of the cytokines TNFα and IL-1β, which preferentially
activate RhoA and contribute to barrier disruption.

Innate cytokine regulation of Rho GTPase signaling controls WNV transmigration across
the in vitro BBB
We next determined if cytokine and Rho GTPase modulation of TEER and TJ integrity
were relevant regulators of viral trafficking across the BBB, limiting access of WNV to the CNS.
For these experiments, 0.01 MOI WNV was added to the top chamber of transwell BBB cultures
for 6h; the top chamber was then removed, such that only virus which had crossed during the 6h
incubation was present in the bottom chamber. Amounts of migrated virus in bottom chambers
were then assessed via multistep growth curve analysis. Consistent with changes in TEER and TJ
integrity, overnight pretreatment in the top chamber with TNFα or IL-1β before infection
significantly enhanced the transendothelial migration of WNV (Figure 4A-B), while IFNβ
pretreatment in the top chamber significantly reduced viral trafficking (Figure 4C). Similarly,
experiments using barriers with WT vs. Ifnar-/- BMECs over WT astrocytes revealed that Ifnar-/BMECs exhibit significantly enhanced viral migration (Figure 4D). In order to control for the
possibility that IFNβ treatment or genetic deletion of IFNAR on BMECs alters basolateral
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secretion of type I IFN by BMECs, which may skew the kinetics of replication in the astrocytes
below, we did concurrent experiments using BBB cultures with Ifnar-/- astrocytes. These
experiments yielded similar results, confirming that differential exposure of astrocytes to IFN did
not account for the difference observed in experiments using WT astrocytes (Figure S4A-B).
Pretreatment of BBB cultures with neutralizing antibodies to TNFα reduced viral migration in
both WT Ifnar-/- cultures, while IL-1β neutralizing antibodies reduced migration only in Ifnar-/cultures, consistent with similar experiments measuring TEER responses (Figure 4E-F). Once
again, neutralizing antibodies to both cytokines had additive effects in Ifnar-/- barriers,
suppressing viral migration back to levels observed in WT cultures.
As cytokine signaling was observed to influence transendothelial viral migration, we next
performed similar experiments in which cultures consisting of WT or Ifnar-/- BMECs over WT
astrocytes were pretreated for 2h in the top chamber with antagonists of Rac1, RhoA, or CDC42
prior to introduction of WNV. Again, consistent with TEER and TJ integrity findings,
antagonism of Rac1 significantly enhanced transendothelial migration of WNV across WT
BMECs, but did not further augment the enhanced migration observed across Ifnar-/- BMECs
(Figure 4G). Likewise, antagonism of RhoA did not significantly alter WNV migration across
WT BMECs, but resulted in a partial rescue of the enhanced migration observed in Ifnar-/BMECs (Figure 4H). As expected antagonism of CDC42 did not impact transendothelial
migration of WNV (Figure S4C). Together, these findings suggest that modulation of BMEC
TEER and TJs caused by type I IFN-dependent regulation of Rho GTPases is consequential to
the ability of WNV to traffic across the BBB endothelium.
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Mice with impaired type I IFN responses exhibit enhanced BBB permeability and loss of
TJ integrity after peripheral WNV infection
Mice lacking type I IFN receptor, ligands, and regulatory transcription factors exhibit
enhanced susceptibility to WNV infection, including early entry of virus into the CNS compared
to WT controls. Thus, in light of our in vitro observations, we wondered if mice with impaired
type I IFN signaling would also exhibit alterations to BBB permeability and TJ integrity
following peripheral infection. To determine whether type I IFN signaling is required for the in
vivo decrease in BBB permeability observed on D6 after WNV infection of the CNS, we
examined BBB permeability in the context of intracranial (IC) inoculation (10 pfu) of WNV in
8wo WT vs. Ifnar-/- mice. WT animals experienced a significant decrease in BBB permeability to
sodium fluorescein on D1 and D2 in each CNS region, followed by a large increase in BBB
permeability on D4 (Figure 5A), coincident with the detection of large numbers of inflammatory
cells at this time-point in this model (209). However, these kinetics were not observed in Ifnar-/animals, which instead exhibited a significant and sustained increase in permeability to sodium
fluorescein each day following infection. For these studies, we examined permeability in tissues
contralateral to the inoculation site, though we ultimately found that permeability did not differ
significantly between hemispheres on any day following IC infection (data not shown).
Concurrent experiments in mice receiving mock IC inoculations with saline showed only
extremely modest increases in BBB permeability which did not differ between WT vs. Ifnar-/mice (Figure S5); thus, the inoculation procedure alone did not explain changes in BBB
permeability following IC inoculation with WNV. In all, these data suggest that local type I IFN
responses in the CNS following WNV entry promote BBB integrity, which may contribute to the
decrease in BBB permeability observed between D4 and D6 following peripheral infection.
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As Ifnar-/- mice experience rapid and uniform mortality due to septic shock (~ d3.5 after
footpad infection) (41, 200), we next used Irf7-/- mice, which have impaired expression of IFNα
(210). These mice experience early neuroinvasion of WNV compared to WT mice following
footpad infection (210). Sodium fluorescein permeability experiments revealed that WNVinfected 8wo WT mice exhibit similar BBB permeability kinetics as previously observed in 5wo
animals, including an increase in permeability during peripheral infection (D0-D4) followed by a
decrease in permeability at D6 (Figure 5B). In contrast, 8wo, WNV-infected Irf7-/- mice exhibit a
sustained increase in BBB permeability over the entire course of infection, with significantly
higher permeability on D6 compared to WT controls. Immunohistochemical (IHC) detection of
extravasated endogenous IgG revealed similar kinetics of permeability following WNV infection
in cortical and cerebellar tissues (Figure 5C). Consistent with this, IHC detection of Zo-1 and
Claudin-5 in CNS tissues revealed that both WT and Irf7-/- mice exhibited loss of TJ integrity on
D4 following WNV infection, characterized by diminished or diffuse cytoplasmic staining of TJ
proteins and substantially decreased co-localization of TJ proteins at cell-cell borders (Figure
5D). Alteration in TJ assembly was reversed at D6 within the microvasculature of WNV-infected,
WT mice, while those of similarly infected Irf7-/- mice showed sustained dysregulation of TJs. As
differences in viral burden in WT vs. Irf7-/- mice over time complicate interpretation of BBB
changes due to type I IFN signaling, we performed control experiments in which WT and Ifnar-/mice were treated with the TLR3 agonist Poly(I:C), which is known to increase BBB
permeability (43). At 24h following treatment, Ifnar-/- mice exhibited enhanced CNS
permeability to sodium fluorescein compared to WT mice (Figure 5E), providing further
evidence that type I IFN signaling is required to preserve BBB integrity in the context of
systemic inflammatory activation.
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4.3 Discussion
While the contributions of innate cytokine responses to virologic control and adaptive
immunity during WNV infection are known, the regulatory potential of these molecules at the
BBB remains poorly understood. Here, we demonstrate that PRR activation in the presence of
WNV in BBB endothelium results in cytokine-dependent modulation of Rho GTPase signaling,
exerting regulatory control over BBB permeability and TJ integrity. This, in turn, is
consequential for the ability of WNV to traffic across BBB endothelium. In particular, our data
suggest that the induction of type I IFN serves to preserve and stabilize BBB structure and
function, both directly and indirectly by limiting barrier disruption caused by the cytokines
TNFα and IL-1β. In vivo, BBB permeability increases during peripheral infection, but sharply
decreases coincident with viral neuroinvasion in WT, but not in animals with attenuated type-I
IFN responses, suggesting that local CNS type I IFN responses may act on the BBB to mitigate
access of WNV to the CNS parenchyma.
The Th1 cytokines TNFα and IL-1β have previously been shown to disrupt barrier
endothelium in vitro and in vivo, increasing permeability (38-40) and dysregulating junction
complexes (1, 60, 211). During viral infections, TNFα, in particular, has been linked to enhanced
vascular permeability, poor tissue perfusion, and endothelial cell death (41, 42). Here, we show
that TNFα signaling in BMECs activates RhoA, disrupting barrier function and increasing
transendothelial movement of WNV. This is in line with Wang et al. (43), who reported a
decrease in BBB permeability in Tnfrsf1a-/- mice following WNV infection. These findings
together indicate that Th1 cytokine-mediated disruption of the BBB provide an access route for
neuroinvasion by WNV.
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In contrast to Th1 cytokines, type I IFN treatment has been established to promote BBB
function (60, 212). However, for the first time, we demonstrate that in vivo induction of type I
IFN following WNV infection is a key regulator of BBB permeability and TJ integrity. Type I
IFN signaling in BMECs in vitro is shown to enhance barrier function over baseline conditions
and to rescue Th1 cytokine-mediated barrier dysregulation, suggesting that CNS type I IFN
responses may be able to reverse BBB permeability caused by Th1 cytokine production during
infection in vivo. This interpretation agrees with in vitro observations suggesting that Dengue
virus activation of type I IFNs reduces vascular leakage in peripheral endothelium, even in the
presence of the barrier disrupting cytokines (42). Type I IFN also preserves barrier integrity by
suppression of Th1 cytokine expression, most noticeably IL-1β. While the interactions of type I
IFN and IL-1β during WNV infection vary across tissues and time after infection (54, 64), type I
IFN has been shown to suppress IL-1β expression, via mechanisms that vary by cell type and
inflamatory stimulus (62, 63). To our knowledge, we are the first to demonstrate IFN-mediated
suppression of endogenous IL-1β in BBB endothelium.
Cytokine-mediated BBB regulation is shown to occur via PRR pathways, independent of
viral replication, as detection of viral PAMPs in BMECs was sufficient for regulation of barrier
physiology. In particular, agonism of WNV-sensing PRRs RIG-I, MDA-5, and TLR7 induced
cytokine responses dominated by type I IFN, thereby enhancing barrier function. Prior studies
have revealed that deficiencies in each of these pathways result in increased disease
susceptibility, including early neuroinvasion and higher CNS viral burden following during
WNV infection (209, 213, 214). Of note, unlike other PRRs, TLR3 agonism increased barrier
dysregulation in both WT and Ifnar-/- BMECs. Compared to other PRRs, TLR3 induced cytokine
responses more heavily skewed towards Th1 cytokines, and, uniquely, stimulated rapid
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expression of IL-1β, even in WT cells. These data align with a report (43) suggesting that TLR3
activation contributed to BBB breakdown and subsequent WNV neuroinvasion. In our study, in
vivo TLR3 agonism also induced BBB permeability, and did so more efficiently in Ifnar-/- vs WT
mice, again suggesting that type I IFN expression may counter-regulate the effects of TNFα and
IL-1β at the BBB. The specific role for TLR3 during WNV encephalitis remains uncertain, as
another report (192) was unable to link TLR3 activation to BBB breakdown. Ultimately, TLR3
signals through a distinct adaptor compared to other PRRs (215), and thus may exhibit different
regulatory properties at the BBB, as has been shown in other tissues (216).
Some studies of murine WNV encephalitis have reported a sustained increase in BBB
permeability over the course of infection, with permeability rising coincident with neuroinvasion
and continuing to increase thereafter (80, 217). However, our findings more closely resemble
those showing markedly enhanced BBB permeability on D3-D4 post infection, prior to
neuroinvasion (43, 84, 85). Wang et al.(43) additionally observed reduced BBB permeability on
D5 post infection, coincident with neuroinvasion, in concordance with our findings. A similar
biphasic response in BBB permeability was also observed in a model of VEEV (218). The
reasons for these discrepancies are unclear, and may include variations in viral inoculation site
and age of experimental animals. Nevertheless, our data suggest that type I IFN suppresses BBB
permeability during viral infection, as loss of intact type I IFN signaling enhanced BBB
permeability following both peripheral and CNS WNV inoculation. While differences in tissue
viral burden and immune activation in Ifnar-/- and Irf7-/- mice after peripheral infection may
independently contribute to observed differences in BBB permeability, we note that, following
IC inoculation, BBB permeability was demonstrated to be significantly higher in Ifnar-/- animals,
even 1 day after infection when CNS viral titers have been shown to be equivalent (200).
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As demonstrated by Verma et al. (83), we found that WNV is capable of trafficking
across BBB endothelium in vitro, though this study used high MOIs over several days, leading to
increased virus in bottom chambers due to replication within endothelium, independent of
paracellular permeability. Alternatively, we show that virus can cross BBB endothelium quickly
after exposure, independently of replication, and that trafficking is correlated with paracellular
permeability. Movement of virus in this manner is likely relevant in vivo, as studies have linked
host factors that contribute to BBB disruption to WNV neuroinvasion (85, 219, 220). We also
demonstrate a rapid (<6h), cytokine-dependent regulation of TJ protein localization after
infection. Type I IFN regulation of BMEC TJs was due to activation of Rac1 and suppression of
RhoA activity, a regulatory regime well known to control TJ integrity (173). This finding is in
line with a report demonstrating that RhoA contributed to dysregulation of BMEC TJs,
enhancing trafficking of HIV-1 infected monocytes across the BBB (49). Thus, regulation of this
pathway may serve to limit CNS trafficking of both free and cell-associated WNV.
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4.4 Materials and Methods
Murine model of WNV encephalitis
5 and 8wo C57Bl/6 mice were commercially obtained (Jackson Laboratories). Congenic
Ifnar-/- and Irf7-/- mice were the generous gift of Dr. Michael Diamond (Washington University
in St. Louis). All animals were housed under pathogen-free conditions in the animal facilities of
Washington University School of Medicine. All experiments were performed in compliance with
Washington University Animal Studies guidelines. Mice were inoculated subcutaneously via
footpad injection (50 µl) or intracranially (2 µl) with either 100 or 10 PFU of WNV, respectively,
as previously described (206). WNV strain 3000.0259 (isolated in New York in 2000 (221)) was
used in all experiments. Viral titers in all experiments were determined via standard plaque assay
in BHK21-15 cells, as described (222).

In vivo assessment of BBB permeability:
At various day intervals after infection mice were injected IP with 100ul of 100mg/ml
fluorescein sodium salt (Sigma-Aldrich) in sterile PBS. After 45 minutes, mice underwent
extensive cardiac perfusion with PBS, followed by collection of blood and harvesting of CNS
tissues. Tissue homogenates and serum were incubated overnight at 4°C at 1:1 dilution in 2%
trichloroacetic acid (TCA, Sigma-Aldrich) to precipitate protein, which was pelleted by 10m
centrifugation at 4000 rpm at 4C. Supernatants were then diluted in equal volumes of borate
buffer, pH 11 (Sigma-Aldrich). Fluorescence emission at 538 nm was determined via a
microplate reader Synergy™ H1 and Gen5™ software (BioTek Instruments, Inc.). Tissue
fluorescence values were standardized against plasma values for individual mice.
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In vitro BBB cultures and TEER recordings:
Primary murine BMECs were prepared from 8-10wo WT and Ifnar-/- mice as described
(223). Primary neonatal murine astrocytes were prepared from WT and Ifnar-/- pups (postnatal
day 1-3) from mixed glial cultures, as described (224). In vitro BBB cultures were then prepared
as previously described (225). Briefly, 105 BMECs were cultured on the apical side of a 0.9 cm2
fibronectin-coated polyethylene terephthalate filter insert with 3.0µm porosity (BD Falcon). 105
astrocytes were cultured concurrently in 12 well plates until they reached confluence (~2d), at
which point BMEC inserts were added to astrocyte cultures. Resistance recordings were
measured via chopstick electrode with an EVOM voltmeter (World Precision Instruments).
Resistance values are reported as Ω/cm2 (recorded values minus values for cell-free inserts).

Immunocytochemical and immunohistochemical analysis:
ICC analysis on primary BMECs was performed after 10 min fixation in ice-cold
methanol, followed by blocking for 30 min in 10% goat serum in PBS at RT. Cells were then
incubated with primary antibodies to Zo-1 (monoclonal rat anti-mouse, clone R40.76, Millipore)
and Claudin-5 (polyclonal rabbit anti-mouse, Invitrogen) in blocking buffer for 1 hour at RT,
washed 3x in PBS, then incubated for 15m in goat anti-rat AlexaFluor® 488 and goat anti-rabbit
AlexaFluor® 555 secondary antibodies in blocking buffer at RT. CNS tissue sections from WT
and Irf7-/- mice were obtained after cardiac perfusion with 4% paraformaldehyde. Tissues were
frozen, blocked, and stained as previously described (52) using primary and secondary antibodies
listed above. Nuclei in all preparations were stained with Topro3. All images were acquired via
confocal microscopy (Carl Zeiss USA). Colocazation statistics were obtained via analysis in
ImageJ software.
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ELISA:
Sandwich ELISA kits were used for detection of cytokine levels in cell culture
supernatants. ELISA kits for IFNβ and IFNα (PBL InterferonSource), TNFα (EBioScience), and
IL-1Β (R&D Systems) were used according to manufacturer’s instructions. Colorometric reading
of ELISA plates was performed with a microplate reader Synergy™ H1 and Gen5™ software
(BioTek Instruments, Inc.).

Virus Inactivation:
2x104 pfu/ml stocks of WNV (NY-2000) were incubated in 0.1% v/v β-propiolactone
(Sigma) for 30m at 4C. BPL in viral stocks was then inactivated by incubating stocks for 2h at
37C, followed by hydrolysis of BPL via subsequent overnight incubation at 4C. Alternatively,
similar stocks were placed in 35mm2 culture plates and incubated in a dark chamber above a UVtransilluminator box (Stratagene) for 2h at RT. Inactivated viral stocks were stored at -80C.

Neutralizing antibody studies:
Neutralizing antibody studies were performed after 2h pretreatment with purified antimouse TNFα (1µg/ml, Clone TN3-19, EBioScience) and anti-mouse IL-1β (1µg/ml, Clone B122,
Leinco). IgG isotype antibodies were used as negative controls.

GTPase studies:
GTPase pulldown experiments were performed with an activated Rac1/RhoA/CDC42
Rhotekin and PAK agarose bead kit (Cell BioLabs, Inc.) according to manufacturer’s
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instructions. Purified GTP-bound protein and unpurified BMEC protein lysates were separated
via gel electrophoresis on 10% Bis-Tris gels (Invitrogen) and transferred onto iBlot
Nitrocellulose transfer membranes (Invitrogen) according to standard protocols. Blots were
probed with primary antibodies against Rac1, RhoA, and CDC42 (Cell Biolabs), followed by
incubation with IRDye® conjuaged secondary antibodies (LI-COR). Blots were imaged with the
Odyssey fluorescent scanning system (LI-COR). TEER and viral trafficking experiments
involving inhibition of GTPase signaling were performed as previously described (226) in in
vitro BBBs after 2h pretreatment in the top chamber at 37C with the following agents: the Rac1
inhibitor, Z62954982 (Cayman Chemical Company), the Rho/ROCK inhibitor, H-1152P
(Cayman Chemical Company), and the Cdc42 inhibitor, ML141 (Tocris-R&D Systems).

Statistical analysis:
All group effects were compared via one-way or two-way ANOVA analysis;
Bonferroni’s post-hoc test was subsequently used to compare individual means. Correction for
repeated measures was also used where appropriate. All statistical analysis was performed using
GraphPad Prism software (v5.0). P<0.05 was considered significant for all comparisons.
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4.6 Figures

Figure 1: West Nile virus infection modulates endothelial barrier integrity via innate
cytokine signaling. (A) 5wo C57Bl/6 mice were inoculated in the footpad with 100pfu WNV.
At time points indicated, mice were administered sodium fluorescein, then examined for BBB
permeability as assessed by fluorescence intensity of tissue homogenates from indicated CNS
regions. Values reported are arbitrary fluorescence values in CNS tissue normalized to values in
serum for individual mice. Group means are normalized to mean value for uninfected animals.
(B) In vitro BBBs were treated overnight in the top chamber with saline vehicle, TNFα
(100ng/ml), IFNγ (100ng/ml), IL-1β (100ng/ml), or IFNβ (100pg/ml), or infected for 6h with
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0.01 MOI WNV, followed by measurement of TEER. (C) BBB cultures were treated in the top
chamber overnight with cytokines, followed by additional 6h infection with WNV and
subsequent measurement of TEER. (D) BBB cultures were treated for 2h with vehicle or
indicated Th1 cytokine, then culture medium was washed and replaced with medium containing
vehicle or IFNβ for 2h, followed by measurement of TEER. (E) In vitro BBBs were constructed
with WT or Ifnar-/- BMECs cocultured with astrocytes of either genotype, denoted on the x-axis
with the BMEC genotype on the left and the astrocyte genotype on the right. TEER
measurements after 6h WNV infection are shown. (F) ELISA analysis of cytokine expression in
top chambers of BBB cultures following 6h WNV infection. (G) Quantification of ICC analysis
of colocalization between Zo-1 and Claudin-5 in WT vs. Ifnar-/- BMEC monolayers treated for
2h with saline vehicle, TNFα (100ng/ml), IL-1β (100ng/ml), or IFNβ (100pg/ml) and
subsequently infected for 6h with 0.01 MOI WNV. Value on y-axis (correlation index)
represents probability of an individual pixel staining positive for both markers if it stains positive
for either. (H) Representative 63x images from cultures in H, with Zo-1 shown in green,
Claudin-5 in red, and Topro3 nuclear stain in blue. Scale bar = 25µm. White arrowheads
highlight junctions with loss of TJ protein colocalization. *p<0.05, **p<0.01, ***p<0.001. Data
in (A-F) are mean values +/- SEM of (A) 6 mice/group/day or (B-F) 9-12 replicates from 2-3
independent experiments. Data in (G-H) are (G) mean values +/- SEM or (F) representative
images of 6 replicates from 2 independent experiments.
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Figure 2: Pattern recognition receptor activation is sufficient to induce cytokine-dependent
changes to endothelial barrier integrity (A) TEER measurements for in vitro BBBs
constructed with either WT or Ifnar-/- BMECs over WT astrocytes, treated for 6h with 0.01 MOI
inactivated WNV (inactivated with either 2h exposure to UV [WNV-UV] light or exposure to
0.1% v/v β-propiolactone [WNV-BPL] prior to infection of BBB cultures), the TLR3 agonist
“naked” Poly(I:C) (1µg/ml), the TLR7 agonist CL264 (10µg/ml), the MDA5-biased agonist
HMW Poly(I:C)-LyoVec™ (1µg/ml), or the RIG-I agonist 5’ppp-dsRNA (1µg/ml). (B)
Representative 63x images showing colocalization between Zo-1 and Claudin-5 in WT vs. Ifnar/-

BMEC monolayers treated for 6h with inactivated WNV or PRR agonist (as in A), with Zo-1

shown in green, Claudin-5 in red, and Topro3 nuclear stain in blue. White arrowheads highlight
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junctions with loss of TJ protein colocalization. (C) Quantification of colocalization in images in
(B). Value on y-axis (correlation index) represents probability of an individual pixel staining
positive for both markers if it stains positive for either. (D) ELISA analysis of cytokine
production in top chambers of BBB cultures as in (A) following 6h treatment with either “naked”
Poly(I:C) or CL264. (E-F) BBB cultures as in (A) were pretreated with neutralizing antibodies to
TNFα (1µg/ml) and/or IL-1β (1µg/ml), or isotype controls. Cultures were then (E) infected for 6h
with 0.01 MOI WNV or (F) treated for 6h with “naked” Poly(I:C) or CL264. Data are expressed
as fold change in infected/treated cultures vs. similarly treated mock infected/vehicle treated
cultures with the same conditions. *p<0.05, **p<0.01, ***p<0.001. Data in (A), (D-F) are mean
values +/- SEM of 6-12 replicates from 2 independent experiments. Data in (B-C) are (B)
representative images or (C) mean values +/- SEM of 5 replicates from 2 independent
experiments.
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Figure 3: WNV modulates endothelial RhoGTPase-mediated regulation of BBB
endothelium. A-G) Activated GTPase pulldown assay in WT or Ifnar-/- BMECs either (A-D)
infected with 0.01 MOI WNV for 6h or (E-G) treated for 2h with recombinant TNFα (100ng/ml),
IL-1β (100ng/ml), or IFNβ (100pg/ml). After treatment, BMEC lysates were incubated with
Rhotekin or PAK agarose beads to purify GTP-bound, activated Rac1, RhoA, and CDC42. Both
purified activated GTPases and total unpurified cell lysates were then probed via Western blot to
assess activated vs. total amounts of each GTPase. (B-D, F-G) Density quantification of
activated (B, F) Rac1, (C, G) RhoA, or (D) CDC42, normalized to total amounts of each protein
in each sample. Group averages are normalized to mean values for uninfected/vehicle-treated
WT BMECs. (H) TEER measurements for in vitro BBBs constructed with WT or Ifnar-/- BMECs
over WT astrocytes, pretreated for 2h with Rac1 inhibitor Z62954982 (1mM), ROCK/RhoA
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inhibitor H1152P (10nM), or CDC42 inhibitor ML 141 (100nM), then infected for 6h with 0.01
MOI WNV. Data are reported as fold-change in TEER in infected cultures compared to
uninfected cultures within each treatment group. (I) Representative 63x images showing
colocalization between Zo-1 and Claudin-5 in WT vs. Ifnar-/- BMEC monolayers treated for 2h
with GTPase inhibitors (as in H), followed by 6h infection with 0.01 MOI WNV, with Zo-1
shown in green, Claudin-5 in red, and Topro3 nuclear stain in blue. White arrowheads highlight
junctions with loss of TJ protein colocalization. (J) Quantification of colocalization in images in
(I). Data are reported as the fold-change in colocalization in infected cells compared to
uninfected cells within each treatment group. *p<0.05, **p<0.01, ***p<0.001. Data in A-G are
representative blots or mean values +/- SEM from 3-4 independent experiments. Data in H are
mean values +/- SEM of 12 replicates from 2 independent experiments. Data in (I-J) are (I)
representative images or (J) means +/- SEM of 5 replicates from 2 independent experiments.
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Figure 4: Innate cytokines differentially regulate WNV transmigration across the in vitro
BBB. A-H) Detection of replicating virus in bottom chamber of in vitro BBBs constructed with
(A-C) WT only or (D-H) WT or Ifnar-/- BMECs over WT astrocytes, infected with 0.01 MOI
WNV in the top chamber for 6h before the removal of the top chamber. Cultures in (A-C) were
treated overnight with saline vehicle or (A) TNFα (100ng/ml), (B) IL-1β (100ng/ml), or (C)
IFNβ (100pg/ml) prior to infection. Cultures in (E-F) were pretreated for 2h with (E-F)
neutralizing antibodies to (E) TNFα (1µg/ml) or (F) IL-1β (1µg/ml) before infection. Cultures in
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(G-H) were pretreated for 2h with (G) Rac1 inhibitor Z62954982 (1mM), or (H) ROCK inhibitor
H1152P (10nM), before infection. Values are viral titers present after 0, 12, 24, and 48h of
replication by virus that crossed during the 6h infection, prior to removal of BMECs from the
culture system. Viral titers reported as plaque forming units (PFU)/ml, as determined via
standard plaque assay in BHK cells. Dotted line represents limit of detection for the assay.
*p<0.05, **p<0.01, ***p<0.001. All data are mean values +/- SEM of 6-12 replicates from 2
independent experiments.
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Figure 5: WT, but not type mice with impaired type I IFN signaling, exhibit increased BBB
integrity following neuroinvasion. A) 8wo WT and Ifnar-/- mice were intracranially inoculated
with 10pfu WNV. On days indicated after infection, mice were administered sodium fluorescein,
then sodium fluorescein levels in tissue homogenates taken from CNS regions contralateral to
the inoculation site were assessed. Values reported are arbitrary tissue fluorescence values
normalized to serum values for individual mice. Group means are normalized to mean value for
mock infected WT animals. B) Sodium fluorescein permeability in CNS regions after footpad
inoculation with 100pfu WNV. Values taken from CNS regions (both hemispheres) are reported
as in (A), with normalization to values for uninfected WT mice. C) IHC detection of serum IgG
in parenchymal CNS tissues after peripheral WNV infection, with quantification of group mean
fluorescence intensity per low power field. Scale bar = 100µm. D) IHC detection of Zo-1 (green)
and Claudin-5 (red) in CNS microvessels on indicated days after footpad infection. Scale bar =
10µm. E) 8wo WT and Ifnar-/- mice were administered 50ug poly(I:C) i.p, followed by sodium
fluorescein 24h later (processed as in B). Data in (A), (B), and (E) are mean values +/- SEM of 6
mice per group/per day across 2 independent experiments. Images and values in C-D are
representative or means +/- SEM of 5 mice/group/day. *p<0.05, **p<0.01, ***p<0.001.
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4.7 Supplemental figures

Figure S1: (A) 5wo WT C57Bl/6 mice were infected via footpad with 100pfu WNV. Data are
viral titers from whole brain homogenates harvested on days indicated. (B) TUNEL staining for
apoptotic cells in BMEC monolayers following 6h infection with 0.01 MOI WNV, compared to
DNAse (100U/ml) treated positive control. (C) Multistep growth curves in BMEC monolayers
following infection with indicated MOIs of WNV. Supernatant viral titers were assessed via
plaque assay, reported as plaque forming units (pfu) per ml. Data in (A) are mean values +/SEM for 3-6 mice per time point. Images in (B) are representative of 3 independent replicates.
Data in (B-D) are mean values +/- SEM of 6 replicates from 2 independent experiments.
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Figure S2: (A-D) ELISA was used to determine cytokine levels in top/apical chambers of in
vitro BBBs constructed with either WT or Ifnar-/- BMECs over WT astrocytes, treated for 6h
with 0.01 MOI WNV, WNV-UV, WNV-BPL, the TLR3 agonist “naked” Poly(I:C) (1µg/ml), the
TLR7 agonist CL264 (10 µg/ml), the MDA5-biased agonist HMW Poly(I:C)-LyoVec™
(1µg/ml), or the RIG-I agonist 5’ppp-dsRNA (1µg/ml). *p<0.05, **p<0.01, ***p<0.001. All
values are mean values +/- SEM of 6 replicates from 2 independent experiments.
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Figure S3: (A-B) ELISA was used to determine IFNβ levels in the top chambers of in vitro
BBBs constructed with WT or Ifnar-/- BMECs over WT astrocytes, pretreated for 2h with (A)
Rac1 inhibitor Z62954982 (1mM), or (B) ROCK/RhoA inhibitor H1152P (10nM), then infected
for 6h with 0.01 MOI WNV. (C) TEER measurements in BBB cultures generated with WT vs.
Ifnar-/- BMECs (both over WT astrocytes). Cultures received 2h pretreatment with indicated
inhibitors, followed by 6h mock infection with saline. (D) ICC analysis of colocalization
between Zo-1 and Claudin-5 in WT vs. IFNAR-/- BMEC monolayers treated for 2h with
inhibitors for Rac1 (Z62954982 (1mM)), ROCK/RhoA (H1152P (10nM)), and CDC42 (ML 141
(100nM)). Following 2 h pretreatment, cells were mock infected with saline for 6h.
Colocalization quantified as correlation index between green and red staining (see Figure 1).
Data in (A-C) are mean values +/- SEM of (A-B) 3 or (C) 12 independent replicates. Images in
(D) are representative of 3 independent replicates.
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Figure S4: Detection of replicating virus in bottom/abluminal chamber of in vitro BBBs
constructed with (A) WT BMECs over Ifnar-/- astrocytes, pretreated in the top/luminal chamber
overnight with 100pg/ml IFNβ or (B-C) WT or Ifnar-/- BMECs over Ifnar-/- astrocytes (not
treated with cytokine). Cultures in (C) were pretreated for 2h with the CDC42 antaonist ML141
(100nM) before infection. Cultures in all panels were infected with 0.01 MOI WNV in the
top/luminal chamber and allowed to incubate for 6h before the removal of the top/luminal
chamber. Values represent viral titers present after 0, 12, 24, and 48h of replication by virus that
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crossed during the 6h infection, prior to removal of BMECs from the culture system. Viral titers
reported as plaque forming units (PFU)/ml, as determined via standard plaque assay in BHK
cells. Dotted line represents limit of detection for the assay. *p<0.05, **p<0.01, ***p<0.001.
Data are mean values +/- SEM of 6-12 replicates from 2 independent experiments.
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Figure S5: 8wo WT and Ifnar-/- received mock intracranial inoculations with saline. On days
indicated following infection, mice were administered sodium fluorescein (see figure 6) and
CNS regions contralateral to the inoculation site were assessed for BBB permeability. Data are
mean values +/- SEM for 3-6 mice per genotype/time point.
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Chapter 5
Interferon-λ restricts West Nile virus neuroinvasion by tightening the bloodbrain barrier

This chapter is adapted from the following publication:
Lazear HM*, Daniels BP*, Pinto AK, Huang AC, Vick SC, Gale Jr. M, Klein RS*, and
Diamond MS*. (2015) Interferon-λ restricts West Nile virus neuroinvasion by tightening
the blood-brain barrier. Science Translational Medicine. 7(284): 284ra59. (*Equal
Contribution)
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5.1 Introduction
IFN-λ belongs to a family of cytokines that signal through the heterodimeric IFN-λ
receptor, IFNLR, which is composed of two proteins, IL-10Rβ and IFNLR1 (IL-28Rα).
Analogous to signaling by IFN-α/β and its heterodimeric receptor, IFNAR, binding of IFN-λ to
IFNLR initiates a JAK-STAT signaling cascade that induces expression of genes with antiviral
and immunomodulatory activities (227). Mice lacking IFNLR1 (Ifnlr1-/-) do not respond to IFNλ but retain relatively normal responses to IFN-α/β (228). In contrast to IL-10Rβ, which is
expressed more widely, IFNLR1 exhibits a cell-type restricted expression pattern (67, 229).
IFNLR1 is preferentially expressed on epithelial cells and the inhibitory effects of IFN-λ in vivo
have been documented against viruses that target epithelial tissues including influenza virus,
rotavirus, norovirus, and herpes simplex virus (HSV) (68, 229-232). In cell culture, IFN-λ
reportedly inhibits infection of a broader panel of viruses with non-epithelial cell tropisms,
including West Nile virus (WNV) (233).
WNV is an encephalitic flavivirus that cycles in nature between birds and mosquitoes
with humans becoming infected as incidental dead-end hosts. Approximately 20% of human
infections produce a febrile illness, and a subset of these (<1%) progresses to severe disease,
which manifests as meningitis, encephalitis, or acute flaccid paralysis (234). Among patients
with neurological symptoms, the case-fatality rate is 5 to 10%, and survivors are commonly left
with debilitating neurological sequelae.
Because WNV is highly neurovirulent, the failure of infections to progress uniformly to
neurological disease suggests that barriers to neuroinvasion exist, and that dissemination into the
central nervous system (CNS) determines clinical outcome. The precise mechanism(s) by which
WNV spreads to the brain and spinal cord remain unclear (79). Neuroinvasion is thought to
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occur preferentially by a hematogenous route. Thus, the blood-brain barrier (BBB), a physical,
metabolic, and transport barrier between the CNS and peripheral circulation, represents a key
defense against WNV neuroinvasion (23). The BBB is composed of tight junctions between
endothelial cells of the CNS microvasculature and the endfeet of astrocytes; the endothelial cells
and astrocytes are separated by two basement membranes and a perivascular space. BBB
permeability is increased in response to pro-inflammatory stimuli, including LPS, TNF-α, and
IFN-γ, and this opening also permits trafficking of immune cells into the CNS (235, 236).
Although BBB opening may be necessary to resolve certain CNS infections, it is regulated to
avoid pathological consequences from infiltrating cells or other substances from the periphery
(23). Dysregulation of BBB permeability can result in adverse outcomes, including autoimmune
disease (e.g., multiple sclerosis) (139). The BBB can present as an obstacle for treatment, as
many drugs cannot enter the CNS efficiently from the peripheral circulation (237).
While some inflammatory stimuli increase BBB permeability, IFN-α/β may enhance
BBB integrity. IFN-β treatment reduces endothelial permeability in an in vitro model of the BBB
(236, 238) and is used therapeutically to treat multiple sclerosis, which features BBB breakdown
and trafficking of autoreactive T cells into the CNS as key components of the disease pathology
(205). In tissue culture, IFN-β directly regulated endothelial permeability and tight junction
formation via the actions of the GTPases Rac1 and RhoA (236). Given the analogous JAKSTAT-dependent signaling pathways induced by IFN-α/β and IFN-λ, we evaluated possible
direct or indirect antiviral effects of IFN-λ on WNV infection. Our results suggest that IFN-λ
signaling inhibits WNV infection of the CNS by modulating endothelial cell tight junction
integrity, which decreases BBB permeability, restricts virus neuroinvasion, and prevents lethal
infection.
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5.2 Results
IFN-λ does not inhibit WNV infection of relevant target cells in vitro
Since IFN-λ reportedly induces an antiviral gene program similar to IFN-α/β (239-241),
we tested whether it would inhibit WNV infection in cell culture. We expected IFN-λ to exert its
greatest effects on epithelial cells, due to the reported tissue-specific expression pattern of Ifnlr1
(67, 68, 229). Prior to assaying for direct antiviral effects, we assessed the relative mRNA
expression levels of the receptors for IFN-α/β (Ifnar1) and IFN-λ (Ifnlr1 and Il10rb) in primary
cells (cortical neurons and bone marrow-derived dendritic cells (DCs) and macrophages) (Figure
1A-D). We also tested a mouse keratinocyte cell line because keratinocytes are one the few
epithelial cells targeted by WNV in vivo (242). All cell types expressed Ifnar1, whereas Il10rb
was detected in keratinocytes, DCs, and macrophages, but not cortical neurons. Moreover, we
detected Ifnlr1 expression in keratinocytes and DCs, but levels in macrophages and cortical
neurons were near the limit of detection. Importantly, Ifnlr1 expression was not detected in DCs
prepared from Ifnlr1-/- mice.
Based on mRNA levels of the IFN-λ receptor, we chose keratinocytes and DCs for
further studies with IFN-λ. We treated keratinocytes with IFN-λ3 (10 or 100 ng/ml) or IFN-β
(0.1 or 1 ng/ml) for 6 h and measured ISG expression by qRT-PCR. Ifit1 and Rsad2 were
upregulated in response to IFN-λ3 or IFN-β (Figure 1E and F), although induction was lower
with IFN-λ than IFN-β. For example, in keratinocytes, 0.1 ng/ml of IFN-β increased Ifit1 mRNA
expression by ~1,700-fold, whereas 100 ng/ml of IFN-λ produced a <150-fold increase. The
effect of IFN-λ on ISG expression was less potent in DCs compared to keratinocytes and as
expected did not occur in Ifnlr1-/- DCs. Although IFN-λ induced expression of the ISGs Ifit1 and
Rsad2, unlike IFN-β, it did not stimulate expression of Irf7 (Figure 1G). An increase in the IFN-
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λ dose to 1,000 ng/ml failed to increase ISG expression further, indicating a plateau effect
(Figure 1H).
We extended these results using RNAseq analysis to obtain a more complete profile of
the IFN-λ gene signature in primary DCs (Figure 1I). Using a 3-fold induction cut-off (relative
to mock) after 6 h of IFN treatment, we detected an increase of 208 genes in IFN-β-treated DCs
whereas no genes were induced to this level in the IFN-λ-treated DCs (Table S1). We also did
not detect any ISGs that were induced uniquely by IFN-λ; the IFN-λ stimulated genes were a
subset of those induced by IFN-β.
To assess whether the gene program induced by IFN-λ inhibited WNV replication, we
treated keratinocytes and DCs with IFN-λ3 or IFN-β prior to infection, using concentrations that
induced expression of antiviral genes. In keratinocytes, we observed a dose-dependent inhibition
of viral replication by IFN-β (Figure 2A). In both WT and Ifnlr1-/- DCs, even the lower dose of
IFN-β blocked WNV infection (Figure 2B and C). We did not observe any inhibition of WNV
replication by IFN-λ3, even at doses that induced ISGs. We performed multi-step viral growth
analyses in primary cells from Ifnlr1-/- and WT mice and found no differences in WNV infection
between Ifnlr1-/- and WT DCs, macrophages, or cortical neurons (Figure 2D-F). Our results
suggest that although IFN-λ induced ISG expression, the effect was not directly antiviral, either
because the magnitude of the response was insufficient or the specific set of genes induced was
not inhibitory against WNV.

IFN-λ signaling limits WNV neuroinvasion
We assessed a role for IFN-λ in restricting WNV infection in vivo. We infected WT and
Ifnlr1-/- mice and measured viral burden in different tissues. WT and Ifnlr1-/- mice displayed no
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significant differences in viral loads at any time point in peripheral compartments, including the
serum, draining lymph node, spleen, and kidney (Figure 3A-D). However, Ifnlr1-/- mice
sustained higher viral titers in the brain and spinal cord at days 6 and 8 after infection (Figure 3E
and F). We also detected virus in the brain earlier in Ifnlr1-/- mice compared to WT (2 of 8 Ifnlr1/-

mice positive at day 4 after infection, compared to 0 of 5 WT mice).
To determine whether the higher WNV titers in the CNS of Ifnlr1-/- mice reflected a

direct antiviral effect of IFN-λ in brain tissues, we infected mice by an intracranial route and
measured viral titers 3 and 5 days after infection. We found no difference in viral titer between
WT and Ifnlr1-/- mice in any of the CNS regions examined (Figure 3G-I). Thus, while Ifnlr1-/mice developed enhanced CNS infection following peripheral WNV infection, no such increase
was observed when the virus was inoculated directly into the brain.

Ifnlr1-/- mice develop normal adaptive immune responses to WNV infection.
Given the early entry and enhanced replication in the brain and spinal cord, we
considered whether IFN-λ might restrict WNV neuroinvasion indirectly by regulating peripheral
immune responses, which are required to prevent dissemination to the CNS (243). However, we
detected no difference between WT and Ifnlr1-/- mice in levels of anti-WNV IgM or IgG in the
serum at days 4, 6, or 8 after WNV infection (P > 0.05) (Figure S1). To assess cellular immune
responses, we profiled leukocytes from the spleen and brain at 8 days after WNV infection and
found no differences between WT and Ifnlr1-/- mice in total numbers or percentages of CD11b+,
CD11c+, CD4+, or CD8+ cells (Figure 4A-D, K-N). Antigen-specific CD8+ T cell responses were
equivalent in WT and Ifnlr1-/- mice (Figure 4E and O) and CD8+ T cell effector functions
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(production of granzyme B, IFN-γ, and TNF-α) also were similar between WT and Ifnlr1-/- mice
in both the spleen and brain (Figure 4F-J, P-T).

Ifnlr1-/- mice have increased BBB permeability following WNV infection
As IFN-α/β signaling can enhance BBB integrity (236), we hypothesized that IFN-λ
might exert an analogous effect to prevent virus transport across the BBB, which could explain
the increased CNS infection in Ifnlr1-/- mice. We assessed BBB permeability in WT and Ifnlr1-/mice 4 days following WNV infection. Compared to mock-infected mice, WNV infection
resulted in increased extravasation of sodium fluorescein dye from the peripheral circulation into
the CNS (Figure 5A-C). Although Ifnlr1-/- mice showed no basal differences in BBB
permeability compared to WT mice, the WNV-induced permeability change was greater in
Ifnlr1-/- mice, suggesting that IFN-λ signaling may tighten the barrier in response to infection. As
an independent measure of BBB permeability, we used confocal microscopy to assess leakage of
endogenous IgG into the brain parenchyma following WNV infection. Although minimal IgG
was detected in the brains of uninfected mice, IgG accumulation became apparent at 4 days after
infection, and Ifnlr1-/- mice exhibited greater leakage than WT mice (Figure 5D and E). Thus, in
the context of WNV infection, the BBB of Ifnlr1-/- mice was more permeable to small molecules
(fluorescein dye, MW of 376) and to proteins (IgG, MW of 150,000). Since inflammatory
cytokines, including IFN-γ and TNF-α, promote BBB opening (43, 236), we considered whether
increased permeability in Ifnlr1-/- mice was due to elevated cytokine production in response to
WNV infection. We measured levels of 21 cytokines in serum at 3 and 5 days after infection and
found no differences between WT and Ifnlr1-/- mice (Table S2). We also assessed IFN-α/β
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activity in the serum and found no differences between WNV-infected WT and Ifnlr1-/- mice
(Figure S2).

IFN-λ signaling improves BBB integrity in vitro
To explore how IFN-λ signaling modulates WNV entry into the CNS, we used an in vitro
model of the BBB (225, 236). In this system, BMECs are cultured in the upper chamber of a
transwell, with supporting astrocytes in the lower chamber. Transendothelial electrical resistance
(TEER) across the BMEC monolayer determines BBB integrity, with higher resistance
representing a tighter barrier. We first measured expression of IFN receptors and WNV
replication in the two primary cell types in this system. BMECs and astrocytes expressed
abundant Ifnar1 and Il10rb mRNA, whereas Ifnlr1 expression levels were lower (Figure 6A and
B). We measured WNV replication in BMECs and astrocytes prepared from WT and Ifnlr1-/mice, and in both cases found no difference in viral yield (Figure 6C and D).
We next infected BMECs with WNV and measured TEER after 6 h, a time point that
precedes secretion of virions and de novo spread of flavivirus infection (244). Although WT and
Ifnlr1-/- BMECs exhibited equivalent TEER in the absence of infection, the increase in TEER
following WNV infection was blunted in Ifnlr1-/- cells (Figure 6E). The effect of IFN-λ was due
to signaling in BMECs rather than astrocytes; in reciprocal culture experiments, only Ifnlr1-/BMECs exhibited the lower TEER phenotype regardless of the astrocyte genotype (Figure 6E).
Therefore, subsequent transwell experiments used WT astrocytes paired with WT or Ifnlr1-/BMECs.
We next treated BMECs with recombinant murine IFNs for 6 h and measured TEER.
IFN-λ3 produced a dose-dependent increase in TEER at 6 h, and this effect was abolished in
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Ifnlr1-/- BMECs (Figure 6F). As observed previously (236, 238), IFN-β treatment produced an
increase in TEER. However, this effect was diminished in Ifnlr1-/- BMECs, suggesting that a
portion of the IFN-β effect may have been due to IFN-λ signaling. To distinguish the
contributions of IFN-α/β and IFN-λ to the WNV-induced TEER increase, we pre-treated BMECs
with a blocking MAb against IFNAR1 or an isotype control (245). When IFN-α/β signaling was
blocked, WNV infection did not produce an increase in TEER in either WT or Ifnlr1-/- BMECs
(Figure 6G). These results suggest that IFN-λ signaling promotes BBB tightening and that IFN-λ
production following WNV infection requires IFN-α/β signaling, as opposed to being induced
directly by pattern recognition receptor signaling pathways.
As it remained possible that the IFN-λ signaling effect on TEER was mediated by an
induced cytokine, we tested the requirement for de novo protein synthesis (Figure 6H). BMECs
were pre-treated with the protein synthesis inhibitor cycloheximide (CHX) and then infected
with WNV or treated with IFN-β or IFN-λ3 for 6 h. When CHX was added, the WNV-induced
increase in TEER was abolished and the IFN-β induced increase was diminished. Remarkably,
CHX treatment had no effect on the increase in TEER produced by IFN-λ3, indicating that
BMECs could form a tighter barrier downstream of IFN-λ-IFNLR signaling without requiring de
novo protein synthesis.
To define further the signaling pathway by which IFN-λ regulates TEER changes in
BMECs, we assessed mRNA levels of Ifnb, Ifna, and Il28b in BMECs following treatment with
IFN-β, IFN-λ3, or LPS for 6 h. We did not detect expression of these IFNs, although the ISGs
Ifit1 and Rsad2 were induced, as expected (Figure S3). Given the results from the CHX
experiments (Figure 6H), we hypothesized that the IFN-λ induced TEER response might occur
through a non-canonical signaling pathway that did not require ISG expression. To evaluate this,
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we prepared BMECs from WT and Stat1-/- mice and measured TEER following treatment with
IFN-β or IFN-λ3 (Figure 6I). Remarkably, both IFN-λ and IFN-β induced increases in TEER
within 2 h of treatment in a STAT1-independent manner. At later time points (e.g. 12 h), TEER
values were somewhat lower in Stat1-/- cells compared to WT cells, indicating a subordinate role
for canonical STAT1 signaling and possibly ISG expression in barrier tightening. To determine
whether IFN-λ also could induce endothelial barrier tightening in human cells, we treated a
human BMEC cell line (HCMEC/D3) (225) in a transwell system with pegylated human IFN-λ1
(100 ng/ml) or human IFN-β (10 ng/ml) and measured TEER over time (Figure 6J). Within 2 h
of IFN treatment, TEER increased markedly, demonstrating analogous effects of IFN-λ on
mouse and human BMECs. Taken together, our experiments suggest a model in which WNV
infection stimulates the production of IFN-λ, possibly downstream of IFN-α/β signaling. Along
with IFN-α/β signaling through IFNAR (236), circulating IFN-λ signals through IFNLR on
BMECs via a non-canonical STAT1- and protein synthesis-independent pathway to tighten the
endothelial barrier and limit virus neuroinvasion.
We questioned whether changes in TEER and cell junction protein localization directly
impacted transit of WNV across the endothelial barrier. We treated HCMEC/D3s first with LPS
for 18 h, and then with IFN-λ1 for 6 h. We then added WNV to the upper chamber and after 6 h
measured virus that had crossed into the lower chamber. As expected, we observed decreased
TEER after LPS treatment and an increase in TEER in response to IFN-λ treatment (Figure 6K).
Consistent with the changes in TEER, LPS treatment resulted in greater crossing of WNV into
the lower chamber and this effect was diminished by IFN-λ treatment (Figure 6L) and not due to
changes in cell viability (Figure S4). Together, these results indicate that IFN-λ signaling
promotes endothelial barrier tightening, which restricts WNV transit.

159

To define how IFN-λ modulates TEER, we analyzed the location of the endothelial cell
junction proteins ZO-1 and claudin-5 in BMECs and brain sections following treatment with
LPS and IFN-λ (Figure 7). While co-localization between ZO-1 and claudin-5 was observed in
mock-treated BMECs, treatment with LPS, which disrupts BBB integrity (235), caused ZO-1
and claudin-5 to dissociate. Remarkably, the effect of LPS on cell junction protein colocalization was reversed by IFN-λ3 treatment (Figure 7A and B). We observed a similar effect
in the brains of mice treated with LPS and pegylated IFN-λ2, such that ZO-1 and claudin-5 colocalization was reduced in animals treated with LPS and restored in mice receiving IFN-λ2
(Figure 7C). ZO-1 and claudin-5 co-localization in endothelial cells also was diminished in
brains of WT and Ifnlr1-/- mice following WNV infection (Figure 7D), as expected from in vivo
BBB permeability measurements.

IFN-λ enhances BBB integrity in vivo
Since Ifnlr1-/- mice displayed increased BBB permeability following WNV infection and
IFN-λ decreased the barrier function of BMECs in vitro, we hypothesized that administration of
IFN-λ might restrict BBB permeability in vivo. We treated WT mice with LPS to open the BBB
and then administered pegylated murine IFN-λ2 or PBS. LPS treatment produced an increase in
BBB permeability compared to mice that received PBS alone, but this effect was diminished in
mice receiving IFN-λ2 (Figure 8A-C).
We next tested whether administration of IFN-λ could restrict WNV neuroinvasion. WT
mice were inoculated subcutaneously with WNV and pegylated murine IFN-λ2 was administered
via an intravenous route on the day of infection as well as two and four days afterwards.
Consistent with data from Ifnlr1-/- mice (Figure 3A), IFN-λ2 treatment did not exhibit a direct
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antiviral effect, as viremia remained unchanged (Figure 8D). Nonetheless, IFN-λ2-treated mice
showed improved survival rates compared to PBS-treated controls (Figure 8E). We also
observed a similar trend toward improved survival after WNV infection in mice receiving IFNλ2 using a different dosing regimen (Figure S5). To determine whether the improved survival
observed in IFN-λ2-treated mice correlated with reduced WNV neuroinvasion, we measured
viral burden in the CNS. WT mice were inoculated with WNV and treated with pegylated murine
IFN-λ2 at days 2, 3, and 4 after infection. As expected, IFN-λ2 treatment did not reduce viremia
(Figure 8F), but at day 8 after infection, IFN-λ2-treated mice had lower titers in the cerebral
cortex compared to control mice that received PBS (Figure 8G). This effect was region-specific,
as reductions in titer were not observed in the cerebellum or spinal cord.
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5.3 Discussion
Prior studies in Ifnlr1-/- mice revealed a role for IFN-λ in controlling viral infection in
epithelial tissues, although no inhibitory effect was observed with several viruses that
disseminate more broadly (68, 228, 229, 231, 232, 246, 247). These observations were consistent
with a preferential epithelial cell expression pattern for IFNLR1 (67, 229) and tissue
responsiveness to treatment with exogenous IFN-λ (67, 68, 230, 231). Although WNV replicates
in a variety of cell types in vitro, its main targets in vivo are myeloid cells and neurons (243). As
WNV is not reported to target epithelial cells beyond keratinocytes in the skin (242), a virologic
phenotype for WNV in the CNS of Ifnlr1-/- mice was unexpected. Our experiments show that
IFN-λ signaling did not directly inhibit WNV infection in vitro or in vivo but instead support a
novel mechanism in which IFN-λ signaling enhances the integrity of the BBB, thereby limiting
the neuroinvasive potential of WNV.
Although IFN-α/β directly stimulates expression of genes that inhibit WNV and other
flaviviruses (200, 248, 249), in our experiments IFN-λ failed to do so in several cell types in
culture, even though the receptors were expressed and ISGs were induced. Although a prior
study reported an antiviral effect of IFN-λ on WNV (233), those observations may not be
comparable, as they were based on luciferase production by WNV replicons in human tumor cell
lines, as opposed to our study, which measured replication of fully infectious virus in primary
mouse cells and a mouse cell line.
Why did we not observe a direct inhibitory effect of IFN-λ in our experiments? Based on
RNAseq and qRT-PCR analyses, the magnitude and breadth of the ISG response to IFN-λ were
reduced compared to IFN-β. While previous studies have compared the transcriptional signatures
induced by IFN-λ and IFN-α/β (239-241, 250), these studies were performed in human tumor
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cell lines with a focus on hepatitis C virus (HCV) infection. Our analysis compared the
transcriptional profiles induced by IFN-λ and IFN-β in mouse cells and may help to explain the
results of other viral pathogenesis studies in Ifnlr1-/- mice. The ability of IFN-λ to induce ISG
expression in a more targeted set of cells compared to IFN-α/β suggests a possible therapeutic
application: to obtain a more focused antiviral or immunomodulatory effect with fewer side
effects (251, 252). Currently, IFN-λ is being tested in more than a dozen clinical trials (e.g.,
http://clinicaltrials.gov/show/NCT01866930) as a therapy for hepatitis B and C virus infections.
We observed early dissemination and increased WNV infection in the brain and spinal
cord of Ifnlr1-/- mice. Because intracranial and cell culture infection experiments failed to show a
direct antiviral effect of IFNLR1 in neurons, we hypothesized that IFN-λ signaling might
minimize WNV spread to the CNS by affecting BBB permeability. The following data support a
model in which IFN-λ signaling restricts the neuroinvasive potential of WNV by improving BBB
function: (a) BBB permeability was greater in WNV-infected Ifnlr1-/- compared to WT mice; (b)
WT and Ifnlr1-/- mice had equivalent viral burden in peripheral compartments including serum,
so the increased infection in the brain was not due to antiviral effects of IFN-λ in the periphery;
(c) pro-inflammatory cytokine levels were similar in WT and Ifnlr1-/- mice and thus did not cause
differential changes in BBB permeability; (d) TEER was lower in WNV-infected Ifnlr1-/BMECs compared to WT cells; (e) TEER was higher after treatment of WT BMECs or
HCMEC/D3s with exogenous IFN-λ; (f) IFN-λ treatment restricted transit of WNV across
HCMEC/D3 monolayers; (g) treatment of mice with IFN-λ minimized BBB permeability
changes associated with LPS administration; and (h) treatment of mice with IFN-λ decreased
WNV infection in the brain without altering viremia, and this was associated with improved
survival rates. Circulating IFN-λ produced in response to infection may serve a protective role by
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limiting virus transit into the CNS and countering the effects of inflammatory cytokines that
increase BBB permeability (e.g., TNF-α, IL-1β, or IFN-γ) (43, 225, 236). Unexpectedly,
although exogenous IFN-λ administration reduced WNV neuroinvasion and improved survival
rates, we did not observe increased in lethality in Ifnlr1-/- compared to WT mice (data not shown).
WNV infection may not induce IFN-λ in a sufficient amount or with appropriate localization to
impact lethality, despite its effect on viral neuroinvasion. Nonetheless, we readily observed BBB
tightening effects of IFN-λ even in the context of intact IFN-α/β responses.
While IFN-λ-induced BBB tightening limited the spread of WNV to the CNS, we
observed no effect on trafficking of immune cells from the periphery into the brain, even though
the BBB is a key regulator of this process (253). Our observations are consistent with the
minimal alterations in the cellular immune response that were observed after LCMV infection of
Ifnlr1-/- mice (247) and highlight that transport of different substances across the BBB is
controlled carefully.
How does IFN-λ signaling affect BBB permeability and limit WNV neuroinvasion?
WNV likely enters the CNS via a hematogenous route, which could be through trafficking of
infected cells across the BBB, transcellular or paracellular transit of virus across the cells of the
BBB, or direct infection of BBB cells (23, 79). As we saw no effect of IFNLR1 expression on
WNV replication in BMECs or on trafficking of immune cells into the CNS, our data suggest a
model in which WNV virions transit through BBB cell junctions and IFN-λ signaling limits this.
Indeed, IFN-λ treatment inhibited the accumulation of viral RNA on the basal side of a
HCMEC/D3 monolayer within 6 h of exposure to WNV. Remarkably, the effect of IFN-λ
occurred via a non-canonical STAT1- and protein synthesis-independent signaling pathway.
IFN-λ signaling enhanced co-localization of the cell junction proteins ZO-1 and claudin-5 under
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conditions of inflammation in vitro and in vivo, which improved the endothelial barrier. As the
rapid effect of IFN-λ preceded completion of the viral lifecycle (244), the phenotype was not due
to the spread of infection through the cell culture, but rather to cellular responses induced rapidly
in response to pathogen sensing. Indeed, prior studies demonstrated that active viral replication
was not required for endothelial barrier tightening, as UV-inactivated WNV also induced an
IFNAR-dependent increase in TEER (236).
As mosquitoes inoculate WNV beneath the epidermis, the BBB may represent one of the
first physical barriers encountered by WNV as it spreads in a vertebrate host. Modulation of
physical barriers to infection represents a novel antiviral mechanism for IFN-λ. Possibly, barrier
tightening by IFN-λ signaling also may restrict dissemination of viruses that transit across
epithelial surfaces, including the skin and gastrointestinal tract. As many viruses (e.g., HSV,
HCV, polio, and measles viruses) use cell junction proteins as entry receptors (254-258), it is
intriguing to consider that some of the antiviral effects of IFN-λ observed in other viral systems
(252) may be explained by relocalization of cell entry receptors.
While our experiments demonstrated a BBB tightening effect of IFN-λ on both human
and murine BMECs in culture, a limitation of these studies is that we did not analyze the effects
of all different IFN-λ subtypes. Mice encode two functional IFN-λ genes (IFN-λ2 and IFN-λ3),
and humans have four paralogs (IFN-λ1, 2, 3, and 4). Whereas IFN-λ2 and IFN-λ3 are nearly
identical (227), IFN-λ1 and IFN-λ4 may have distinct properties; a polymorphic allele that
enables IFN-λ4 production is associated with impaired HCV clearance (259). Due to the limited
recombinant proteins available, we were unable to assess whether IFN-λ subtypes vary in their
BBB tightening activity.
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In summary, our results suggest a novel function of IFN-λ whereby signaling through
IFNLR1 rapidly modulates endothelial cell junctions without a requirement for STAT1 signaling
or protein synthesis. This results in a tighter BBB, which restricts pathogen entry into the CNS
parenchyma. In humans, multiple polymorphisms in the IFN-λ locus are associated with
differential clearance of hepatitis B and C virus infections (259), as well as the severity of HSV
or human cytomegalovirus disease (260, 261). Further analysis may be warranted to define
similar genetic linkages to neuroinvasive infections or CNS autoimmune diseases (262). Such
information may provide new contexts for therapeutic interventions with IFN-λ.
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5.4 Materials and Methods
Experimental design
We initiated this study to determine whether IFN-λ controls WNV pathogenesis. Our
initial observation was that Ifnlr1-/- mice had increased viral burden in the CNS, and subsequent
experiments evaluated why this occurred. We measured viral titers in tissues and replication in
primary cells. We also assessed immunologic parameters including antibody and cytokine levels
in serum and leukocyte phenotypes in the spleen and brain. After excluding antiviral or
immunomodulatory effects of IFN-λ, we considered whether increased neuroinvasion might be
due to altered BBB permeability. We employed an in vitro model of the BBB, in which
resistance across an endothelial monolayer corresponds to barrier tightness. Sample sizes and
endpoints were selected based on our extensive experience with these systems. Mice were ageand sex-matched between groups. Investigators were not blinded when conducting or evaluating
the experiments.

Viruses
WNV strain 3000.0259 was isolated in New York in 2000 and passaged once in C6/36
Aedes albopictus cells (263). Virus titers were measured by plaque assay on BHK21-15 cells
(264).

Mouse experiments
Mice were genotyped and bred at the Washington University School of Medicine.
C57BL/6 WT mice were obtained commercially (Jackson Laboratories) or bred in-house. Stat1-/mice (265) were provided by H. Virgin (Washington University). Ifnlr1-/- mice (originally called
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IL-28RA-/-, obtained from Bristol-Myers-Squibb) lack the entire Ifnlr1 coding sequence (228).
Five or 9 to 12 week-old WT and Ifnlr1-/- mice were used for in vivo studies, as indicated in the
figure legends. For peripheral infection, 102 PFU of WNV in 50 µl was inoculated into the
footpad. For intracranial infection, 101 PFU of WNV in 25 µl was injected into the right cerebral
hemisphere. Experiments were approved and performed in accordance with Washington
University Animal Studies Guidelines.

Cells
Macrophages, DCs, and cortical neurons were generated from WT or Ifnlr1-/- mice as
described (266, 267). Astrocytes were prepared from mixed glia cultures generated from 1- to 3day old pups as described (236). Murine BMECs were prepared as described previously (225).
Briefly, blood vessels were isolated from cerebral cortex tissue by digestion with type 2
collagenase (Worthington) and DNase (Sigma-Aldrich), followed by centrifugation (1,000 x g
for 20 min). Isolated vessels were digested in collagenase-dispase (Roche) and DNase then
centrifuged through a Percoll gradient (1,000 x g for 10 min), washed and plated in flasks coated
with mouse collagen type IV (Sigma-Aldrich) and human fibronectin. The human BMEC cell
line HCMEC/D3 was cultured in transwells (225). The mouse keratinocyte cell line PDV was
purchased (Cell Lines Service) and cultured in DMEM supplemented with 10% FBS, Lglutamine, and non-essential amino acids.

IFN treatment and viral infection of cells
Keratinocytes and DCs were treated with recombinant murine IFN-λ3 (0.1 to 1000 ng/ml)
or IFN-β (0.1 or 1 ng/ml) (PBL Assay Sciences) for 6 h and then infected with WNV at a MOI of
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0.1. Supernatants were titered by focus-forming assay on Vero cells using anti-WNV MAb E16
(264). Gene expression was analyzed 6 h following IFN treatment. Total RNA was isolated using
an RNeasy Mini Kit (Qiagen) and fluorogenic quantitative reverse transcription PCR (qRT-PCR)
was performed using One-Step RT-PCR Master Mix and a 7500 Fast Real-Time PCR System
(Applied Biosystems). Gene expression was measured using the indicated Taqman reagents
(Integrated DNA Technologies) (Table S3). Multi-step virus growth analysis was performed
after infection at a multiplicity of infection (MOI) of 0.01 for macrophages, astrocytes, and
BMECs or 0.001 for DC and cortical neurons. Viral infection was measured by focus-forming
assay.

RNAseq analysis
DCs were generated from WT mice and treated with serum-free media (mock), IFN-β
(20 ng/ml), or IFN-λ3 (10 ng/ml) for 6 h. Total RNA was isolated using an RNeasy kit (Qiagen).
Samples were multiplexed and barcoded for sequencing on the Illumina HiSeq 2000. A
minimum of 25 million (50 bp pair-end) reads was generated per sample. Sequencing reads were
mapped to the mouse genome (NCBI mm10) using Bowtie (2.10) and Tophat (2.010). Transcript
assemblies and quantifications (FPKM) were calculated using the Cufflinks package (2.11).
Genes with larger than 3-fold differences with IFN treatment (relative to mock) were retained,
sorted, and displayed in a summarizing heatmap using the Matlab software package.

Tissue viral burden
To monitor viral spread in vivo, mice were infected with 102 PFU of WNV by
subcutaneous inoculation and sacrificed at specified time points. To monitor viral replication
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directly in the CNS, mice were infected with 101 PFU of WNV by intracranial injection and
sacrificed at days 3 or 5 after infection. After cardiac perfusion with PBS, organs were harvested,
weighed, and homogenized and virus was titered by plaque assay. Viral RNA was isolated from
serum and plasma using a Viral RNA Mini Kit (Qiagen) and from draining lymph nodes using an
RNeasy Mini Kit (Qiagen). Viral load was measured by qRT-PCR with the indicated primer and
probe sequences (Table S3).

Cellular immune responses
WT and Ifnlr1-/- mice were infected in the footpad with 102 PFU of WNV and at 8 days
after infection, spleens and brains were harvested after cardiac perfusion with PBS (214). Cells
were incubated with the following antibodies and processed by multi-color flow cytometry on an
LSR II flow cytometer (Becton Dickinson): CD3 (eBiosciences, clone 145-2C11), CD4
(Biolegend, clone RM4-5), CD8α (Biolegend, clone 53-6.7), CD19 (Invitrogen), CD45
(Biolegend, clone 30-F11), CD11b (Biolegend, clone M1/70), CD11c (Biolegend, clone N418),
Granzyme B (Invitrogen), IFN-γ (Biolegend, clone XMG1.2), TNF-α (Biolegend, clone MP6XT22). IFN-γ and TNF-α staining was performed after ex vivo restimulation with a Db-restricted
NS4B immunodominant peptide using 1 µM of peptide and 5 µg/ml of brefeldin A (Sigma).
Flow cytometry data were analyzed using FlowJo software (Treestar).

BBB permeability measurements and confocal microscopy
Mice were infected with 102 PFU of WNV or diluent (mock) and BBB permeability was
assessed after 4 days. In other experiments, mice were treated with LPS (List Biological
Laboratories, 3 mg/kg via intraperitoneal injection) and pegylated murine IFN-λ2 (Bristol-Myers

170

Squibb, 25 µg via intravenous injection), and BBB permeability was assessed 24 h later. Sodium
fluorescein dye (100 mg/ml) was administered via an intraperitoneal route in 100 µl. After 45
min, blood was collected by cardiac puncture into EDTA-coated tubes. Mice were perfused and
CNS tissues were harvested, homogenized into PBS, clarified by centrifugation, precipitated in
1% trichloroacetic acid, and neutralized with borate buffer (Sigma-Aldrich). Fluorescence
emission at 485 and 528 nm was determined using a microplate reader Synergy™ H1 and
Gen5™ software (BioTek Instruments, Inc.). Fluorescein concentration was calculated from a
standard curve and tissue fluorescence values were normalized to the plasma fluorescence values
from the same mouse.
Polarized BMECs on chamber slides were treated first with 100 ng/ml LPS for 18 h and
then with 100 ng/ml murine IFN-λ3 for 6 h. Cells were fixed in ice-cold methanol and blocked
with 10% goat serum. Mice were perfused with PBS and then 4% paraformaldehyde.
Cryoprotected brains were embedded in OCT Medium (Tissue-Tek) and 8 μm frozen sections
were mounted on slides. Cells and sections were stained with primary antibodies against the cell
junction proteins ZO-1 (rat monoclonal R40.76, Millipore) and claudin-5 (rabbit polyclonal,
Invitrogen) followed by AlexaFluor-conjugated secondary antibodies. Endogenous mouse IgG
was detected in brain sections using an AlexaFluor-488 anti-mouse IgG antibody. Nuclei were
stained with Topro3. Images were acquired with a laser scanning confocal microscope (Zeiss
LSM 510 META) and analyzed with LSM image browser software (Zeiss). Co-localization of
ZO-1 and claudin-5 staining was calculated using ImageJ software.

Transwell cultures and transendothelial electrical resistance measurements
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BMECs and HCMEC/D3s were grown until fully polarized in transwell cultures (225).
BMECs were grown above astrocyte cultures, whereas HCMEC/D3s were grown without
astrocytes. Transendothelial electrical resistance (TEER) was measured via chopstick electrode
with an EVOM voltmeter (World Precision Instruments). Resistance values are reported as Ω x
cm2, with the resistance value for transwell inserts with no cells subtracted as background. TEER
measurements were collected at 6 h following infection with WNV at MOI 0.01 or treatment
with murine IFN-λ3 (10 or 100 ng/ml), murine or human IFN-β (10 ng/ml) (PBL Assay Science)
or pegylated human IFN-λ1 (100 ng/ml) (Bristol-Myers Squibb); mock wells were treated with
culture medium. To block IFN-α/β signaling, BMEC cultures were treated with 25 µg/ml of the
blocking MAb MAR1-5A3 (245) for one hour prior to infection. A non-binding MAb (GIR-208)
was used as an isotype control (245). To block de novo protein synthesis, BMEC cultures were
pre-treated with 20 µg/ml CHX for 18 h prior to treatment with IFN-β or IFN-λ3 or infection
with WNV. To measure virus transit across the endothelial barrier, polarized HCMEC/D3s in
transwells were treated first with 100 ng/mL of LPS for 18 h and then human IFN-β or pegylated
human IFN-λ1 (100 ng/ml) for 6 h. WNV was added to the upper chamber of the transwell at an
MOI of 0.01. After 6 h, virus in the lower chamber was measured by qRT-PCR.
Statistical analysis
Tissue titers and immunophenotyping experiments were analyzed by the Mann-Whitney
test, whereas parametric tests (t-test and 2-way ANOVA) were used in other experiments.
Survival experiments were analyzed by the log-rank test.
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5.6 Figures
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Figure 1: IFN-λ produces cell-type restricted induction of ISGs. A-D. Expression of Ifnar1,
Ifnlr1, and Il10rb was measured by qRT-PCR from total cell RNA from uninfected keratinocytes,
DCs, macrophages, or cortical neurons. Gene expression was normalized to 18s rRNA levels.
Dotted lines indicate the sensitivity of the assay. E-G. Keratinocytes and DCs were treated with
murine IFN-λ3 (10 or 100 ng/ml) or IFN-β (0.1 or 1 ng/ml) for 6 h. Expression of Ifit1, Rsad2,
and Irf7 was measured by qRT-PCR from total cell RNA. Gene expression was normalized to
18s rRNA and to mock-treated cells. Results represent mean ± standard error of the mean (SEM)
of 9 samples from 3 independent experiments. Dotted lines indicate the expression level in
mock-treated cells. H. Keratinocytes were treated with 0.1 to 1000 ng/ml of IFN-λ3 for 6 h and
expression of Ifit1 was measured by qRT-PCR. Gene expression was normalized to Gapdh. The
dotted line represents the expression level in mock-treated cells. Results represent mean ± SEM
of 2 (0.1 ng/ml only) to 10 samples from 3 independent experiments I. DCs were treated with
IFN-λ3 (10 ng/ml) or IFN-β (20 ng/ml) for 6 h. Total RNA was isolated and analyzed by RNASeq. Genes that were induced or repressed by more than 3-fold (relative to mock) are shown in
heatmap representation.
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Figure 2: IFN-λ does not directly inhibit WNV infection. A-C. Keratinocytes and DCs were
pre-treated with murine IFN-λ3 (100 or 10 ng/ml) or IFN-β (1 or 0.1 ng/ml) for 6 h and then
infected with WNV at an MOI of 0.1. Viral infection was measured by focus-forming assay.
Results represent mean ± SEM of 9 samples from 3 independent experiments. Dotted lines
indicate the sensitivity of the assay. Viral titers in IFN- treated cells were compared to mocktreated cells. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001 (2-way ANOVA). D-F.
Primary cells prepared from WT and Ifnlr1-/- mice were infected with WNV at MOI 0.001 (DCs
and cortical neurons) or MOI 0.01 (macrophages), for 72 h and viral replication was measured
by focus-forming assay. Results represent mean ± SEM of 9 samples from 3 independent
experiments. The differences between WT and Ifnlr1-/- cells were not statistically significant (2way ANOVA).
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Figure 3: Viral burden in WT and Ifnlr1-/- mice after subcutaneous or intracranial
inoculation. Nine to twelve week old mice were infected with 102 PFU of WNV via a
subcutaneous route (A-F) or 101 PFU via an intracranial route (G-I). A and B. Viral RNA in the
serum and draining inguinal lymph node was measured by qRT-PCR. C-F. Viral burden was
measured by plaque assay from spleen, kidney, brain, and spinal cord. Symbols represent
individual mice from several independent experiments; bars indicate the mean of 5 to 15 mice
per group. Dotted lines represent the limit of sensitivity of the assay. *, P < 0.05; **, P < 0.01
(Mann-Whitney test). G-I. Viral replication in the cortex, cerebellum, and spinal cord was
measured by plaque assay at days 3 and 5 after infection. Bars indicate the mean of 5 to 6 mice
per group from 2 independent experiments. Dotted lines represent the limit of sensitivity of the
assay. The differences between WT and Ifnlr1-/- mice were not statistically significant (t-test).
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Figure 4: Cellular immune responses in infected WT and Ifnlr1-/- mice. Eight to ten week-old
mice were infected with 102 PFU of WNV via a subcutaneous route. At day 8 after infection,
leukocytes were harvested from the spleen (A-J) and brain (K-T) and analyzed. Cells were
stained with antibodies against CD45, CD19, CD11b, CD11c, CD3, CD4, CD8, and granzyme B.
Cells were either stained with a tetramer displaying the immunodominant WNV peptide (DbNS4B) (E and O) or they were re-stimulated with NS4B peptide for 6 h and then stained with
antibodies against IFN-γ and TNF-α. (G, H, Q, and R). Total numbers of the indicated cell
populations. Symbols represent individual mice and data are combined from two independent
experiments. The differences between WT and Ifnlr1-/- mice were not statistically significant
(Mann-Whitney test). I-J and S-T. Representative flow cytometry plots showing CD8+ and
NS4B+ cells (I and S) or CD8+ and IFN-γ+ cells (J and T). Numbers indicate the percentage of
cells in each quadrant and the results are representative of two independent experiments.
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Figure 5: BBB permeability in infected WT and Ifnlr1-/- mice. Eight week-old WT and Ifnlr1/mice were infected via a subcutaneous route with 102 PFU of WNV or diluent (mock). A-C.
BBB permeability was assessed at 4 days after infection by measuring the accumulation of
sodium fluorescein dye in CNS tissues following intraperitoneal administration. Tissue
fluorescence was normalized to the plasma fluorescence from the same animal. Symbols
represent individual animals from two independent experiments. ****, P < 0.0001 (t-test). D-E.
Brain sections were stained with anti-mouse IgG to detect endogenous antibody leakage into the
CNS parenchyma. IgG staining is shown in green, nuclei are shown in blue. Representative
images were taken at 40X magnification. E. Levels of IgG staining were quantified from 2 fields
from 3 independent mice per group. *, P < 0.05 (2-way ANOVA)
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Figure 6: IFN-λ increases TEER and junction integrity in BMECs. A and B. Expression of
Ifnar1, Ifnlr1, and Il10rb was measured by qRT-PCR from total cell RNA from WT uninfected
BMEC and astrocytes. Gene expression was normalized to 18s rRNA levels. C and D. BMEC
and astrocytes prepared from WT and Ifnlr1-/- mice were infected with WNV at MOI 0.01 for 72
h and viral replication was measured by focus-forming assay. Results represent mean ± SEM of
9 samples from 3 experiments. The differences between WT and Ifnlr1-/- cells were not
statistically significant. E-H. BMECs were prepared from WT or Ifnlr1-/- mice and cultured on
transwell inserts with astrocytes prepared from WT (E, left; and F-H) or Ifnlr1-/- (E, right) mice.
E. BMECs were infected with WNV at a MOI of 0.01 and TEER was measured 6 h later. F.
BMECs were treated with murine IFN-β or IFN-λ3 and TEER was measured 6 h later. G.
BMECs were pre-treated with an IFNAR-blocking (MAR1-5A3) or isotype control (GIR-208)
MAb and then infected with WNV at a MOI of 0.01. TEER was measured 6 h after infection. H.
WT BMECs were pre-treated with 20 µg/ml of CHX for 18 h and then infected with WNV at a
MOI of 0.01 or treated with murine IFN-β (10 ng/ml) or IFN-λ3 (100 ng/ml). TEER was
measured 6 h later. Results represent mean ± SEM of 9 samples from 2 experiments. I BMECs
were prepared from WT and Stat1-/- mice and treated with murine IFN-β or IFN-λ3 and TEER
was measured 2, 6, and 12 h after treatment. Results represent mean ± SEM of 6 samples from 2
experiments. IFN-treated cells produced significantly higher TEER compared to controls by 2 h;
IFN-β treatment produced significantly higher TEER in WT cells compared to Stat1-/-, but the
difference in IFN-λ3-treated cells was not significant. J. HCMEC/D3 cells were cultured on
transwell inserts, treated with human IFN-β (10 ng/ml) or pegylated human IFN-λ1 (100 ng/ml),
and TEER was measured after 2, 6, and 12 h. Results represent mean ± SEM of 8 samples from 2
experiments. IFN-treated cells produced significantly higher TEER compared to controls by 2 h;
IFN-β treatment produced significantly higher TEER compared to IFN-λ1 treatment. K and L.
HCMEC/D3s were cultured on transwell inserts and pre-treated for 18 h with 100 ng/ml of LPS
(or media), followed by 100 ng/ml of pegylated human IFN-λ1 for 6 h (or media). The cells were
then infected with WNV at an MOI of 0.01 from the upper chamber. TEER was measured over
the course of the experiment (K) and at 6 h post-infection virus crossing into the lower chamber
was measured by qRT-PCR (L). Results represent mean ± SEM of 12 samples from 3
experiments. IFN-λ1 treatment produced a significant increase in TEER compared to media or
LPS alone. All statistical comparisons were by 2-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P
< 0.001; ****, P < 0.0001.
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Figure 7: Cell junction protein localization in endothelial cells. A and B. BMECs were
prepared from WT mice and grown on chamber slides. Cells were pre-treated for 18 h with 100
ng/ml of LPS and subsequently treated with 100 ng/ml of murine IFN-λ3 for 6 h. A. Cells were
co-stained for the cell junction proteins ZO-1 (green) and claudin-5 (red); nuclei are shown in
blue. Images were taken by confocal microscopy at 63X magnification. Arrows indicate ZO-1
and claudin-5 co-localization at intact tight junctions. B. Co-localization of ZO-1 and claudin-5
staining was determined using Image J software. Results are representative of two independent
experiments. **, P < 0.01 (2-way ANOVA). C. Eight week-old WT mice were treated with LPS
(3 mg/kg via intraperitoneal route), LPS and pegylated murine IFN-λ2 (25 µg via intravenous
route), or PBS alone. D. Nine week-old WT and Ifnlr1-/- mice were infected via a subcutaneous
route with 102 PFU of WNV or diluent (mock). C and D. Brain sections were stained with ZO-1
(green) and claudin-5 (red); nuclei are shown in blue. Images were taken by confocal
microscopy at 63X magnification and are representative of 6 fields from 3 mice.

183

Figure 8: IFN-λ enhances BBB tightness and restricts WNV neuroinvasion. A-C. Eight
week-old WT mice were treated with LPS (3 mg/kg via intraperitoneal route), LPS and
pegylated murine IFN-λ2 (25 µg via intravenous route), or PBS alone. BBB permeability was
assessed 24 h later by fluorescein or IgG permeation as described in Figure 5. Symbols represent
individual animals from two independent experiments. ***, P < 0.001, **, P < 0.01, *, P < 0.05
(2-way ANOVA). D and E. Five-week-old WT mice were infected with 102 PFU of WNV via a
subcutaneous route. On the day of infection and at days 2 and 4 afterwards, 20 µg of pegylated
murine IFN-λ2 protein (or PBS) was administered via an intravenous route. D. Viral RNA in the
plasma was measured by qRT-PCR on days 2 and 4 after infection. E. Survival was monitored
for 21 days after infection. n = 22 mice, *, P < 0.05 (log-rank test). F and G. Nine-week old WT
mice were infected with 102 PFU of WNV via a subcutaneous route. At days 2, 3, and 4 after
infection, 25 µg of pegylated murine IFN-λ2 protein (or PBS) was administered via an
intravenous route. F. Viral RNA in the plasma was measured by qRT-PCR on days 3, 4, and 5
after infection. G. Viral burden in the CNS was measured by plaque assay at day 8 after infection.
Symbols represent individual animals. Dotted lines represent the limit of sensitivity of the assay.
***, P < 0.001 (Mann-Whitney test)
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5.7 Supplemental figures

Figure S1: Serum antibody responses in WT and Ifnlr1-/- mice. Eight to ten week-old mice
were infected with 102 PFU of WNV via a subcutaneous route in the footpad. Serum IgM (A)
and IgG (B) against WNV E protein were measured by ELISA. Results represent the mean ±
SEM of 6 to 10 mice per group. The differences between WT and Ifnlr1-/- mice were not
statistically significant (2-way ANOVA, P > 0.05).
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Figure S2: Serum type I IFN responses in WT and Ifnlr1-/- mice. Eight to ten week-old mice
were infected with 102 PFU of WNV via a subcutaneous route in the footpad. IFN-α/β activity in
serum was measured by an EMCV cytopathic inhibition bioassay. The differences between WT
and Ifnlr1-/- mice were not statistically significant (2-way ANOVA, P > 0.05).
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Figure S3: IFN-stimulated gene induction in BMECs. WT BMEC were treated with IFN-β
(0.1 or 1 ng/ml), IFN-λ (10 or 100 ng/ml) or LPS (100 ng/ml) for 6 h then expression of the
indicated genes was measured by qRT-PCR from total cell RNA. Gene expression was
normalized to 18s rRNA and to mock-treated cells. Results represent mean ± SEM of 6 samples
from two independent experiments.
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Figure S4. Viability of HCMEC/D3 cells after LPS and IFN treatment. HCMEC/D3 cells
were treated for 18 h with 100 ng/ml of LPS (or media), followed by 100 ng/ml of pegylated
human IFN-λ1 or human IFN-β (or media) for 6 h. Viability was measured via colorimetric
assay. Results represent mean ± SEM of 4 samples from 2 independent experiments.
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Figure S5: IFN-λ treatment prevents lethal WNV infection. Five week-old WT mice were
infected with 102 PFU of WNV via a subcutaneous route. Mice received 20 µg of pegylated
murine IFN-λ2 protein (or PBS) via an intravenous route one day before infection as well as one
and three days afterwards. A. Viral RNA in the plasma was measured by qRT-PCR on days 1
and 3 after infection; P > 0.05 (2-way ANOVA). B. Survival was monitored for 21 days after
infection; n = 8 to 10 mice, P = 0.1 (log-rank test).
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5.8 Supplemental tables

Gene Name
Ifi44
Isg15
Plac8
Mx2
Ifit3
Oas3
Slfn3
Ifit1
Oasl1
Ddx60
Rsad2
Herc6
Oasl2
Ifit2
Ube2l6
Stat2
Irf7
Stat1
H2-T24
Zbp1
Usp18
Trim30d
Cmpk2
Gbp4,Gbp9
Nt5c3
Pyhin1
Dhx58
Ifih1
Slfn5
Gm12250
Mir1932
Uba7
Serpina3f
Gbp5
Oas1g

Log2 IFN-treated/mock
IFN-β
IFN-λ
5.49
4.94
3.81
3.91
5.41
3.39
3.65
4.70
5.02
3.65
5.65
3.49
3.31
5.38
3.18
2.89
5.06
2.79
2.91
3.19
3.62
2.55
4.99
4.09
3.58
3.58
2.90
3.19
3.31
3.23
3.26
2.92
3.74
3.91
2.96

1.12
1.01
1.00
0.92
0.90
0.82
0.79
0.78
0.74
0.73
0.69
0.68
0.68
0.65
0.64
0.62
0.60
0.53
0.52
0.51
0.50
0.49
0.48
0.48
0.48
0.48
0.47
0.47
0.47
0.46
0.45
0.45
0.45
0.45
0.44
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Oas1a
Cxcl10
Socs1
Slfn1
1600014C10Rik
Ccl5
Ch25h
2010002M12Rik,Gm14446
Rasa4
Parp12
Mxd1
Rilp
Phf11a
Irgm1
Nlrc5
Ccnd2
Psmb9
Helz2
Mx1
Xaf1
Casp4
Irgm2
Bst2
Ifi47
Zufsp
Gm5431
Trafd1
Tmem184b
Mthfr
Parp14
Ly6c1
Gbp6
Trim30a
Cant1
Etnk1
March5
Znfx1
Trim34a
Tor1aip2

2.71
4.69
3.08
3.11
2.94
1.89
2.94
6.60
2.50
2.88
2.38
1.95
3.86
3.52
2.70
2.35
2.20
2.18
3.10
3.16
2.62
2.92
2.88
3.77
2.23
2.91
2.16
1.81
3.03
2.39
2.04
3.57
2.35
1.91
1.94
2.27
2.78
1.94
1.94

0.43
0.43
0.43
0.43
0.42
0.41
0.41
0.40
0.40
0.40
0.40
0.39
0.39
0.39
0.39
0.39
0.39
0.39
0.38
0.38
0.38
0.37
0.36
0.36
0.36
0.35
0.35
0.35
0.34
0.34
0.33
0.32
0.32
0.32
0.30
0.30
0.30
0.29
0.29

191

Igtp
Sp100
Ifi204
Ddx58
AW112010
Parp9
Sp110
Il15
Trim12a
Phf11c
Tap1
Dtx3l
Lgals9
Ly6a
Cnp
Slfn8,Slfn9
Hmgn3
Gbp2
Gbp3
Pttg1
Adar
Tor1aip1
Ifi35
Fgl2
H2-T22,H2-T23,H2-T9
Ifi203
Fcgr4
Rgl2
Apol7c
Ifitm3
Trex1
Daxx
Aida
Trim21
Treml2
S1PR2
Rtp4
Car13
C2,Cfb

3.39
2.23
3.25
2.68
2.90
2.20
2.30
2.56
1.77
2.31
2.39
2.41
2.42
3.43
2.16
2.84
2.02
3.37
3.36
2.41
1.67
1.61
2.17
3.70
1.99
2.77
3.01
1.77
1.86
1.67
2.06
2.85
2.11
2.50
1.60
1.59
2.57
1.83
2.84

0.29
0.29
0.29
0.28
0.28
0.28
0.28
0.28
0.28
0.27
0.27
0.26
0.26
0.25
0.25
0.25
0.25
0.25
0.24
0.24
0.24
0.24
0.24
0.24
0.24
0.23
0.23
0.23
0.22
0.22
0.21
0.20
0.20
0.20
0.20
0.20
0.19
0.19
0.19
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Tap2
9930111J21Rik1
Il18bp
Cd69
Usp25
Ms4a6d
Eif2ak2
Fbxw17
Themis2
Chpt1
Tor3a
Xdh
Sell
Ogfr
Usb1
Amica1
Cd40
Samhd1
Epsti1
Tdrd7
Ly6i
Ehd4
Mlkl
Tapbpl
Gbgt1
Ly6c2
Samd9l
Slamf7
Slc7a8
Peli1
Gm4759
Irf1
5730508B09Rik
Fcgr1
Ms4a6c
Clic4
Tagap
Tnfsf8
Cd86

1.76
2.12
3.09
3.26
1.71
2.83
1.64
1.88
2.28
1.91
2.41
2.32
2.10
1.93
1.83
1.71
3.17
2.43
2.46
1.71
1.66
1.77
2.62
2.06
1.73
1.81
2.27
1.84
1.80
1.67
1.69
1.65
1.79
3.51
3.53
1.60
1.61
2.03
1.86

0.18
0.18
0.18
0.18
0.17
0.17
0.17
0.17
0.17
0.17
0.17
0.17
0.17
0.16
0.16
0.16
0.16
0.16
0.16
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0.14
0.14
0.14
0.14
0.14
0.13
0.13
0.13
0.12
0.12
0.11
0.11
0.11
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Gnb4
Ncoa7
Hpse
1110018G07Rik
Parp3
Sepw1
Psmb10
Nmi
Dhcr24
Stard3
Irg1
Gbp7
Mitd1
H2-Q4
Abcg1
Pdk3
Cd274
Acsl1
Slfn2
Fndc3a
Lap3
A530064D06Rik
Dck
Pnp
Ppbp
Tpst1
Rgs2
Rnf34
Ly86
Sqle
Ccl12
C3ar1
Ccnd1
Adap2
Scimp
Dpy19l1
Hk3
Tfrc
AA467197

1.65
1.97
1.82
1.86
1.73
1.68
2.11
2.38
-1.67
1.62
2.43
2.58
2.01
1.65
1.65
1.59
1.96
2.27
1.64
1.85
2.34
2.22
2.34
2.76
-1.85
2.39
1.87
1.74
1.78
-1.82
3.68
1.74
2.48
1.81
2.32
2.00
1.76
-1.67
1.95

0.10
0.10
0.10
0.10
0.09
0.09
0.09
0.09
0.09
0.08
0.07
0.07
0.07
0.07
0.07
0.06
0.06
0.05
0.05
0.05
0.05
0.05
0.05
0.03
0.03
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.00
-0.01
-0.01
-0.01
-0.02
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Aldh1b1
Slamf8
Rabggtb
Ppa1
Ctsc
Casp1
Cd180
Ccrl2
Srm
Ccdc23
Mmp13
Il18
Prpf38a
Ccl7
Xrcc6
Bc1

2.84
1.75
5.12
1.77
1.68
1.72
1.74
1.76
-2.03
1.73
2.04
1.70
1.85
2.25
-2.56
-2.01

-0.02
-0.02
-0.02
-0.02
-0.04
-0.04
-0.04
-0.05
-0.06
-0.08
-0.08
-0.11
-0.13
-0.17
-0.54
-0.79

Table S1: Transcriptional profiling of DC treated with IFN-β or IFN-λ. RNA-Seq analysis
of DCs treated with IFN-β (20 ng/ml) or IFN-λ3 (10 ng/ml) for 6 h. Gene expression differences
are expressed as Log2 fold change relative to mock-treated cells and are shown in order of
induction level following IFN-λ treatment.
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Cytokine
IL-1α
IL-1β
IL-3
IL-4
IL-6
IL-9
IL-10
IL-12
(p40)
IL-12
(p70)
IL-13
IL-17
Eotaxin
G-CSF
GM-CSF
IFN-γ
KC
MCP-1
MIP-1a
MIP-1b
RANTES

Genotype
WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT
Ifnlr1-/WT

3 dpi
pg/ml
8.8 (± 1.6)
11.3 (± 2.1)
424.8 (± 25.7)
393.0 (± 39.4)
2.3 (± 0.2)
2.6 (± 0.6)
5.2 (± 0.0)
5.2 (± 0.4)
4.7 (± 0.8)
4.6 (± 2.0)
195.7 (± 11.4)
173.7 (± 25.4)
60.1 (± 4.5)
40.1 (± 8.0)

P
0.37
0.52
0.67
0.95
0.98
0.45
0.06

5 dpi
pg/ml
10.6 (± 2.0)
10.9 (± 1.0)
406.7 (± 25.1)
344.6 (± 20.1)
5.3 (± 1.6)
2.4 (± 0.4)
5.9 (± 0.2)
5.6 (± 0.2)
8.3 (± 1.5)
17.5 (± 8.0)
222.5 (± 8.3)
190 (± 14.7)
63.2 (± 5.5)
59.8 (± 5.2)

P
0.90
0.09
0.13
0.50
0.30
0.09
0.67

177.2 (± 13.1) 0.26

136.3 (± 9.0) 0.12

150.3 (± 17.6)

115.4 (± 8.1)

50.0 (± 6.0) 0.96
49.4 (± 10.5)
69.6 (± 7.3)
72.4 (± 24.9)
24.2 (± 2.7)
25.8 (± 3.3)
585.4 (± 117.5)
641.0 (± 244.9)
73.2 (± 4.1)
56.4 (± 5.1)
130.4 (± 20.5)
184.9 (± 44.6)
8.6 (± 0.9)
7.8 (± 1.3)
100.7 (± 9.1)
79.4 (± 10.7)
143.0 (± 16.6)
91.4 (± 21.9)
19.8 (± 0.9)
16.1 (± 1.5)
28.3 (± 6.7)
23.3 (± 5.9)
33.4 (± 3.5)

0.92
0.73
0.83
0.04
0.25
0.64
0.17
0.10
0.07
0.59
0.06
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54.0 (± 5.8) 0.32
62.2 (± 5.2)
102.1 (± 8.1)
112.2 (± 22.6)
28.3 (± 2.0)
30.9 (± 3.6)
345.3 (± 49.6)
370 (± 46.1)
66.8 (± 5.3)
72.9 (± 6.9)
143.4 (± 21.9)
140.6 (± 23.0)
7.7 (± 0.8)
8.6 (± 1.2)
68.3 (± 1.8)
84.4 (± 5.8)
137.5 (± 8.2)
134.8 (± 32.1)
18.1 (± 1.4)
20.2 (± 2.4)
33 (± 5.2)
56.4 (± 7.9)
19.7 (± 0.9)

0.69
0.56
0.73
0.51
0.93
0.61
0.03
0.94
0.47
0.04
0.02

TNF-α

Ifnlr1-/WT
Ifnlr1-/-

24.3 (± 2.3)
24.3 (± 1.2)
356.6 (± 62.1) 0.56 488.1 (± 57.7) 0.12
412.7 (± 67.1)
626.0 (± 53.0)

Table S2: Serum cytokine levels after WNV infection. Mice were infected with 102 PFU of
WNV in the footpad. Serum was collected at 3 and 5 days after infection and the indicated
cytokines were measured by Bio-Plex array. Data represent the mean (± SEM) in pg/ml of 5
mice per group. Statistical significance was determined using t-tests and the Holm-Sidak method
to correct for multiple comparisons.
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Target
18s

Fwd
Rev
Probe
Fwd
Rev
Probe
Fwd
Rev
Probe
Fwd
Rev
Probe
Fwd
Rev
Probe
Fwd
Rev
Probe

Sequence (5’-3’)
CGGCTACCACATCCAAGGAA
GCTGGAATTACCGCGGCT
/56-FAM/TGCTGGCAC/ZEN/CAGACTTGCCC/3IABkFQ/
AATGGTGAAGGTCGGTGTG
GTGGAGTCATACTGGAACATGTAG
/56-FAM/TGCAAATGG/ZEN/CAGCCCTGGTG/3IABkFQ/
GTGGAATGAGGTTGATCCGTT
AGAGATGTGGACTAGTATGGCT
/56FAM/CCCCCAGAA/ZEN/GTACGTTTAGAAGCTGAAG/3IABkFQ/
CCTGTACTCGTCCTTTGAACT
GTGACCTATTTCGTGACCTACC
/56-FAM/TGTGTCCCC/ZEN/TGATGTGCCTGAAG/3IABkFQ/
GAAAGATGAGAGAAGTCGCACT
GAACATTCTACAGTGGGAGGT
/56-FAM/CCAAAACGA/ZEN/ACCTGACTTTCACAGCT/3IIABkFQ/
TGAAGCAGATTCTCCATGACC
GCAAGAGAGCAGAGAGTCAAG
/56-FAM/ACAGCTACC/ZEN/ACCTTTACAGCAACCAT/3IABkFQ/
ACACAGCCAAGACATCCTTC
CAAGTATTCACCCCTGTCCTG
/56-FAM/TGTTTGAGCAGAAGCAGTCCTCGC/3IABkFQ/
CTGGAGCCATGGGTATCGA
AAGCACAAGCCGAGACTGCT
/56-FAM/ CTGGAGGGCGTGCAGCGTGA/36-TAMSp/
GGCTTCCATCATGAACAACAG
GTTGATGGAGAGGGCTGTG
/56FAM/CTGCGTTCCTGCTGTGCTTCTC/36-TAMSp/

Ifna
(nona4)

Fwd

ARSYTGTSTGATGCARCAGGT

Il28b

Rev
Probe
Fwd
Rev
Probe

GGWACACAGTGATCCTGTGG
/56-FAM/CAGGAACCTCCTCTGACCCAGGA/36-TAMSp/
GCTGAGTCATTTATGTTCTCCCA
AGTTCCCACCTCATCTCCA
/56FAM/CTGCAGGTC/ZEN/CAAGAGCGCC/3IABkFQ/

WNVNY (E)

Fwd

TCAGCGATCTCTCCACCAAAG

Gapdh
Ifnar1

Fwd
Rev
Probe
Fwd
Rev
Probe
Fwd
Rev
Probe

Ifnlr1
Il10rb
Ifit1
Rsad2
Irf7
Ifnb

Rev
GGGTCAGCACGTTTGTCATTG
Probe /56-FAM/TGCCCGACCATGGGAGAAGCTC/36-TAMSp/
Table S3: Primer and probe sequences used for qRT-PCR
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Chapter 6
Summary and future directions
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6.1 Summary
Establishment of a human BBB culture system
Early work in this dissertation sought to establish an in vitro model of the BBB that used
human cells. To this end, we characterized BBB cultures generated with the human BMEC cell
line HCMEC/D3. This immortalized cell line had been extensively characterized as a less
expensive and more logistically feasible alternative to primary human BMECs (HBMECs).
However, the fidelity of the HCMEC/D3 cell line to primary HBMECs in studies of cytokines
and immune transmigration had yet to be established. Flow cytometric analysis of primary
human leukocyte migration across in vitro BBBs generated with either HCMEC/D3 or primary
HBMECs revealed that HCMEC/D3 maintains the immune barrier properties of primary
HBMECs. Leukocyte migration responses and inflammatory cytokine production were
statistically indistinguishable between both endothelial cell types, and both cell types responded
similarly to astrocyte coculture, stimulation of leukocytes with PMA and ionomycin, and
inflammatory cytokine treatment. These findings demonstrate that HCMEC/D3 is a powerful
tool for less expensive and higher throughput in vitro investigations of immune migration at the
BBB. Following the establishment of this model system, we went on to use it extensively in
studies of CNS autoimmunity and viral infection.

Sexually dimorphic S1PR2 expression contributes to female susceptibility to CNS
autoimmunity
In this study, we sought to investigate potential molecular mechanisms at the BBB that
contribute to sexual dimorphism in the CNS autoimmune disease multiple sclerosis and its
mouse model, EAE, as it occurs in the SJL strain. We identified S1PR2 as a sex- and strain-
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specific, disease-modifying molecule that regulates BBB permeability by destabilizing adherens
junctions. Increased expression of S1PR2 was detected in disease-susceptible CNS regions of
female versus male SJL mice and in female MS patients. Pharmacological blockade or genetic
silencing of S1PR2 signaling decreased disease severity in EAE by enhancing endothelial barrier
function. Mechanistically, S1PR2 signaling dysregulated adherens junction formation via
Rho/ROCK, CDC42, and caveolin endocytosis-dependent pathways, with loss of apicobasal
polarity, and relocation of abluminal CXCL12 to vessel lumina. These findings disclose new
links between S1PR2 signaling and BBB polarity and implicate S1PR2 in sex-specific patterns of
disease during CNS autoimmunity.

Host detection of WNV preserves BBB integrity via type I IFN
Detection of PAMPs, such as viral RNA, drives innate immune responses against WNV,
an emerging neurotropic pathogen.

In this study, we demonstrated that WNV PAMPs

orchestrate endothelial responses to WNV via competing innate immune cytokine signals at the
BBB, a multicellular interface that normally prevents pathogen entry into the CNS. While Th1
cytokines increased the permeability of endothelial barriers, type I IFN promoted and stabilized
BBB function. Induction of innate cytokines by pattern recognition pathways directly regulated
BBB permeability and tight junction formation via balanced activation of the small GTPases
Rac1 and RhoA, which in turn regulated transendothelial trafficking of WNV. In vivo, mice with
attenuated type I IFN signaling or IFN induction (Ifnar-/-, Irf7-/-) exhibited enhanced BBB
permeability and tight junction dysregulation after WNV infection. Together, these data identify
a novel protective role for type I IFN in the CNS and provide new insight on host-pathogen
interactions at the BBB during neurotropic viral infection.

201

Type III IFN preserves BBB integrity, limiting WNV neuroinvasion
Although type III IFNs, also known as IFN-λ or IL28/IL-29, restrict infection by several
viruses, their mechanism of inhibitory action has remained uncertain. In this study, we used
recombinant IFN-λ and mice lacking the IFN-λ receptor (IFNLR1) to evaluate the effect of IFNλ on infection with WNV. Cell culture studies in keratinocytes and dendritic cells showed no
direct antiviral effect of exogenous IFN-λ even though ISGs were induced. Correspondingly, we
observed no differences in WNV burden between wild-type and Ifnlr1-/- mice in the draining
lymph node, spleen, and blood. However, we detected earlier dissemination and increased WNV
infection in the brain and spinal cord of Ifnlr1-/- mice, yet this was not associated with a direct
antiviral effect on infection of neurons. Instead, an increase in BBB permeability was observed
in Ifnlr1-/- mice. Accordingly, treatment of mice with pegylated IFN-λ2 resulted in decreased
BBB permeability, reduced WNV infection in the brain, and improved survival against lethal
virus challenge. In vitro BBB studies showed that IFN-λ signaling in BMECs increased TEER,
decreased virus movement across the barrier, and modulated TJ protein localization in a protein
synthesis- and STAT1-independent manner. Our data establish a novel indirect antiviral function
of IFN-λ in which non-canonical signaling through IFNLR1 tightens the BBB and restricts viral
neuroinvasion and pathogenesis. This finding suggests new clinical applications for IFN-λ in
treating viral and autoimmune diseases of the CNS.
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6.2 Conclusions and future directions
In vitro assessments of BBB biology
Much of the work in this dissertation was made possible by the development of robust
assays measuring BBB structure and function using in vitro culture models. While the use of
endothelial cell cultures in transwell systems to model the BBB has a long history (105), our
work takes advantage of more recent innovations, including the use of primary adult endothelial
cells taken directly from the CNS (as opposed to more abundantly available endothelia or
epithelia taken from peripheral organs). Other improvements in BBB culture models include the
use of co-cultured glial cells, which we and others have shown to greatly improve the fidelity of
cultured endothelia to the gene expression and barrier function observed in vivo (3, 225, 268).
The recent availability of human BMEC cell lines, such as HCMEC/D3, has also enhanced our
ability to validate experimental observations in murine systems using human cells (269).
However, despite these advances, studies using in vitro BBB culture systems may benefit
from several additional improvements. One such improvement are culture models which more
fully represent the cell populations present in the neurovascular unit. Most notably, a growing
body of work has demonstrated that pericytes are essential cell types at the BBB and may
improve the fidelity of BBB culture systems when included in addition to astrocytes (181, 270).
Of note, the role of pericytes in CNS infection and autoimmunity has scarcely been addressed
thus far. Thus, culture systems incorporating these cells are likely to yield crucial new advances
in understanding how the BBB is regulated during neuroinflammatory states.
Despite this promise, the addition of new cell types to in vitro BBB models significantly
increases the cost and logistic complexity of the culture system, negatively impacting the
throughput of in vitro BBB assays, which is among their key strengths. Moreover, it is difficult
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to approximate the physical relationship of pericytes to BMECs in vitro; some studies, for
instance, have grown confluent monolayers of pericytes on the “basolateral” side of a filter
membrane with BMECs on the “apical” side, rendering a BMEC:pericyte ratio that is likely far
smaller than that observed in situ (96, 271) (though, we note, there are similar issues with
astrocyte coculture systems, as well). Perhaps the greatest caveat to these systems is that
pericytes grown on filter membranes occlude the pores of filter inserts, and thus are likely to
confound studies that rely on permeability measures such as TEER. Thus, future in vitro culture
systems may benefit from innovations that allow discrimination of monolayer resistance from
individual layers in co- and tri-culture BBB models.
Another key improvement in in vitro BBB cultures to emerge recently is the
incorporation of shear stress to the culture system. Such cultures use various culture apparatuses
that allow media to flow across endothelial cells at a controlled rate, mimicking the shear stress
exerted by circulating blood in vivo. Such culture systems have been shown to enhance the
barrier properties of cultured endothelial cells beyond those observed under static culture
conditions (272). Recent iterations of these systems even allow coculture of glial cells, as well as
the presence of collection chambers for studies of leukocyte transmigration, further enhancing
their utility to studies of neuroinflammatory diseases (103, 273). However, as noted before, the
enhanced complexity and cost of shear stress cultures limit their throughput compared to static
cultures. Technologies that allow automation of the culture process and subsequent
experimentation would address this issue, in part.

Contributions of S1PR2 to CNS autoimmunity
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Our findings that sexually dimorphic S1PR2 expression impact BBB integrity and
chemokine display are exciting, as they suggest possible targeted therapies for CNS
autoimmunity that are not directly immunomodulatory. Such treatment options are crucial, as
current therapies have numerous off-target effects such as immunosuppression, rendering
patients susceptible to opportunistic infection. However, while our work showed that diminished
S1PR2 signaling decreased lesion formation and ameliorated clinical signs of disease, we have
yet to characterize what infiltrating immune cell populations are most impacted by S1PR2
signaling at the BBB. Future studies examining the consequences of S1PR2 signaling at the BBB
during autoimmunity would benefit from immunologic studies examining the cellular
composition and activation states of inflammatory infiltrates in the CNS.
While our studies suggest that S1PR2-mediated disruption of CXCL12 polarity at the
BBB prevents the perivascular capture of CXCR4+ leukocytes, the relative impact of this process
on the capacity of various leukocyte subsets to infiltrate the CNS parenchyma remains unknown.
While previous studies in our laboratory have shown that antagonism of CXCR4 during EAE
leads to the enhanced parenchymal infiltration of autoreactive CD4+ lymphocytes (140), we have
also shown that endothelial CXCL12 is important for other processes, including antigen
presentation and T cell activation in perivascular spaces during WNV infection (55). Thus, loss
of proper CXCL12 localization at the BBB may result in multifactorial consequences during
CNS inflammation. Moreover, while our study focused heavily on S1PR2 signaling in CNS
endothelia, we also detected S1PR2 expression on other neurovascular cells, including pericytes
and astrocytes. Future studies would benefit from dissection of cell-type specific effects of
S1PR2 signaling in individual neurovascular cells through the use of Cre-lox or related
technologies.
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Interferon signaling at the BBB
Our studies have defined novel protective functions for IFNs during viral infections,
specifically at the BBB. While indications that type I IFNs could preserve BBB integrity in the
context of CNS autoimmunity had been previously shown, our studies are the first to show that
IFNs (types I and III) are critical regulators of BBB function that limit neuroinvasion by a
neurotropic virus, thereby protecting the CNS from infection. Moreover, our studies suggest an
exciting new therapeutic potential for IFN-λ. While the effects of type III IFN overlap
considerably with type I IFNs, the preferential distribution of type III IFN receptor expression at
tissue barriers suggests that treatment with exogenous IFN-λ may allow therapeutic manipulation
of the BBB during neuroinflammatory diseases, without the myriad side effects of type I IFN
treatment.
Despite these advances, many key questions remain unanswered. One intriguing outcome
of our studies was the discovery that both type I and III IFNs regulate BBB function through
non-canonical pathways, independent of STAT-1 signaling (71). While our studies did implicate
the Rho-GTPases Rac1 and RhoA in IFN-mediated effects on BBB function in vitro (44), other
molecular components of the signaling cascade between IFN receptor activation and cellular
outcomes such as TJ protein localization have yet to be identified. Biochemical studies to date
point to possible mechanisms such as IFNAR-mediated tyrosine phosphorylation of guanine
exchange factors (GEFs), small GTPase activating proteins (199, 274, 275). For example, it has
been shown that activation of IFNAR leads to the STAT-1-independent phosphorylation of the
Rac1-activating protein VAV, which is a critical step in IFNAR-mediated signaling via the
MAPKK/p38 pathway (199, 275). However, no detailed biochemical studies of IFNAR or
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IFNLR engagement of GTPase regulatory pathways has been performed in BMECs, specifically.
Thus, future studies employing immunoprecipitation and related techniques may provide
important new details demonstrating how IFNs regulate BBB function at the molecular level.

IFNs and immune migration at the BBB
While our studies demonstrate that IFN-mediated effects on the BBB can hinder
neuroinvasion by virus, it is likely that type I and III IFNs influence immune trafficking at the
BBB during viral encephalitis, as well. As noted previously, type I IFNs are known to potently
regulate leukoycte migration during CNS autoimmunity, and thus, may perform similar functions
during viral infections. Of note, IFN-β has been used successfully as a treatment for multiple
sclerosis (MS), and mice treated with IFN-β exhibit reduced immune invasion across the BBB
and reduced pathology in the course of EAE (276). IFN-β preserves BBB integrity during CNS
autoimmunity via numerous mechanisms, including the downregulation of proinflammatory
cytokines by T cells (277). In vitro studies suggest that IFN-β treatment enhances tight junction
protein expression (212) and inhibits the production of matrix metalloproteinases that
permeabilize endothelial barriers (278). IFN-β has also been shown to impair monocyte
trafficking into the CNS both in vitro and in vivo via downregulation of the immune cell
adhesion molecules VCAM and ICAM on vascular endothelial cells (279). MS patients receiving
IFN-β treatment also exhibit higher levels of soluble VCAM in serum, suggesting that type I-IFN
can cause shedding of VCAM from endothelial surfaces, resulting in blockade of VLA-4 binding
sites on circulating leukocytes by soluble VCAM, inhibiting VLA-4 mediated leukocyte binding
to endothelial VCAM (280).
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It remains to be fully determined if IFN signaling at the BBB influences immune
trafficking during viral encephalitis via any of these mechanisms, and, if so, if these effects are
protective or pathogenic. An intriguing hypothesis is that type I IFNs protect the CNS via two
mechanisms following WNV infection: first by limiting neuroinvasion by virus in the serum,
then again by limiting CNS inflammation, thereby preventing bystander injury and
immunopathology in the CNS. Studies examining the functions of type I IFN at the BBB during
these different stages of disease would benefit greatly from the generation of mice with cell-type
specific, inducible deletions of IFNAR in CNS vascular endothelium. In addition, the potential
for type III IFNs to regulate immune trafficking at the BBB has yet to be addressed at all, even
using in vitro systems. Such experiments will be crucial to establish the utility of IFN-λ as a
potential therapy for neuroinflammatory diseases beyond viral encephalitis.
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